Cabrini Institute Annual Report 2019-20 by Cabrini Health

CABRINI INSTITUTE: ANNUAL REPORT 2019-20

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

THE CABRINI INSTITUTE MISSION

The Cabrini Institute is committed to improving the clinical outcomes of patients of Cabrini. It embraces the mission, values and vision of Cabrini and works within an ethical framework. The Cabrini Institute has a vital role in helping Cabrini to achieve its vision – that is: “We will provide clinical excellence by learning, researching and continuously improving the quality of our care, and having motivated staff committed to our healthcare mission… We will enhance health and quality of life by treating sickness, and by working with our patients and their families to anticipate, prevent and ease suffering.”

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Cabrini Mission Who we are: We are a Catholic healthcare service inspired by the spirit and vision of Saint Frances Xavier Cabrini and the Missionary Sisters of the Sacred Heart of Jesus. What we believe: We are a community of care, reaching out with compassion, integrity, courage and respect to all we serve. What we do: We provide excellence in all of our services and work to identify and meet unmet needs.

Cabrini Values Our values form the base of our mission, are built around what we believe and drive how we act. They are drawn from Saint Frances Xavier Cabrini’s life and reflect her heart, her spirit, her conviction and her approach. Compassion: Our drive to care is not just a professional duty to provide excellent quality care but is born of a heartfelt compassion for those in need, motivated by God’s love for all people. Integrity: We believe in the power of hope to transform people’s lives and remain faithful to the bold healing mission and legacy of Saint Frances Xavier Cabrini. Courage: We have the strength, determination, vision and conviction to continue the work of Mother Cabrini and the Cabrini Sisters. Respect: We believe that every person is worthy of the utmost respect and the best possible healthcare. We know that our resources are entrusted to us to use for the benefit of others.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

TABLE OF CONTENTS

6 8 10 12 14 18 20 22 24 26 28

Message from the Chair, Cabrini Institute Council Year in Review: Executive Director Report Highlights 2019-20 Who We Are Year in Review Cabrini Research Week 2019 Cabrini Partnerships Cabrini Institute Council Message from the Director, Cabrini Foundation Scholarships and Grants at Cabrini Many Thanks to Our Supporters

OUR RESEARCH

32 36 40 43 44 46 50

53 55 56 58 62 64 68 72

Cabrini Monash University Department of Nursing Research Monash-Cabrini Department of Clinical Epidemiology Cabrini Monash University Department of Surgery, The Fröhlich West Chair of Surgery In the Spotlight: Mr Raymond Yap Let’s Beat Bowel Cancer Centre for Allied Health Research and Education (CAHRE) Cabrini Monash University Department of Medical Oncology – The Szalmuk Family Department of Medical Oncology In the Spotlight: Dr Anis Hamid In the Spotlight: Li Hoon Lai In the Spotlight: Dr Tali Lang Palliative and Supportive Care Research Unit Szalmuk Family Psycho-Oncology Research Unit Alan, Ada, and Eva Selwyn Emergency Department Intensive Care Research Unit Department of Urology

OUR EDUCATION

76 80 84

Clinical Education Department Department of Medical Student Education Broader Medical Education

OUR RESEARCH INFRASTRUCTURE

88 90 95 96 97 98

Cabrini Library Clinical Database Registries In the Spotlight: Melissa Vereker Providing Best Cancer Management for our Patients – Multidisciplinary Team Meetings In the Spotlight: Associate Professor Wei C. Wang Cabrini Research Governance Office

104 Publications, Books, Book Chapters, Reports and Grants Held 115 Key Partners of the Cabrini Institute

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Message from the Chair, Cabrini Institute Council Our 2019-20 Cabrini Institute annual report is provided to you in the context of the global COVID-19 pandemic. This has been a period of rapid change. The virus has touched people from all walks of life and has affected the Cabrini community and our consumer engagement, clinical practice, research, education and partnerships. Especially during this period, our focus has been on the safety, care and wellbeing of all.

Despite the challenges that everybody has faced, this report demonstrates the outstanding and unique achievements of the Cabrini Institute over the last 12 months. Our researchers, leadership teams, clinicians, staff, patients, clients and partners have worked together to quickly adapt and respond to the changing demands associated with the pandemic. The Cabrini Institute has continued to generate and implement world-standard, high quality research, education, training and clinical practice. Using the principles of Implementation Science, Cabrini continues to ensure an evidence based, compassionate and caring culture, delivering safe, effective and person-centred care. The Cabrini Institute Annual Report 2019-20 highlights the proud commitment that Cabrini has to research-informed, patient centred care. Continuing professional education and clinical education for medical, nursing and allied heath clinicians continues to be a high priority. Activity in these domains has been disrupted by the pandemic. Nevertheless, all members of the team have shown great resolve in continuing to produce high quality research, education and practice using flexible responses. Digital health and tele-medicine have played a strong role in adapting workforce training, research and clinical services. Workforce capability also continues to be fostered through high quality education of entry to practice, post-graduate and research higher degree students. Cabriniâ&#x20AC;&#x2122;s strong partnerships with universities, industry and community stakeholders, continue to foster value-based care and a person-centred approach. The Cabrini Institute Council continues to provide independent advice and support to the Cabrini Board,

the Chief Executive of Cabrini Health and the Director of the Institute. I would particularly like to thank the Cabrini Board Chairman, Sylvia Falzon, for her inspirational and very positive leadership through this challenging time. She has continued to provide the Institute with sound counsel and clear direction throughout a period of rapid change. In November 2019 we welcomed Sue Williams to the Cabrini Institute Council. As the new Chief Executive at Cabrini, Sue Williams brings a clear vision, rigorous standards and outstanding leadership of people and teams. Her experience in senior leadership, administration and clinical practice contribute a unique skill set that is greatly valued. We also welcomed to the Cabrini Institute Council Professor Gary Richardson OAM as the Acting Director of the Cabrini Institute. Professor Richardson has worked very hard to ensure the success of all elements of the Institute despite the challenges of the pandemic. He leads the Szalmuk Family Department of Medical Oncology, and is a leader in clinical trials, especially in cancer. His world-class research includes phase 1 trials through to large scale randomised controlled trials, organoid research, and important work on patient reported outcome measures. In November 2019 we farewelled Dr Michael Walsh, who retired as Chief Executive and a member of the Institute Council after 11 years of service. Michael was an outstanding leader and key contributor to the ongoing success of the Institute. His commitment to evidence-based policies and clinical practice formed a strong foundation for translational research, quality, safety and outstanding patient experience. We also farewelled Professor Leanne Boyd, who left us in October 2019 after serving as Group Director of Nursing

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

and Cabrini Institute for more than five years. Lee’s strong contributions to partnerships, client-centred care and embedding a research culture have been highly valued. Professor Rosemary Calder AM retired in April 2020 and we thank her for her dedication, wise counsel and promotion of research policies affecting population health and education. The Institute Council continues to be impressed with the transformational leadership, dedication and achievements of the Heads of each of the Institute Departments. Professor Rachelle Buchbinder AO, Head of the Monash-Cabrini Department of Clinical Epidemiology continues to provide inspiration and great success in grants and research discoveries. Professor Paul McMurrick, the Frolich West Chair of Surgery, has continued to provide world-class leadership of academic surgical colorectal cancer research through the Cabrini Monash Department of Surgery. Associate Professor Natasha Michael, Head Palliative and Supportive Care Research Unit, continues to lead important research on end of life care, advanced care planning and spirituality. Professor David Kissane AC, Head Szalmuk Family Psycho-oncology Research Unit, continues to foster collaborative care and evidence-based clinical practice. Associate Professor Philip Russo leads the Department of Nursing Research and has been an advisor to the Federal Government on infection control during the pandemic. The Allied Health Research Unit welcomed Dr Annemarie Lee as the Senior Consultant Allied Health Research. With Dr Lee’s research expertise in cardiac and respiratory physiotherapy align well with Cabrini’s priorities. Rick Peebles, Acting Director Clinical Education, is leading

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

the development of educational resources and training programs for nursing, allied health and midwifery staff, ensuring quality standards are maintained throughout our organisation. Rick reports to Anne Zandegu, Group Director of Nursing and Clinical Education. Congratulations go to many in our community, including David Curtin, John Santamaria and Rachelle Buchbinder who received Australia Day Honours and Doug Lording, who received a Queen’s Birthday Honour. We congratulate them all for their outstanding achievements. None of these achievements would have occurred without the commitment and dedication of Professor Gary Richardson OAM, who has worked tirelessly in his dual roles as Institute Director and oncologist. The Department Heads and all of the dedicated staff at the Cabrini Institute have contributed to the success, as well as the patients, families and friends that continue to make the research and its translation possible. Please join me in thanking all of the Cabrini community for their collaboration and support. Enjoy reading about the many achievements of the Cabrini Institute and please stay safe.

PROFESSOR MEG E. MORRIS, PHD, FACP CHAIR, CABRINI INSTITUTE COUNCIL

Year in Review: Executive Director Report No review of 2020 could start without mention of the COVID-19 pandemic. To think such a small piece of RNA could cause all this trouble! The Institute recognises the circumstances associated with the COVID-19 pandemic are affecting the whole Australian community. Our primary concern is for the health and safety of our communities, including health consumers, health and medical workers, researchers and support staff.

The pandemic cannot be underestimated. It has posed one of the most significant threats in history to Australia’s national research sector, and well beyond the medical sciences. Australia’s researchers have answered the call to help with urgent pandemic clinical trials and other research needs, placing other work on hold. Laboratories in medical research institutes not working on COVID-19 have been closed. They have effectively paused much of Australia’s medical research including in cancer, heart disease, motor neurone disease and diabetes. This will seriously impact Australia’s capacity to pick up when it is safe to re-open these laboratories. The universities sector estimates its revenue will drop by at least $3 billion in 2020 due to the pandemic, and the decline could be as high as $4.6 billion. This drop is likely to be worst for researchintensive universities. Normal Institute activities have been severely curtailed because of the pandemic. From March, we followed government recommendations, and all non-clinical staff have been working from home. This was initially disruptive, but now is working effectively. Despite all of these hardships, research activity has continued and in some areas increased. I am immensely proud of all of our staff for their response to this crisis. Not surprisingly, a large proportion of research activity has shifted to COVID-19. The institute has participated in state-wide and national research activities. Much of this has focused on the Intensive Care and Emergency Departments, where activity has been frenetic.

Activity in Medical Oncology has also greatly increased. Because the impact of the pandemic has been far greater in the USA, we have been given the opportunity to recruit higher numbers to our current oncology trials, and initiate more clinical trials. All other departments’ research activities have significantly reduced. It is assumed that mitigation measures will be in place until at least the end of this year. We therefore have plans to gradually increase research activities in all departments with appropriate safety, research activity will resume with social distancing still required. There will be a planned return to work for staff that are currently at home, although this will be careful and gradual, in case more austere restrictions return. That is enough of the depressing, as the Annual Report is a celebration of the research we have done and is designed to show our highlights, and there have been many. David Curtin, John Santamaria and Rachelle Buchbinder received Australia Day Honours and Doug Lording received Queen’s Birthday Honours. Paul McMurrick was appointed Professor of Surgery by Monash University. We congratulate them all. Despite the COVID-19 slow-down, research activity has been high. There are currently over 300 active research projects being carried out by the Institute departments. These studies are funded by a mixture of government grants, industry sponsorship and the generosity of our donors. They have allowed research into the optimal treatment of patients with COVID-19, the effect of the

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

virus on patients and medical staff, discovery of new drugs for cancer, understanding the mechanisms of cancer cell growth, psychosocial support of cancer, reduction in low value medical practices, just to name a few. There have been over 160 publications by the departments in peerreviewed journals, and many presentations at national and international conferences. The Institute has been successful in obtaining research grants from multiple sources, including the Medical Research Future Fund, the NHMRC, the Victorian COVID-19 Cancer Network Grant, and from a number of extremely generous donors. The Foundation Grant Round once again went ahead, with $620,000 offered to the successful applicants. All of this money has been provided by our generous donors. Projects funded included creation of an exercise research laboratory for cancer patients, development of a patientreported outcome measures instrument in partnership with the Victoria Lung Cancer Registry, development of a high throughput drug screening platform using patient derived colorectal cancer organoids, and measuring the experience of the healthcare worker during the COVID-19 response. The grants are listed in detail later in this document. Congratulations to all the successful applicants. Research Week was once again a great success. There were 72 abstracts submitted, highlighting the wide array of high-level research the Institute undertakes. The keynote presentation was titled “Researchers behaving badly – The importance of research integrity,” delivered by Professor David Vaux AO. This presentation directly aligned with the Institute strategic plan.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

I would like to take this opportunity to thank our excellent researchers, clinicians, administration team and educators who have worked with such passion and commitment during these trying times. We are also grateful to our Cabrini doctors, nurses, and allied health staff for their support of our research and education programs. We thank Cabrini, as a whole, for their support, particularly the Board, Chief Executive Sue Williams and the Cabrini Institute Council. I would like to acknowledge every patient who has contributed by participating in a clinical trial or supporting education for our health professionals and thank our donors for their continuing support of the Cabrini Institute. And last, but by no means least, I wish to thank the Cabrini sisters for their ongoing commitment to everything we do. Despite the effect of the virus, this is a tremendously exciting time for medical research, and your support is invaluable in this journey of hope and discovery to benefit all of our patients. We are grateful to have all of you on our team.

PROFESSOR GARY RICHARDSON OAM DIRECTOR, CABRINI INSTITUTE AND MEDICAL EDUCATION, SZALMUK FAMILY DEPARTMENT OF MEDICAL ONCOLOGY

IMPA Highlights 2019-20

COVID PPE TRAINING

1,700

SEMINARS AND P R E S E N TAT I O N S

NEW ONCOLOGY TRIALS OPENED

MASTERS AND PHD STUDENTS SUPERVISED

168 19 23 U P 7. 7 % F R O M LAST YEAR

C A B R I N I F O U N DAT I O N G R A N T S A N D SCHOLARSHIPS AWARDED

$699,113 10

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

ACT TOTA L G R A N T F U N D I N G H E L D A N D AWA R D E D

$91,901,531 U P 8 9. 7 % F R O M L A S T Y E A R

P U B L I C AT I O N S , B O O K S , CHAPTERS AND REPORTS

164

NEW PROJECTS APPROVED BY RESEARCH GOVERNANCE

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

G R A D U AT E N U R S I N G POSITIONS OFFERED (2020)

15.5% INCREASE FROM LAST YEAR

TOTA L R E S E A RC H P ROJ E C T S APPROVED AND ONGOING IN 2020

336

Who We Are

CABRINI INSTITUTE

The Cabrini Institute supports research and education activities across the health service, as well as health promotion activities on behalf of Cabrini. Senior medical staff and researchers oversee a diverse research program, as well as developments in clinical education. The research program includes arthritis, back pain, cancer, care of the elderly, health literacy, medicine, nursing, patient safety and surgery. The Cabrini Institute also plays a significant role in the education of our young healthcare professionals. Let’s Beat Bowel Cancer, a Cabrini health promotion initiative, is designed to raise awareness and prevent the incidence of bowel cancer disease. CABRINI HEALTH

CABRINI FOUNDATION

Cabrini Health provides a comprehensive range of acute, subacute, palliative care, primary care, residential aged-care, diagnostic and community-based health services. Cabrini’s services span cancer care, chronic disease, emergency medicine, general practice, health promotion, heart services, homecare and community-based care, maternity services, paediatric care, palliative care, rehabilitation and residential aged-care, as well as education, health promotion and research. Clinical services are provided from large acute hospitals at Brighton and Malvern, Cabrini Palliative Care in Prahran, Cabrini Residential Aged Care in Ashwood and Cabrini Rehabilitation in Elsternwick.

Cabrini does not rely on direct government or church funding. The Cabrini Foundation helps Cabrini to deliver essential healthcare services, provide medical equipment and fund programs through workplace giving, major campaigns, direct mail and individual/community donors. Please call the Cabrini Foundation if you wish to assist any Cabrini program on (03) 9508 1380.

CABRINI OUTREACH

CABRINI TECHNOLOGY GROUP

Since 1992, we have expressed our missionary identity through charitable and social services, reaching out and continually looking beyond our current services to help support and engage with those who are marginalised. Believing strong and collaborative community partnerships are the best way to address social and economic disadvantage, we endeavour to form long-term relationships and to leverage our human, financial and material resources. We seek opportunities for staff to participate which, in turn, enables them to help create a better world.

Cabrini Technology Group provides an innovative, independent information and healthcare technology service to organisations throughout Australasia and has headquarters in Mount Waverley. It comprises of ALTER, AWA Technology Services, Cabrini’s Centre for Innovation, Chemtronics Biomedical Engineering, Chemtronics Direct, Hospitech Facilities and Asset Management, In-a-Tick Compliance Testing Services and Victorian Home Health Equipment.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

CABRINI ASYLUM SEEKER AND REFUGEE HEALTH HUB

CABRINI HAWTHORN EAST

CABRINI PALLIATIVE AND SUPPORTIVE CARE

CABRINI MALVERN PATRICIA PEAK EDUCATION AND RESEARCH PRECINCT CABRINI RESIDENTIAL AGED CARE CABRINI REHABILITATION AND ALLIED HEALTH

CABRINI HOPETOUN

CABRINI GENERAL PRACTICE CABRINI TECHNOLOGY GROUP

CABRINI BRIGHTON

KEY: HEALTH SITES OFFICE SITES

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

YEAR IN REVIEW

Paul McMurrick Promoted to Professor The outstanding work of colorectal surgeon Paul McMurrick has recently been recognised by Monash University and Paul has been promoted from Associate Professor to Professor.

Professor Paul McMurrick started at Cabrini in 1999 after becoming a surgeon in 1996. Paul became a member of the Colorectal Surgical Society of Australia and New Zealand (CSSANZ) in 2001, and a Fellow of the American Society of Colon and Rectal Surgeons in 2009. In 2009, Paul was appointed Frölich-West Chair of Surgery and Head, Cabrini Monash University Department of Surgery. One of the major pillars of Paul’s success was the idea of creating a colorectal surgery database. The database was initially set up in 2006 then taken online in a webpage format at the start of 2010. For many years, this has been a huge success with the database collecting more than 370 data fields on every patient undergoing major colorectal surgery at Cabrini and Alfred hospitals. In 2014, the database was expanded to include Peninsula Health and Monash Health patients and now has clinical data for more than 4,700 patients. This excellent resource is used not only for research to improve patient outcomes but also as a key quality assurance tool within Cabrini.

In 2013, the success of Paul’s database was recognised by the CSSANZ (where Paul is a Councillor) and, using a reduced dataset for each patient, was rolled out across Australia and New Zealand. Currently, this bi-national colorectal audit has 435 surgical contributors over 93 sites and covers 35,000 patients. Paul remains a very active surgeon at Cabrini with a full clinical workload but this has not hindered his impressive clinical research output with 23 papers published in the last six years. If that wasn’t enough, Paul has also had immense success in competitive research grant funding in the last 15 years being involved with research grants totalling $6.6 million. This is in addition to large amounts of money for research raised through, and/or donated to, Let’s Beat Bowel Cancer (a benevolent fundraising and public awareness organisation), of which Paul is Chairman. We congratulate Professor Paul McMurrick on his past successes, his well-deserved promotion, and wish him well for all future achievements!

Professor Paul McMurrick 14

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

YEAR IN REVIEW

Farewell to Three Great Contributors and Welcome to a New Chief Executive

Associate Professor Peter Lowthian

Professor Lee Boyd

Associate Professor Peter Lowthian was our first Director of the Cabrini Institute, holding the role from 2002 until 2014. At the beginning of August Peter finished up at Cabrini after 17 years of service, the last five as Group Director Medical Services where he carried responsibility for relationships with our doctors as well as leading our clinical governance work. A Rheumatologist by professional background, Peter’s contribution in establishing the Institute was immense. He forged relationships with our University partners, particularly Monash University. He also developed strong relationships with a number of donors, and their generous contributions have been instrumental in enabling the Institute to grow over time. Professor Lee Boyd took over from Peter as Director of the Cabrini Institute in 2014. Lee was initially recruited to Cabrini Institute from Monash University as Manager of Education. Since taking over from Peter, Lee built on strong foundations and the Institute flourished as a result. Lee renewed our Clinical Education efforts and tirelessly promoted Cabrini Research, as exemplified by our Research Week which continues to grow year on year. In addition to mentoring researchers and supervising PhD students, Lee established the annual Cabrini Foundation Research Grants and, more recently, the Innovation Grants. Lee also led our

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Ms Sue Williams

Dr Michael Walsh

Patient Experience work, resulting in greater visibility for the customer view of Cabrini service delivery. Lee departed Cabrini in October 2019 following her appointment as Executive Director Learning and Teaching / Chief Nursing and Midwifery Officer with Eastern Health. Lee made a wonderful contribution to Cabrini Institute and to our participation in Monash Partners, a central element in the Institute’s future. In August 2019 Cabrini Australia Board Chairman Sylvia Falzon announced the appointment of Ms Sue Williams as the incoming Chief Executive. Dr Michael Walsh finished in that role after eleven years on 30 November 2019. Michael wished Sue well in her new job and thanked all in Cabrini Institute for their work over his time as Chief Executive. Michael said “It has been a joy to see the Institute punch above its weight in many areas, to forge new partnerships, and to expand our contribution to biomedical research and to clinical education”. Michael went on to pay tribute to and thank his colleagues on the Institute Council for their expertise and advice, and in particular the three Council Chairs with whom he served: Professor Lawry St Ledger, Professor Peter Fuller and Professor Meg Morris. He was sure that the Institute will go from strength to strength over the coming years, and wished everyone success.

YEAR IN REVIEW

COVID-19 Clinical Research

COVID-19 Advice to the Federal Government Since March, the Federal Governmentâ&#x20AC;&#x2122;s Infection Control Expert Group (ICEG) has been busy working on COVID-19. We congratulate Deputy Chair of ICEG, Associate Professor Philip Russo PhD, MClinEpid, BN. CICP-E, MACN, FACIPC, Director, Cabrini Monash University Department of Nursing Research, President, Australasian College of Infection Prevention and Control on his tireless and excellent work through the pandemic. The ICEG advises the Australian Health Protection Principal Committee (AHPPC) and its other standing committees on infection prevention and control issues. ICEG provides expert advice and information to support best practice related to infection prevention and control in community, hospital and other institutional settings.

Associate Professor Philip Russo

Dr David Sheffield and Dr James Pollard are Infectious Disease Specialists who are performing clinical research into COVID-19 infection. They are collaborating with researchers from the University of Melbourne to involve Cabrini Health in the Australasian COVID-19 Trial (ASCOT), a randomised clinical trial involving multiple hospitals in Australia and New Zealand to investigate possible therapeutic options to treat COVID-19. They are currently randomising patients to receive convalescent plasma, derived from donors who have recovered from COVID-19, and compare outcomes to those receiving standard of care. ASCOT is an adaptive trial, with options over time to investigate different potential treatments. They are also collaborating with investigators at the Alfred Hospital in a multi-site observational trial on the clinical course of COVID-19 infection. Clinical and pathological samples of consenting individuals suffering from COVID-19 will be correlated prospectively over time, to construct a biobank of data to further the understanding of the pathogenesis of COVID-19.

Dr David Sheffield and Dr James Pollard.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

1,700 COVID-19 PPE Training for over

staff from Marchâ&#x20AC;&#x201C;June 2020

= 100 C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Cabrini Research Week 2019 Cabrini hosts a research event every year to showcase and celebrate the clinical research being undertaken across the organisation. The week-long event from 7-11 October 2019, saw poster and oral sessions being held across multiple campuses, demonstrating the growth and strengthening of the research culture at Cabrini. This year’s event was generously supported by MIA Radiology.

The calibre of presentations was extremely high and a wide variety of topics and projects were presented. Dr Kune travelled from Modilon Hospital in Papua New Guinea to present his work on ‘Orthopedic Audit of 2018 and the challenges for Modilon General Hospital’. Dr Kune was the recipient of the John Griffiths Research Travel Scholarship, a joint initiative of Cabrini Outreach and Modilon Hospital in recognition of John Griffiths’ years of voluntary service to Modilon Hospital. We had the pleasure of holding this year’s highly anticipated keynote on the topic of ‘Researchers behaving

badly.’ A large gathering of people from a variety of disciplines from across campuses and Monash Partners filled the lecture rooms. Professor David Vaux AO, the Deputy Director of Walter and Eliza Hall Institute, focused his presentation on Research Integrity and highlighted where researchers are falling short. Professor Vaux was passionate about this topic, delivering an entertaining yet eye-opening talk, and made such an impact that folk from across Monash Partners sites called for an impromptu meeting to consider action. The program showcased a high calibre of presentations across a wide variety of research topics.

(Clockwise from left) Dr Tali Lang. Dr Simon Wilkins receiving his award from Dr Jeremy Druce representing our sponsors from MIA Radiology, Anne Spence and Professor Lee Boyd. The audience enjoying our Research Week keynote address by Professor David Vaux AO. 18

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Professor David Vaux AO entertaining the audience with his wonderful presentation.

This year’s awards and prize winners were:

Poster Session

•

Cancer-Care, Outcomes, Treatment and Biology – Dr Rebekah Engel ‘Using patient-derived organoids to predict treatment outcomes in rectal patients’ Improving Healthcare Systems – Associate Professor Philip Russo ‘The prevalence of healthcare associated infections among adult inpatients at nineteen large Australian acute-care public hospitals: a point prevalence survey’ Improving Healthcare Treatment – Dr Jason Wallis ‘Engaging in evidence-based osteoarthritis management program: Referrer and patient perspectives’ and ‘The experience of living with knee osteoarthritis: A systematic review of qualitative studies’ Outreach and Community – Professor David Kissane AC ‘The feasibility of implementing an innovative shared care model to treat cancer-related depression in the community’ Research Students – Caitlin Farmer ‘Consumer understanding of terms used in imaging reports requested for low back pain’ Medical Students – Dana Yen Lin Lee and Shiva Sridhar ‘Higher intraoperative haemoglobin levels protect renal function in cardiac surgery patients’

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

•

Dr Simon Wilkins ‘Australian recalibration of risk prediction models for 30-day mortality after surgery for colorectal cancer’ Associate Professor Anna Rosamilia ‘Hysterectomy or Uphold Uterine Conservation in women with apical prolapse: a parallel cohort study of 12 months’ Caroline Xue ‘Patient views and interest in integrating diet, exercise and other lifestyle measures into their standard cancer management’ Kavitha Gnanasambantham ‘Clinicians interest and attitudes to referring patients to a cancer lifestyle program’ Stephanie Groube ‘Consumer driven genetic testing in the self-funded era’

Best Cancer Poster – sponsored by MPCCC •

Karen Oliva ‘Influence of primary site on metastatic distribution and survival of early-stage colorectal cancer’

This year the poster session was opened to a public vote for best poster: •

People’s Choice Award’ for best poster – Claire Matthews Poster 22 ‘Development and Implementation of a pictorial hospital food menu’ Voting winner – Associate Professor Wei Wang

Cabrini Partnerships Partnerships with other research organisations are critical to the success of the Cabrini Institute. Successful partnerships strengthen the capacity of projects and services to broaden their reach, engage more stakeholders and achieve shared objectives. Our partnerships are both strategic and operational. Strategic partnerships are concerned with the broad program concept, scope, direction and planning; or operational, being concerned with resources, incentives, engagement and communication.

Our major partners are Monash University and the Monash Partners Academic Health Sciences Centre (MPAHSC). Monash Partners is Australia’s first Academic Health Science Centre (AHSC), and in 2015 was recognised by the National Health and Medical Research Council as one of four internationally leading centres of its kind in Australia. Since its inception in 2011, MPAHSC has worked as a collaborative force to improve the health and wellbeing of about 15% of Australia’s population, or 3.5 million people, throughout Melbourne’s south-east corridor. MPAHSC consists of a mix of public and private hospitals, health research and teaching organisations, and care for Victoria’s most culturally and diverse communities, where more than 100 different languages are spoken. The Department of Medical Oncology is a member of Cancer Trials Australia (CTA), which includes a large number of Victorian clinical sites, and a number interstate. CTA provides a range of benefits to network members. They support and strengthen the capacity and capability of the Institute via key service areas, including attracting clinical trials, developing strategic partnerships within the clinical trials sector, trial administration of ethics and governance activities, and financial administration of trial activity. The partnership has been extremely beneficial to the Department of Medical Oncology, and allowed significant expansion in trial activity. The Department of Epidemiology is a founding member of the Australia & New Zealand Musculoskeletal Clinical Trials Network (ANZMUSC), an international, multidisciplinary collaborative clinical trials network composed of clinicians, consumer groups, consumer representatives, policy makers, professional associations and funders with an interest in investigator-initiated clinical trials focusing on musculoskeletal conditions. The Department of Surgery is a founding member of the Australian Living Organoid Alliance (ALOA), a network of researchers from SAHMRI, Walter and Eliza Hall Institute (WEHI) and Monash University, whose mission is to enable Australian scientists and clinicians to use human organoid technology to improve outcomes for cancer patients. Organoids are tissues grown in 3D cultures from epithelial stem cells to model normal and disease processes. The Departments within the Institute partner with many other clinical, research, and benevolent organisations. These partnerships strengthen the organisation and allow us to provide better care for our patients.

KEY PARTNERS OF THE CABRINI INSTITUTE CANCER TRIALS AUSTRALIA (CTA) DIGITAL HEALTH COOPERATIVE RESEARCH CENTRE MONASH PARTNERS ACADEMIC HEALTH SCIENCE CENTRE (KNOWN AS MONASH PARTNERS) ACU ACU COLLEGE LA TROBE UNIVERSITY MONASH UNIVERSITY SWINBURNE UNIVERSITY UNIVERSITY OF MELBOURNE UNIVERSITY OF NOTRE DAME

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

83 Active Clinical Trials

= 10 trials C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Cabrini Institute Council The Cabrini Institute Council is responsible for overseeing and advising on the Cabrini Institute’s clinical education, research and health promotion strategies and governance. The group brings a broad range of clinical and managerial experience to the Cabrini Institute Council’s governance role.

PROFESSOR MEG MORRIS Member since February 2015, Chair from January 2019 Professor Meg Morris is a physiotherapist and fellow of the Australian College of Physiotherapists. She is Professor of Clinical and Rehabilitation Practice at La Trobe University and an Honorary Professor at James Cook University. She is an international expert in ageing and neurological conditions such as Parkinson’s disease and is widely published. Professor Morris is known for her allied health research policies and work on physical activity, exercise and dancing for people with neurological conditions. She has strong international research collaborations in Italy, Ireland, UK, USA, Thailand, and Singapore. DR EMMA BAKER Invitee since July 2015 (Maternity leave October 2019 – October 2020) Dr Emma Baker joined Cabrini in May 2015 and is the Director of Research. Emma has a research background in epigenetics and preclinical testing in cancer models and is a previous recipient of National Health and Medical Research Council and Cure Cancer Australia Fellowships. Her role includes organising the annual Cabrini Research Week, driving the research strategy at Cabrini including oversight of the oncology clinical trials program and undertaking activities to strengthen and build the reputation of research at Cabrini. PROFESSOR ALISON HUTCHINSON Member since November 2017 Alfred Deakin Professor Alison Hutchinson is a Registered Nurse and holds a Doctor of Philosophy from The University of Melbourne, a Master of Bioethics from Monash University and a Bachelor of Applied Science (Advanced Nursing) from La Trobe University. Alison is Chair in Nursing, Centre for Quality and Patient Safety Research at Monash Health, and Professor of Nursing in the School of Nursing and Midwifery at Deakin University. She 22

is Director of the Deakin University Centre for Quality and Patient Research in the Institute for Health Transformation. Throughout her career she has worked in a variety of clinical, management, education and research roles across a range of public and private healthcare settings. Her research interests centre on translation of research evidence into clinical practice and the care of older people. PROFESSOR JUDY LOWTHIAN Member since November 2018 Professor Judy Lowthian is the Head of Research and Principal Research Fellow at Bolton Clarke, an adjunct Professor in the Faculty of Health and Behavioural Sciences at The University of Queensland, and Associate Professor in the School of Public Health and Preventive Medicine at Monash University, and in the Institute of Future Environments, Queensland University of Technology. Her research is underpinned by a 25-year career as a speech pathologist and health service manager. Judy’s specific interest is health services research that is codesigned with end-users, to improve the quality and safety of care for older people. She is recognised internationally for her research in health services use and models of care for older people. PROFESSOR ROBYN E O’HEHIR AO Member since September 2010 Professor Robyn O'Hehir is an academic consultant physician, educator and internationally renowned medical researcher with more than 30 years' experience in adult medicine. She is Professor/ Director Respiratory Medicine (Research), Alfred Health, and Professor and Head of Department, Allergy, Immunology and Respiratory Medicine, Central Clinical School, Monash University. Robyn holds honours degrees in science and medicine and a doctoral degree in immunology. She is a fellow of the Royal Australasian College of Physicians, the Australian Academy of Health and Medical Sciences and the Thoracic Society of Australia and New Zealand. Robyn is an Officer of the Order of Australia and is on the Victorian Honour Roll for Women. She sits on the Health Innovation C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Advisory Committee of the National Health and Medical Research Council and is a Member of the Australian Institute of Company Directors. She serves as a Director of Cabrini Australia and sits on the Patient Experience and Clinical Governance Committee in addition to the Cabrini Institute Council. SOPHIE PENNINGTON Member since March 2019 Sophie Pennington is a partner at HWL Ebsworth and heads up the Melbourne Health Group. She has over 20 years’ experience as a litigation lawyer, specifically in the area of professional negligence in the health sector. Sophie acts for public and private hospitals, pathology and radiology clinics and individual medical practitioners in negligence claims, coronial inquests, disciplinary matters and employment disputes. She also advises on emerging health issues including voluntary assisted dying, electronic medical records and human rights issues in the health context. Prior to returning to private practice Sophie spent seven years in-house at Australia’s largest medical defence organisation. SUE PARKES Invitee since July 2015 Sue Parkes, Director of the Cabrini Foundation, has more than 20 years’ experience working in not-for-profit organisations including some of Australia’s leading non-government organisations. Sue has held leadership roles at Melbourne City Mission, Sacred Heart Mission, Brotherhood of St Laurence and Eastern Health. She has a strong commitment to social justice and is currently on the Board of the Fitzroy Learning Network. PROFESSOR JULIAN SMITH Member since July 2015 Professor Julian Smith is Head of the Department of Cardiothoracic Surgery at Monash Health, Head of Monash University’s Department of Surgery and Deputy Head of the School of Clinical Sciences at Monash Health. He has served as a Counselor of the Royal Australasian College of Surgeons and as a Board Member of several secondary and tertiary education organisations. He is a consultant cardiothoracic surgeon at Monash Health and has broad basic and clinical research interests in robotic and minimally invasive surgical techniques, acute kidney injury after cardiac surgery, utilising large databases to monitor patient outcomes and in surgical education. He is currently Editor-in-Chief of the ANZ Journal of Surgery.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

PROFESSOR GARY RICHARDSON OAM Member since January 2020 Professor Gary Richardson is the Director of the Cabrini Institute Research and Education, and the Szalmuk Family Department of Medical Oncology in the Cabrini Institute. He is a past chairman of the Medical Oncology Group of Australia and immediate past-president of the Private Cancer Physicians of Australia. He is a member of ASCO’s International Affairs Committee and the MOGAPBAC Working Party. He established the oncology clinical research program at Cabrini, the Cabrini Family Cancer Clinic and the Oncology Service at Cabrini Brighton. He was awarded the Medal of the Order of Australia in 2017. SUE WILLIAMS Member since January 2020 Sue Williams was appointed Chief Executive of Cabrini Australia in December 2019. She has more than 25 years’ experience in the healthcare industry at senior management level in both the public and private sectors. She has held various roles including the Director of Nursing at the Royal Melbourne Hospital, Chief Operating Officer of 44 hospitals at Healthscope and Chief Executive Officer at Peninsula Health. Sue originally trained as a nurse and has postgraduate qualifications in business management and a Master of Business Administration from Monash University. She has completed an Advanced Management Program at Harvard University and the Australian Institute of Company Directors course. She joined Cabrini as Chief of Health Operations in October 2017. ANTHONY GRECH Member since January 2020 As Cabrini’s Director of Financial Planning & Analysis (DFPA), Anthony holds responsibility over budgeting and management reporting functions across Cabrini Australia Ltd. Prior to joining Cabrini he has worked extensively in both public health services in metropolitan Melbourne in management accounting and business support roles. Anthony is a certified practicing accountant and holds a Bachelor of Commerce degree majoring in Accounting. ANNE SPENCE Invitee since October 2019 Director of Infrastructure.

Message from the Director, Cabrini Foundation Following on from the increase in 2018-19, the ongoing generous support of our donors has enabled Cabrini to maintain our commitment to fostering research and education in 2019-20. The year saw numerous scholarship opportunities delivered to our nursing staff, as well as $620,000 of grants dispersed across a range of areas to support Cabrini research projects.

The continued generosity of donors is heartening evidence of the high level of gratitude Cabrini patients, their families and friends have for the excellent care they have received. We continue to work closely with donors to facilitate their wishes to invest in the future of care at Cabrini.

Scholarships Scholarships present an ideal way for our donors to thank Cabrini by supporting staff to further their skills and training, ultimately improving the care that Cabrini can provide to patients in the future. In 2019, $136,000 was raised to fund scholarships covering the areas of nursing, leadership, cancer, midwifery, cardiac and team collaboration. $79,112 was awarded in scholarships in 2019-20. Due to coronavirus the first priority for our nursing staff has been on patient care, we will continue to encourage staff to upskill once the pandemic situation improves. In 2019, a new scholarship was created in memory of Margaret Grenda, who passed away at Cabrini Malvern. Margaret, together with her husband Ken and their family, have been supporting Cabrini for many years. Margaret was a dear friend of Cabrini Foundation. She spent her last days being nursed at Cabrini and the Grenda family have named a leadership scholarship in Margaret’s honour to express their appreciation for the outstanding care she received. This annual scholarship will support further training of aged care nursing staff who care for our most vulnerable patients. With the current COVID-19 pandemic tending to affect the more susceptible in our community, the training and upskilling of aged care workers is more relevant now than ever. We thank Ken, Margaret and their family for their ongoing support of Cabrini and look forward to awarding this scholarship in 2020.

Auric Innovation Grant For the second year, Cabrini donors Brian and Lee Johnstone have generously funded the Auric Innovation Grant, an opportunity for a Cabrini staff member to fund their next BIG IDEA. This grant encourages staff members to innovate and develop projects which elevate Cabrini’s position as a leading healthcare provider. Two applicants were funded in 2019. In 2020 Professor Gary Richardson OAM, Director of Cabrini Institute and his team were the successful recipients of this grant to set up the Academic Exercise Physiology program. The aim of the Academic Exercise Physiology program is to research the benefit of specific and independent exercises on cancer patients to improve their quality of life. This research project is the first of its kind in Australia, and will build on Cabrini’s already established cancer expertise as the biggest private cancer service in the country.

Cabrini Foundation Grant Round Cabrini Foundation has proudly awarded $420,000 in 2019-20 to support research projects which align with Cabrini’s strategic objectives.

Lung Research Project: Development and Implementation of a Patient-Reported Outcome Measures Instrument for Lung Cancer Patients Lung cancer is one of the most common cancers in Australia. For the patient, the focus on simply surviving cancer can be all encompassing. It is important that we also care for patients’ emotional and functional wellbeing to ensure that their quality of life is protected both during and after their treatment. With the generous support of some special donors,

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

in 2020 Cabrini will develop a comprehensive lung cancer database incorporating patient reported outcome measures (PROMs) in partnership with the Victorian Lung Cancer Registry. This will allow understanding of the patient’s physical, mental and social perspectives throughout each stage of their cancer experience. It offers the potential to enable more personalised treatment and drive improvements in the quality of care.

Veronica Png bequest Cabrini is very grateful for the remarkable opportunities made possible by Veronica Choo Neo Png’s bequest. Veronica wanted her gift to both support complementary therapies for patients receiving palliative care at Cabrini, and to further pancreatic cancer research at Cabrini Institute. Her gift has allowed Palliative and Supportive Care at Cabrini to extend its Music Therapy program to a 3-day-aweek program, and to commence an Art Therapy Program in July 2020, improving the wellbeing of patients at Prahran. Art therapy was previously provided by a trained volunteer, and Veronica’s bequest has enabled Cabrini to now develop a more sustainable service. In line with her wishes, Veronica’s gift will also be used to establish a dedicated pancreatic cancer database as a repository for all patient information, ranging from patient experience, to clinical outcomes, to genomic and epigenetic information. These data are complex and heterogeneous, consequently, the storage, mining, retrieval and analysis of these data in an efficient and meaningful manner is of paramount importance. An increased volume of data and new data types, such as PROMs and patientreported experience measures (PREMs), clinical imaging and biomarkers, will dramatically increase the power of the knowledge system and offer new insights into cancer biology and potential treatments.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

$620k

GRANTS SUPPORTING CABRINI RESEARCH PROJECTS

Thank you We would like to thank our donors for creating a learning environment for staff throughout Cabrini to explore opportunities to further their careers and also build on the high quality care that Cabrini offers. It takes leadership from our donors to support the Institute’s culture of research and innovative thinking, and we are grateful for the support of our donors in enabling the expansion of research and innovation at Cabrini. If you wish to donate to Cabrini’s Scholarships and Grants program, please call Cabrini Foundation on (03) 9508 1390 or email foundation@cabrini.com.au.

SUE PARKES DIRECTOR, CABRINI FOUNDATION

Scholarships and Grants at Cabrini For the 2019-20 period, a massive combined value of $699,112 was awarded across the entire education scholarships and research grants program, despite the impact of COVID-19.

More than $79,000 of this was scholarship funding, awarded across a multitude of disciplines. This encompassed the main scholarship round as well as nine postgraduate nursing program positions and 13 medical student scholarships, just to name a few. In essence, the purpose of the Scholarship program is to: - Honour the intent of funds donated by patients of Cabrini and their families, as well as funds provided by the Cabrini Medical Staff and Cabrini Institute; - Award these funds to Cabrini staff to support their education and the workforce need (excluding mandatory clinical practice requirements); - Positively impact as many departments and disciplines across Cabrini as possible; - Distribute donor funds responsibly, transparently and equitably; - Ensure good reporting of the funded activity outcomes; and - Engage with our donors. Scholarships awarded in the main round included: Paul Archbold – Postgraduate Scholarship Angela Baird – Richard Nossbaum Scholarship Sharni Clark – Aged Care Scholarship Jo Mcleod – Postgraduate Scholarship Monica Palise – Brian Sutton Scholarship Sonya Imbesi – Maureen Coomber Scholarship Sarah Paterson – Brian Sutton Scholarship James Sherwood – Maureen Coomber Scholarship Rachle Varias – Brian Gillies Palliative Care Scholarship Alice Wandke – Jean St Leger Scholarship Summer Xia – Peter Meese Scholarship Likewise, the 2019-20 period saw a total of $620,000 research grants awarded collectively, encompassing the AURIC Innovation grant and the Foundation grant round. Specifically, the grants program purpose is to provide a single mechanism for Cabrini employees and visiting medical officers (VMO’s) accessing funds from Cabrini Foundation 26

for research or quality improvement activities. The Cabrini Foundation is committed to supporting quality improvement activities and research that facilitates the strategic and operational program articulated in the Cabrini Strategic Plan. The objectives of this grant program are to: • Facilitate a research culture within the organisation • Encourage multidisciplinary research; and • Produce high quality clinical research. There are three categories of Foundation Grants: 1. Quality Improvement Projects (two grants up to $15,000 each). Designed for staff/teams engaged in quality projects. 2. Research Projects (four grants up to $30,000 each). Designed for experienced researchers/teams. 3. Specific purpose research grants in line with donor intent. Measures of success for the grants program objectives are to identify: 1. Increased numbers of multidisciplinary research projects within Cabrini. 2. Research projects aligned with the Cabrini Strategy. 3. Contributions to quality and safety. In June 2020, members of Cabrini’s grant review panel convened to review applications and select the successful recipients of Cabrini Foundation’s annual Clinical Research and Quality Improvement grant round. Led by Sylvia Falzon, Chairman of the Cabrini Foundation Board – the review panel discussed 19 shortlisted applications from an incredibly diverse group of disciplines and research areas. Ultimately, the following studies were deemed successful: Emily Bell – Using supported motivational intervention (SUMIT) to improve physical activity in people with knee osteoarthritis. Dr Rebekah Engel – Personalising cancer medicine: the development of a high throughput drug screening platform using patient derived colorectal cancer organoids. Dr Denise O’Connor – Evaluating a patient decision aid for people with degenerative knee disease considering arthroscopic surgery: a randomised controlled trial. C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Dr Merlina Sulistio & Associate Professor Natasha Michael – A prospective open label study of methadone rotation for the treatment of cancer induced bone pain. Associate Professor Michael Ben-Meir – My Health Record in the emergency department: An investigation of adoption, utilisation and utility. Associate Professor Natasha Michael – Efficacy of an ambulatory supportive care clinic on patient reported outcomes and clinical service utilisation: A retrospective, single centre observational study. Dr Tali Lang – Development of a comprehensive lung cancer database incorporating patient reported outcome measures to interact with the Victorian lung cancer registry. Professor Gary Richardson OAM – Development and implementation of a gynaecologic cancer database. Associate Professor Philip Russo – The experience of the healthcare worker during the COVID-19 response. Associate Professor Philip Russo – The effect of COVID-19 on healthcare associated infections in a multicampus private healthcare facility. Kirsten Seletto & Dr Tali Lang – Is there a relationship between frequency of port-care maintenance and associated complications in oncology patients? The successful projects will vary in duration from 12-month to 24-month studies. All recipients are required to disseminate their research findings via presentation at Cabrini Research Week, submission of manuscripts for publication in peer review journals, and submission of abstracts to present at domestic and international conferences.

Auric Innovation Grant Round Additionally, the Auric Innovation grant is a specific grant that supports the development of innovation across Cabrini. The grant is for up to $200,000 per year and can be awarded for use by any campus or department across Cabrini. The grant is made possible thanks to the generosity of major donors Brian and Lee Johnstone, through the Cabrini Foundation. C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Sambor Family – perpetual donors of the ‘Sambor Family Award’ given to the best application for a research grant each year. Pictured is the late Susi Sambor (bottom middle) and son Perry (top middle) long time supporters of research at Cabrini.

AURIC is open to leaders, potential leaders, thinkers, planners and developers in their field, at any stage of their career. This year saw a large number of very high calibre applications, with the recipient of the $200,000 Auric Innovation Grant, Professor Gary Richardson OAM for his project ‘Development and Implementation of an Academic Exercise Physiology Program at Cabrini’. As always we express our sincere gratitude to the numerous donors that give so generously to ensure these important sponsorship programs can live on within the Cabrini community. Details on how to become involved as a donor can be found through the Foundation. 27

Many thanks to our supporters The Cabrini Foundation is grateful to our generous supporters, both those listed and those who wish to remain anonymous.

Institute donors

Institute Bequestors

In Memory of Beverley Barlow Percy Baxter Charitable Trust Colin and Imelda Bourke Maureen Coomber The Alfred & Jean Dickson Foundation Robert A Dunster Collie Foundation Rodney & Ann Smorgon Family Brendon Finnegan Professional Development Scholarship Prue and Brian H Gillies Palliative Care Nursing Scholarship and Research Fund Judi & Michael Gronow Mr Alan Jackson AO & Mrs Esme Jackson Mr John Laidlaw AO & Mrs Betty Laidlaw Eirene Lucas Foundation Mr David and Mrs Barbara MacDonald Mr Louis Mangan AO & Cecile Mangan Peter Meese Cancer Nursing Fund Nancy Fay Nicholson Richard and Dorothea Nossbaum The Moniek Sambor Family Memorial Research Fund – The Sambor Family The Sasse Family Richard Smith The Lionel and Yvonne Spencer Trust Mr George and Mrs Mira Szalmuk Szalmuk Family Department of Medical Oncology Mrs Anne Wollach-Szalmuk Mr Geofff Szalmuk Mrs Simone Szalmuk-Singer Michael and Donna Tricarico & Family Brian and Lee Johnstone Auric Innovation Fund In Memory of Lyndell McLaughlin

Elaine Louise Benger Nance Nevasa Buchanan Dr Betty Elliot Harold Francis Pamela Golding John Sutherland Hamling Florence Johannes Doreen Johnson Heather Jones Douglas Alan Keillor Irene Kozica Belinda Lim June Masson Veronica Choo Neo Png Paula & Alexander Reinders Grace Saunders Leslie Alfred Shapland Brian J Sutton FRNA Hugh Lauder Wallace

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

89.7 Total grant funding held and awarded up

from last year to $91M

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Our Research

01. 30

Dr Rebekah Engel is a Senior Postdoctoral Research Fellow at the Cabrini Monash University Department of Surgery. She is pictured using the organoid seeding machine donated through LBBC. C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

+$1.88m IN GRANT FUNDING

P U B L I C AT I O N S

P R E S E N TAT I O N S

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Cabrini Monash University Department of Nursing Research

Head: Associate Professor Philip Russo As we are vividly experiencing in 2020, the threat of emerging infectious diseases presents many challenges. Together with healthcare associated infections, novel viruses such as the coronavirus (COVID-19) underline the importance of infection prevention in the provision of safe healthcare, both in the community and the healthcare setting.

Director Associate Professor Philip Russo Research Assistant Elizabeth Todio PhD Students Ali Tehrani, Monash University Angela Ballard, Monash University Pheona van Huizen, Monash University Masters of Advanced Practice Khanh Truong, Monash University Honours Shanely Miranda, Deakin University Cabrini Medical Staff Research Scholarship Carmela Cosentino, Monash University Acknowledgement of Staff who have left (2019-2020) Professor Lee Boyd, former head of Department Julia Caissutti, Research Assistant

Nurses have the highest and most intimate contact with patients, and therefore are crucial in the prevention of infection transmission. Research being conducted by the Cabrini Monash University Department of Nursing Research will help improve our understanding of infection transmission, prevention and identifying those patients who are at greater risk. The recently completed study on the prevalence of healthcare associated infections in large public hospitals will be repeated at Cabrini to identify the prevalence in the private setting. This information will assist in identifying preventative strategies in the future. The use of invasive devices will also be measured in this study, and these findings will inform value-based strategies moving forward. This work aligns well with the Cabrini Institute strategy of the use of data to inform strategy, improve patient quality and safety, and strengthen value-based care. The Nursing Research Department is excited to be undertaking two further studies relating to our current response to COVID-19. The first will be exploring the experience of healthcare workers at Cabrini during the response to COVID-19. This will help us understand what worked well at Cabrini and identify any areas where improvements could be made for preparedness for future emerging threats. Many of the infection prevention activities implemented and scaled up as part of the response are fundamental to all infection prevention. So in the second study, we are aiming to identify if these preventative activities also had an impact on other types of infection. Clearly the impact of infections on patients can be significant. A previous study informed us that consumers are interested in understanding more about the frequency of healthcare associated infections. Other work that we are currently involved in is exploring the impact of infections on consumers. This is a collaboration being undertaken with external researchers and involves speaking to patients who have acquired an infection and understanding the impact this has had on their lives.

Highlights As a fledgling research department, the Cabrini Monash University Department of Nursing Research has had a number of highlights. We are delighted to welcome an increase in staff with the appointment of a research assistant, and a new research fellow to assist with the new projects. The department was successful in being awarded two

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Cabrini Institute Alan Jackson Research Grants. This will allow us to undertake two exciting projects related to COVID-19. Director Philip Russo is also involved in a number of leadership roles. He is the President of the Australasian College for Infection Prevention and Control and was recently appointed Deputy Chair of the Infection Control Expert Group to the Australian Department of Health. He is also a member of the COVID Evidence Taskforce Steering Committee, the Australian Strategic and Technical Advisory Group on Antimicrobial Resistance, the Healthcare Associated Infection Advisory Committee to the Australian Commission on Safety and Quality in Health Care, and is also a member of the Australian College of Nursing.

Our Research The effect of COVID-19 on healthcare associated infections in a multi-campus private healthcare facility. RESEARCHERS: RUSSO P (PI), RENTON R (CI), WANG W (CI), MITCHELL B (CI).

Preparedness and response to COVID-19 has resulted in a heightened awareness of infection prevention. An increased emphasis on infection prevention education for all healthcare workers, hand hygiene, cleaning and the use of personal protective equipment are some of the interventions that have been implemented. These fundamentals of infection prevention should also prevent all healthcare associated infections. This study will measure the impact on the infection prevention interventions implemented for COVID-19 has on other healthcare associated infections.

The experience of the healthcare worker during the COVID-19 response. RESEARCHERS: RUSSO P (PI), ILANGAKOON C (CI), RICHARDSON G (CI), BEN-MEIR M (CI).

Healthcare workers (HCW) are at the forefront of the COVID-19 pandemic. Previous pandemics have demonstrated that HCWs are required to respond quickly and adapt to new situations, and manage the threats posed by caring for patients with highly infectious diseases. Despite the amount of preparedness, the novelty of pandemics will present many new challenges. The aim of this study is to explore the HCWs experience during preparations and response to COVID-19, and to identify what worked well and areas that could be improved, during this unprecedented event. Improved Detection of Infections Following Surgery for Meaningful Public Reporting. RESEARCHER: RUSSO P

Surveillance for surgical site infections is resource intensive and consistent application of definitions is challenging. International studies have demonstrated that by applying a uniform algorithm sourcing data from microbiology, admissions, pharmacy and operating room, patients who have an infection are easier to identify. This project is exploring the use of algorithms in the Australian setting that will generate more meaningful and accurate data that could be used for public reporting.

Associate Professor Philip Russo presenting at the 2019 Peter Meese Lecture.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

... novel viruses such as the coronavirus (COVID-19) underline the importance of infection prevention in the provision of safe healthcare, both in the community and the healthcare setting... The department was successful in being awarded two Cabrini Institute Alan Jackson Research Grants. This will allow us to undertake two exciting projects related to COVID-19.

ASSOCIATE PROFESSOR PHILIP RUSSO

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

+$65m IN GRANT FUNDING

P U B L I C AT I O N S

P R E S E N TAT I O N S

ACTIVE CLINICAL TRIALS

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Monash-Cabrini Department of Clinical Epidemiology

Head: Professor Rachelle Buchbinder AO We conduct high-quality clinical research and drive translation of research knowledge into practice and policy change for improved healthcare. Our work strives to optimise the value of healthcare, reduce low-value care arising from over-diagnosis and over-treatment, and identify ways to create a more sustainable healthcare system able to support future generations. We engage consumers as advisors, partners and participants in our research.

Director and NHMRC Senior Principal Research Fellow Professor Rachelle Buchbinder AO Deputy Director, NHMRC Translating Research into Practice (TRIP) Fellow, Senior Research Fellow and Director of Australasian Satellite of Cochrane Effective Practice and Organisation of Care (EPOC) Dr Denise Oâ&#x20AC;&#x2122;Connor Managing Editor of Cochrane Musculoskeletal Dr Renea Johnston Executive Officer, NHMRC, Centre of Research Excellence for the Australia & New Zealand Musculoskeletal (ANZMUSC) Clinical Trials Network and Postdoctoral Research Fellow Dr Allison Bourne Biostatistician Dr Lucy Busija

Assistant Managing Editor of Cochrane Musculoskeletal Dr Sheila Cyril Postdoctoral Research Fellows Dr Emma Gearon Dr Romi Haas Dr Polina Putrik Dr Jason Wallis Dr Tom Rozbroj Research Fellows Dr Liesl Nicol Dr Jodie Avery Melanie Hawkins, Honorary Research Fellow Dr Teemu Karjalainen, Visiting Honorary Fellow (Finland) Dr Lars Christian Haugli BrĂĽten, Visiting Honorary Fellow (Norway) Practitioner Fellow Dr Sam Whittle Project Manager, Targeted Therapies Alliance Program Dr Vanessa Glennon

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Australian Rheumatology Association Database (ARAD) Vibhasha Chand, Data Manager Ashley Fletcher, Project Officer Research Assistant and Assistant Managing Editor for Cochrane EPOC Jia Xi (JC) Han Research Assistant, PCHSS and Targeted Therapies Alliance Program Bayden McKenzie Administrative Assistant Elizabeth Wolff PhD Students Dr Bethan Richards, PhD (University of Sydney, 20112019) Michael Di Donato, PhD (Monash University, 2017-) Caitlin Farmer, PhD (Monash University 2017-) Liana Cahill, PhD (La Trobe University, 2016-) Gayanika Senarath, PhD (Monash University, 2019-)

Pramila Rai, PhD (Monash University, 2020-) Jade Ting, Honours (Monash University, 2020-) Ahinsa Gunatilaka, Cabrini Medical Staff Research Scholarship Program (Cabrini Institute and Monash University, 2020) Dana Lee, Cabrini Medical Staff Research Scholarship Program (Cabrini Institute and Monash University, 2020) Xin Kwok, Cabrini Medical Staff Research Scholarship Program (Cabrini Institute and Monash University, 2020) Shiva Sridhar, Cabrini Medical Staff Research Scholarship Program (Cabrini Institute and Monash University, 2020) Acknowledgement of Staff who have left (2019-2020) Dr Aislinn Lalor, Postdoctoral Research Fellow Dr Amanda Cross, Postdoctoral Research Fellow Cathy Matthews, Administrative Assistant

Highlights Professor Buchbinder AO was recognised in the Australia Day Honours 2020 and became an Officer of the Order of Australia for ‘distinguished service to medical education in the fields of epidemiology and rheumatology, and to professional associations’. Seven staff and students from our department attended the International Preventing Overdiagnosis Conference in Sydney on 5-7 December 2019 and delivered nine presentations (including a plenary presentation by Professor Buchbinder AO on ‘Wiser healthcare for musculoskeletal conditions’). Professor Buchbinder AO contributed to the conference scientific committee and Dr O’Connor contributed to the local organising committee. Dr O’Connor also delivered a plenary presentation at the Rehabilitation Medicine Society of Australia and New Zealand Annual Scientific Meeting in Adelaide on 20-23 October 2019 on ‘The landscape of research translation in back pain: what do we know and where to next?’ The Wiser Healthcare Collaboration National Scientific Meeting was organised by our department and hosted at Cabrini Institute on 4-5 March 2020. Cabrini Chief Executive Sue Williams and Professor Buchbinder AO opened the meeting and participants included representatives from the Commonwealth Department of Health, Safer Care Victoria and the Australian Deprescribing Network.

Our Research We are a large research department of over 30 research staff and students conducting numerous research projects. Below are three examples of projects being undertaken in the department. Living guidelines for the management of rheumatoid arthritis RESEARCHERS: BUCHBINDER R, WHITTLE S, JOHNSTON R, GLENNON V, NICOL L, AVERY J, MCKENZIE B, O’CONNOR D AND TARGETED THERAPIES ALLIANCE PROGRAM AND ANZMUSC COLLABORATORS

Rheumatoid arthritis involves chronic inflammation of the joints and other tissues resulting in pain, deformity and disability. Early use of disease modifying medicines can suppress disease activity and prevent joint damage. As part

(L-R) Professor Lee Boyd and Dr Denise O’Connor at Cabrini Research Week 2019 Poster Session.

of a three-year Targeted Therapies Alliance Program, we are developing a living clinical practice guideline for the pharmacological management of adults with rheumatoid arthritis. This guidance will assist medical practitioners to provide evidence-based care to people with rheumatoid arthritis based on up-to-date syntheses of best available evidence with the aim of optimising health outcomes for patients. The Targeted Therapies Alliance Program is funded by the Australian Government and involves a consortium of health organisations including ANZMUSC, Cochrane Musculoskeletal, Australian Rheumatology Association, NPS MedicineWise and other partners. Systematic reviews of alternative models of care with potential to enhance health system sustainability RESEARCHERS: BUCHBINDER R, O’CONNOR D, PUTRIK P, GEARON E, NICOL L, WALLIS J, MCKENZIE B AND PCHSS COLLABORATORS

Sustainability of healthcare systems is a key challenge worldwide. Our recent scoping review of systematic reviews has identified a number of models of healthcare delivery that provide alternatives to traditional models and that could increase sustainability by reducing costs while delivering equal or better outcomes for patients. Funding from the NHMRC Partnership Centre for Health System Sustainability

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

is being used to generate Cochrane systematic reviews of alternative models of healthcare delivery identified as high priority by policy-makers, health service managers, clinicians, consumer experts and academics. The models of care being investigated include provision of primary and/or specialist care to older adults living in aged care facilities and provision of chemotherapy at home vs. in hospital. Rigorous reviews of the value (effectiveness, cost-effectiveness and safety) of promising alterative models will inform future health system decision making. Meta-synthesis of qualitative research exploring how patients and the public understand over-testing and over-diagnosis RESEARCHERS: ROZBROJ T, HAAS R, Oâ&#x20AC;&#x2122;CONNOR D, BUCHBINDER R AND WISER HEALTHCARE COLLABORATORS

Over-testing is when diagnostic tests that are not needed are used. Over-testing can lead to over-diagnosis which is when a diagnosis is made according to professional guidelines or standards but is unlikely to alter care and benefit the patient. Funding from the NHMRC Wiser Healthcare Collaboration is being used to conduct a thematic meta-synthesis of primary qualitative research exploring patient and public understanding of over-testing and over-diagnosis in order to identify common themes, inform the design of communication strategies about over-testing and over-diagnosis, and identify future research priorities.

Grant Success Profile In the 12 months of this report we hold and have been awarded 31 grants totaling over $65 million. One important area of our departmentâ&#x20AC;&#x2122;s research over the past year has been the Targeted Therapies Alliance Program grant, funded by the Australian Government ($8.4 million over three years). The aim of the program is to optimise the quality use of medicines, including diseasemodifying anti-rheumatic drugs, to achieve better health outcomes for people with chronic inflammatory conditions. The program involves a consortium of health organisations including NPS MedicineWise, ANZMUSC, Cochrane Musculoskeletal, Australian Rheumatology Association, Arthritis Australia, Council of Australian Therapeutic Advisory Groups, Pharmaceutical Society of Australia, Quality Use of Medicines and Pharmacy Research Centre at the University of South Australia and the Society of Hospital Pharmacists of Australia. Our department is leading the development of living clinical practice guidelines for rheumatoid arthritis and contributes to other evidence-based tools, resources and interventions including clinician decision support algorithms, patient decision aids, clinician feedback reports, and educational webinars and resources. The program is facilitating increased collaboration between health practitioners and patients with inflammatory conditions about these complex medicines and is likely to lead to better quality use of medicines and better patient outcomes.

IN THE 12 MONTHS OF THIS R E P O RT W E H AV E H E L D AND BEEN AWARDED

G R A N T S TOTA L I N G OV E R $65 MILLION

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

+$3.7m IN GRANT FUNDING

P U B L I C AT I O N S

P R E S E N TAT I O N S

ACTIVE CLINICAL TRIALS

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Cabrini Monash University Department of Surgery, The Frรถhlich West Chair of Surgery Head: Professor Paul McMurrick Safety in Surgery through research: The cornerstone of all our research is the colorectal neoplasia database allowing us to carry out a large number of clinical research projects. For example, research projects investigate which patients are at most risk of developing complications after surgery, which patients might have a recurrence of their cancer, and how we can improve cancer care for improved patient outcomes.

Head of Department Frรถhlich West Chair of Surgery Professor Paul McMurrick Consulting Surgeons Mr Stephen Bell, Colorectal surgeon, Senior Lecturer Mr Peter Carne, Colorectal surgeon, Senior Lecturer Mr Martin Chin, Colorectal surgeon and

Director of Colorectal Fellowship Program Mr Chip Farmer, Colorectal surgeon, Senior Lecturer Emeritus Professor Adrian Polglase Mr Pravin Ranchod, Colorectal surgeon, Lecturer Mr Paul Simpson, Colorectal surgeon

Mr Raymond Yap, Colorectal and Academic surgeon, Research Fellow Dr Evan Williams, Colorectal Fellow Dr Gemma Solon, Colorectal Fellow Senior Research Fellows Dr Simon Wilkins

Dr Rebekah Engel Dr Christine Koulis Database Manager Karen Oliva PhD Students Stephen Bell, Monash University Sara Hlavca, Monash University Honours Student Claudia Corrente

In conjunction with clinical governance at Cabrini Hospital, we have a quarterly quality assurance loop to ensure that not only are the overall results for the treatment of bowel cancer at Cabrini at an international standard but also that the individual outcomes of every surgeon are scrutinised and reported.

Personalised medicine tissue platform Through our three main collaborative projects with Monash University, namely organoids, tissue microarray and the new tissue-slice assay, we are able to match individual tumour responses to drug treatments, gene expression, and immune responses in the laboratory to clinical data in the colorectal neoplasia database on patient outcomes and the success of their treatment. When combined, these three major projects will have the potential to personalise treatment for each bowel cancer patient in the future.

Highlights 1. Colorectal Cancer organoid program Our program is developing a high throughput screening platform to test known and

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

novel compounds with anti-cancer properties on patientderived tumour organoids. Organoids are “mini-organs” that can be grown in a laboratory dish, recapitulating the features of the tissue from which they are derived. This project aims to not only determine the likelihood of a patient responding to treatment before they receive it in the clinic, but to create a platform for testing novel compounds that may have efficacy for the treatment of CRC. Grant award: •

•

Eirene Lucas Foundation ‘Anti-cancer compound library resource for drug discovery’ (2019-2020) $10,000 Engel, R (CI) McMurrick, P (CI) Cabrini Foundation Research Grant ‘Personalising cancer medicine: the development of a high throughput drug screening platform using patientderived colorectal cancer organoids’ (2020-2021) $30,000 Engel, R (CI) McMurrick, P (CI)

Presentation at a national conference: Engel, R 'Organoids as a model for colorectal cancer: the first 50 patient lines' ASSCR - AGCTS - ISCT ANZ 2019 Joint Scientific Meeting, Brisbane, 13th-15th November 2019 Significant Publication: Engel, R et al., (2020) Patient-derived colorectal cancer organoids upregulate revival stem cell marker genes following chemotherapeutic treatment. J Clin Med. 9, 128

Our Research Highlighted project: The Colon Cancer Tissue Microarray Project Personalised medicine allows a tailored approach to medical treatment based on each patient’s specific biology and relies on scientifically developed correlations between responses to treatment and specific biomarkers. The colon cancer tissue microarray project aims to personalise treatment for colon cancer patients by creating a valuable resource to understand each patient’s biology. We create tissue microarrays, comprising of tumour and normal tissue taken from the patient at the time of surgery, and correlate between specific biomarkers of interest and patient outcomes through proteomics. We are on target to complete over 1000 patients with up to five years follow-up by the end of 2020. The results from this study will provide important novel prognostic and predictive information that may identify factors that can influence chemotherapy choice, leading to more personalised streamlining of therapy to each individual patient, as well as identifying new protein targets that could form the basis of targeted therapies. Highlighted project: The prognostic implications of primary tumour location on recurrence and patient outcomes in early-stage colorectal cancer

Mr Raymond Yap re-joined Cabrini after a fellowship at AdventHealth Orlando, under world leaders in advanced minimally invasive surgery, Professor John Monson and Professor Matthew Albert. Mr Yap, previously clinical colorectal fellow in 2015, has now been appointed to coordinate research projects. Mr Yap will be able to provide our research fellows with a clinical eye to their research and together the team strives to break new ground in combating bowel cancer through research.

There is significant interest in identifying markers of indicators to predict outcomes including tumour recurrence and patient survival from colorectal cancer. This project aims to examine the implications of tumour location in early colorectal cancer on recurrence and outcomes. This project shows that overall and cancer-specific survival is worse in those patients with right-sided tumours. A paper from this project is under review at the journal Diseases of the Colon and Rectum. This project also won best MPCCC cancer poster award at last year’s Cabrini Research Week: Oliva K, Bell S, Wilkins S, McMurrick P (2019) Influence of primary site on metastatic distribution and survival of early-stage colorectal cancer.

3. Peri-operative care

Selected other projects:

Oversewing staple lines and the relationship to anastomotic complications in colorectal cancer

Screening and prevention

2. New Team Member

•

RESEACHERS: BAQAR A, WILKINS S, OLIVA K, MCMURRICK P

Comparison of outcomes of colorectal cancer depending on patients within the screening ages

During bowel cancer surgery an anastomosis can be formed with a surgical stapler or hand sewn. This project aims to examine whether oversewing staple lines reduces postsurgical complications for patients.

Perioperative care

Podium Presentation and award at an national conference:

•

Wilkins S (2019) The post-operative effect of oversewing stapled anastomoses in colorectal cancer surgery. AGITG Annual Scientific Meeting 21-23rd August 2019 Adelaide, Australia Best Fast Forward Presentation

• •

Publication: Baqar, A et al., (2020) The post-operative impact of oversewing stapled anastomoses in colorectal surgery: A retrospective Australian cohort study. International Journal of Surgery Open 24:91-95. 42

•

The impact of double stapled anastomosis in restorative colorectal cancer surgery

Patient outcomes

•

Factors affecting the short- and long-term outcomes from colorectal cancer surgery in older patients Patient reported outcome measures Preoperative glycated haemoglobin and insulin treatment: Risk factors for patients with type 2 diabetes undergoing colorectal cancer surgery Outcomes after colorectal cancer surgery in patients with Stage IV disease

Collaborative research projects •

Defining the T cell-suppressive mechanisms and phenotypic identity of cancer-associated fibroblasts C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

IN THE SPOTLIGHT

Mr Raymond Yap COLORECTAL AND ACADEMIC SURGEON, RESEARCH FELLOW

(After and) Before Cabrini Between his time as the Cabrini research fellow and his appointment as a colorectal and academic surgeon both at Cabrini Hospital and Institute, Mr Raymond Yap has completed the Australian and New Zealand Sub-specialty colorectal training over two years at the Prince of Wales, Sydney and St Vincentâ&#x20AC;&#x2122;s, Melbourne. After this, he decided to pursue an advanced minimally invasive colorectal fellowship at AdventHealth in Orlando, Florida, the largest hospital by bed count in the USA, with around 2000 beds, four intensive care units and a multitude of operating theatres. The colorectal program was led by Professor John Monson, an internationally renowned academic surgeon as well as Dr Matthew Albert, who invented the Transanal Minimially Invasive Surgery (TAMIS) platform used throughout the world today. The ability to tap into these resources and knowledge was an enlightening experience that allowed Raymond to explore the limits of minimally invasive surgery. There was a strong emphasis on research, and its place within the clinical and cultural milieu of surgery within the USA. There were opportunities to meet many visiting professors, each famous in their own right in the field of colorectal surgery. In the midst of this activity, he completed a Masters in Surgical Education through the University of Melbourne, focusing on the use of virtual reality simulation in the training of colonoscopy. This allows great insight into the place of simulation in procedural training, and broader exposure to many theoretical and practical concepts that exist in medical education. He was the fellow representative on the

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Colorectal Surgical Society of Australia and New Zealandâ&#x20AC;&#x2122;s governing council and an executive member of the Section Committee for Colon and Rectal Surgery for the Royal Australasian College of Surgeons. Research Interests During his time at Cabrini, he developed a keen interest in surgical outcomes research. He has continued along this path and looks forward to continuing to pursue this at Cabrini. The unique position that Cabrini holds, being the originator of both the minimum and extended datasets of the Bi-National colorectal cancer audit, combined with the volume of colorectal cancer surgery conducted at Cabrini, allows for a fruitful ground for this kind of research. Although currently on hold due to COVID-19, he is interested in medical education research. Raymond hopes that with restrictions slowly lifting, there will be opportunities to conduct further research with Associate Professor David Brewster and the clinical school into how education might be better evaluated and performed. Future Focus Raymond is a strong believer that Cabrini, as a healthcare leader, needs to continue to develop a strong academic profile. He looks forward to integrating more deeply with the Department of Surgery and Professor Paul McMurrick to increase our research output even further. He is also interested in increasing our links with the Monash Partners Consortium, to further collaboration between sites both for patient recruitment and patient trials. Raymond is eager to see the future of the Cabrini Institute under the leadership of Professor Gary Richardson OAM, and the development of the future Cabrini Cancer Institute.

Let’s Beat Bowel Cancer

Let’s Beat Bowel Cancer (LBBC) is a health promotion initiative of Cabrini. Our mission is to significantly lower deaths related to bowel cancer through prevention and research.

Bowel cancer, also known as colorectal cancer, is a leading cause of cancer death in Australia and has one of the highest (and increasing) incidence rates in the world. In Australia in 2020, it is estimated that there will be 15,494 new cases of bowel cancer, and that globally the incidence of bowel cancer will increase by 60% by 2035. If found early, approximately 90% of bowel cancer cases can be treated successfully, however fewer than 50% are detected early. Our work mitigates suffering and ultimately, we hope will help find a cure for bowel cancer. Through the LBBC initiative, we are campaigning for awareness, prevention and cure of bowel cancer.

New equipment to further research Let’s Beat Bowel Cancer donated an organoid seeding machine to the Cabrini Monash University Department of Surgery’s organoid research project. The machine is a liquid handling robot that enables researchers to plate (seed) organoids into multi-well plates for drug screening analyses. Our research department will use this machine to screen drugs that are already used in the clinic to determine if we can predict how patients will respond to therapy. It will also be used to screen panels of other drugs that are not currently used to treat bowel cancer so that we can determine whether any may be effective in treating patients who might otherwise be unresponsive or develop resistance to traditional chemotherapy drugs. This is an incredible step forward for us and will hopefully lead to some groundbreaking treatments and future clinical trials for patients, potentially saving more lives. The machine is currently being used by Cabrini Monash University Department of Surgery’s senior research fellow Dr Rebekah Engel.

LBBC Golf Classic 2019.

LBBC Golf Classic 2019 Blue skies and the perfectly manicured greens of Melbourne’s premiere sand belt course, Kingston Heath, welcomed our sponsors and guests for the 2019 Let’s Beat Bowel Cancer (LBBC) Golf Classic. Held annually on the second Tuesday in October, this year marked the 15th year of this wonderful fundraising event. Twenty-nine teams comprising 116 players, our biggest group of players since its inception, joined our special guest golf pro Nick O’Hern for another sensational day raising funds for LBBC’s public awareness and research projects.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Dr Rebekah Engel, Dr Christine Koulis, Dr Simon Wilkins and Professor Paul McMurrick participating in the Cadel Evans Great Ocean Road Race 2019.

Spirits were high across the day with players enjoying a number of on-course competitions together with exceptional on-course hospitality. Mark Allen, former golf pro and radio broadcaster and patient Tony James each shared their personal and moving bowel cancer stories. Dr Rebekah Engel gave our guests an update on the organoid project explaining the difference the golf day fundraising can and has made to the progress of this key research program. Team Energy Ease took out top honours as the overall winning team with 15-year supporter Jon Broome and his Proclaim team a very close runner-up. We would like to extend sincere thanks to all of our brilliant sponsors, in particular those who celebrated their 15th anniversary with us: David Deague, Deague Group; Geoff Stansen, Crestone; Ross Savas, Kay & Burton; Jon Broome, Proclaim; Russell Hutchinson, Logical Staffing; and Andrew Facey, Parklea. We are humbled that LBBC continues to be the beneficiary of this exceptionally generous group of supporters and their guests who all helped us to raise an outstanding $95,000 for Let’s Beat Bowel Cancer.

ASGA Golf Day The Australian Sporting Goods Association held a members golf day as a team building day and also to raise money for

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Let’s Beat Bowel Cancer. The day was held at Victoria Golf Club in Cheltenham, where they enjoyed a beautiful sunny afternoon of golf and managed to raise $1300 towards Bowel Cancer Research. Each player was provided with a bowel screening kit from Clinical Genomics and the response from each player was excellent. Participants included members from Acushnet, Sportspower, Russell Athletics, Callaway Golf and Nike Australia. We hope the initial success of this will lead to future partnership of events in the future.

Cadel Evans Great Ocean Road Race and the LBBC Ride for Research 2020 The Let’s Beat Bowel Cancer Ride for Research team (20 members) assembled in Geelong early on Saturday 1 February 2020. The wind and rain forecast for that morning meant that the longest of the three rides, 115 km, was cancelled with the riders directed to do the 65 km course or the 35 km course. One team member, James Page, kept pace with the lead pack (including 2011 Tour de France winner Cadel Evans) on the 65 km course and finished in a very quick 1h and 32 mins. The team, consisting of surgeons, researchers and staff, has raised just under $15,000 for bowel cancer research.

+$312,472 IN GRANT FUNDING

P U B L I C AT I O N S

P R E S E N TAT I O N S

ACTIVE CLINICAL TRIALS

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Centre for Allied Health Research and Education (CAHRE)

Head: Dr Annemarie Lee Our vision is to be the leader in allied health research in Australian private healthcare. We strive to improve the health of Cabrini patients and the local community through development and implementation of clinically focused research, which translates into best clinical practice.

Senior Research Consultant, Allied Health Dr Annemarie Lee Allied Health & Ambulatory Services Clinical Educator; Allied Health Research Assistant Sophie Jennings Honorary Research Fellows Assocaite Professor Helena Frawley Dr Tash Brusco Dr Kuan-Yin Lin PhD Students Edwina Lamborn, La Trobe University John Pierce, La Trobe University Masters Students Sonya Imbesi, University of Melbourne Helen Kugler, La Trobe University Medical Students Matthew Giacchi, Monash University Thao-My Nguyen, Monash University

Our current research themes are: • rehabilitation and management of chronic conditions and comorbidities • exercise rehabilitation and wellness interventions for oncology patients and their caregivers We are characterised by our commitment to allied health education that enhances quality patient care and develops future health service leaders. We strive to creatively deliver student education, and look forward to incorporating more interprofessional learning for staff and students.

Highlights Two medical students are undertaking their Scholarly Intensive placement (SIP) within CAHRE. They are part of the team examining the relationship between cardiorespiratory parameters and physical activity following cardiac surgery. Currently in the phase of data analysis, the findings from this study will be presented as part of Cabrini Research Week. We look forward to offering future SIPs for medical students as part of our department’s plan to foster research training. CAHRE will be part of a team of researchers establishing an academic exercise physiology research program at Cabrini. Supported by an AURIC Innovation grant, this funding will enable a clinical exercise testing laboratory for patients with cancer and development of a research and clinical program investigating the clinical benefits of exercise across the cancer continuum. Aligning closely with Cabrini’s strategic goals for cancer care, CAHRE is looking forward to developing this project and further this opportunity for research into the benefits of exercise in cancer.

Our Research As a follow on from work undertaking examining Cabrini’s GLA:D program for hip and knee osteoarthritis, this group of GLA:D Australian researchers is part of a study examining self-management for people with persistent or recurrent low back pain through the implementation of evidence-based patient education and exercise as a feasibility study.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

RESEARCHERS: WALLIS J (PI), BAENZIGER S, FERNANDEZ M.

Within this feasibility study, recruitment rates for clinicians to undergo GLA:D Back training and patient recruitment and retention will be examined. The ability of clinicians to deliver and ability of patients to complete the program as well as barriers and enablers for delivering treatment will be explored.

Other Projects •

•

A prospective multicentre phase 3 randomised controlled trial of early activity and mobilisation compared with standard care in invasively ventilated patients in intensive care Do post-operative sitting and activity restrictions impact on the outcome following elective lumbar micro discectomy? Barriers and enablers for referrals and participation in Cabrini’s new evidence-based osteoarthritis management program: Capturing referrer and patient perspectives The relationship between cardiorespiratory parameters during physical activity following cardiac surgery

•

• • • •

• •

Telephone or electronic nutrition care delivery (TEND) to upper GI cancer patients: a randomised controlled trial A multidisciplinary rehabilitation program for patients following surgery for abdomino-pelvic cancer Development and implementation of a pictorial menu Is spontaneous swallowing reduced in Parkinson’s compared to healthy controls? The NOURISH point prevalence study: Nutritional outcomes of patients undergoing resection for upper gastrointestinal cancer in Australian Hospitals Using the consumers voice to inform interprofessional education GLA:D Back Australia: improving self-management for people with persistent or recurrent low back pain through the implementation of evidence based patient education and exercises: a feasibility study

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Nursing and Allied Health student placement days reduced to

14,400 due to COVID-19

= 365 days C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

+$8.3m IN GRANT FUNDING

P U B L I C AT I O N S

P R E S E N TAT I O N S

ACTIVE CLINICAL TRIALS

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Cabrini Monash University Department of Medical Oncology â&#x20AC;&#x201C; The Szalmuk Family Department of Medical Oncology Head: Professor Gary Richardson OAM The department undertakes a wide range of research activities, largely building upon the second largest clinical service in Victoria (the largest private service in Australia). Activities include new drug trials, translational research in breast, colorectal and ovarian cancers, medical informatics and patient-reported outcome measures.

Head of Department Professor Gary Richardson OAM (Phase I trials, Gynaecologic Cancers, Lung Cancer) Principal Investigators Dr Yoland Antill (Breast Cancer) Associate Professor Ben Brady (Melanoma, Lung Cancer) Dr Anis Hamid (Phase I trials) Dr Andrew Haydon (Gastrointestinal Cancers, Melanoma) Associate Professor Melita Kenealy (Haematologic Malignancies) Associate Professor Lara Lipton (Gastrointestinal Cancers) Dr David Pook (Genitourinary Cancers)

Associate Professor Jeremy Shapiro (Gastrointestinal Cancers, Genitourinary Cancers) Associate Investigators Dr Michael Dickinson Dr Lucy Gately Associate Professor Ian Haines Dr Despina Handolias Dr Henry Januszewicz Dr Sem Liew Dr Esther Lin Dr Ben Markman Professor Miles Prince Dr Gaurav Srivastava Dr Robert Stanley Dr Mark Voskoboynik Dr Michelle White Associate Professor Max Wolff Dr Kirsten Herbert Dr Dan Tran Dr Emma Beardsley

Dr Samantha Dean Dr Peter Lau Dr Jo Ann Chow Senior Research Fellow Dr Tali Lang Research Coordinators Li Hoon Lai (Team Leader) Demis Balamatsias Lyanne Cottee Theresa Ealdama Kate Hurford Simona Infantino Simer Khaira Leyna Tran Rochelle Woods CTA Ethics Specialist Dr Luz YĂŠvenes

Brightways Breast Cancer Program Dr Joanna Morgan, Specialist Breast, Thyroid and Parathyroid Surgeon Dr Karen Taylor, Radiation Oncologoist Melissa Vereker, Data Manager and MDT Meeting Coordinator Acknowledgement of Research Coordinator Staff who have left (2019-2020) Daphne Antonopoulos, Research Coordinator Stephanie Groube, Associate Genetic Counsellor Jacqui Hastings, Acting Brightways Coordinator Anna Uhe, Clinical Trials Assistant

Family Cancer Clinic Lynne McKaye, Genetic Counsellor

The program provides significant benefits for patients, including access to treatments not yet in the marketplace, close monitoring and testing, and collection of valuable information that can help others. The department is seen as a partner of choice by the pharmaceutical and biotech industries, particularly in the area of precision medicine. We have a highly trained dedicated team that provide the highest level of care for all patients participating in clinical trials. Development and maintenance of a robust research program not only benefits patients in terms of access to new active anti-cancer agents. It also allows us to attract the best and brightest researchers and clinicians, who improve the consumer experience even more.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Highlights

Our Research

Cancer Institute Phase I

Phase I Trial Program

Cabrini secured a $6m grant to begin development of a Cancer Institute. Phase I involves establishment of an interim “Cancer Institute” in the old Day Oncology Unit at Malvern incorporating a Cancer Trials Unit, Trials Pharmacy, Exercise Research (gymnasium and exercise laboratory) and Wellbeing (dietetics, psycho-oncology and pastoral care). The express purpose of phase I is doubling patient numbers on clinical trials and commencing formalised research into exercise and wellbeing in cancer patients. It is anticipated this will be completed by the end of 2020.

A phase I study of APL-501, an anti-PD-1 antibody, in patients with recurrent or advanced solid tumours. APL-501 is a humanised monoclonal antibody targeting programmed cell death-1 (PD-1). It was evaluated in patients with advanced recurrent and relapsed solid tumors who had not been previously treated with an immune checkpoint inhibitor. Twenty-two patients were enrolled with a mean age of 62.1 (SD: 12.2) years. No dose limiting toxicities were reported. Fifteen patients (68.2%) had related AEs; two patients (9.1%) had Grade ≥ 3 related AEs to APL-501. Eight patients had stable disease and two patients had partial response by RECIST (esophageal adenocarcinoma and cancer of unknown primary). Seven patients remained on therapy for ≥ 24 weeks. The recommended phase 2 dose (RP2D) has been determined to be 400 mg IV every 14 days (non-weight-based) based on safety and PK modeling. Preliminary results indicate clinical activity of APL-501 in relapsed/refractory malignant disease with a generally tolerable safety profile. Clinical trial information: NCT03053466.

Auric Grant The successful grant application will allow development of an innovative project to create a new research stream at Cabrini to investigate novel approaches to improve the outcomes for cancer patients. It will assess the potential positive benefits of exercise and exercise therapy/rehabilitation in patients with cancer, by systematic, sequential, objective physiologic measurements of patients during and after cancer treatment. It is an ambitious project, as there are very few exercise laboratories in the world dedicated to cancer patients. The only other facility like this in Australia is at the Edith Cowan University, and it has a more general exercise laboratory centred on cardiovascular research. The only comparable program is at Memorial Sloan Kettering in New York, one of the world’s leading cancer centres, which concentrates study on the utility of different methods to characterise the chronic and long-term adverse cardiovascular side-effects of conventional and novel cancer therapies. The grant will create a facility that allows original research to break new ground in cancer management. Phase I Trial Program The Phase I Oncology Clinical Trials program at Cabrini Health addresses a key clinical need in the longitudinal care of cancer patients in the service. Specifically, the program is designed to offer patients with advanced and refractory cancer the opportunity to access therapeutics in development with the primary aim of trialling potentially effective therapy in the context of a clinical trial. The nature of phase I trials is collaborative, involving multiple clinical disciplines, providers and industry sponsors in both research and patient-directed activities. The suite of phase I studies comprise either novel immunotherapy drugs or targeted therapies designed to attack a particular growth regulatory pathway in cancer cells. We have recruited Dr Anis Hamid, who was previously working at the highly esteemed DanaFarber Cancer Institute in Boston, USA, to develop and run the program. He has opened trials for both unselected tumour types and in selected tumour types. The program is highly successful and offers our patients treatments that would normally not be available for years.

Immunotherapy Program Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: EORTC 1325-MG/Keynote 054 double-blinded phase 3 trial. Phase 3 double-blind trial to evaluate pembrolizumab vs placebo in patients with resected high-risk stage III melanoma. A total of 1019 patients were randomised to pembrolizumab at a flat dose of 200 mg (N=514) or placebo (N=505) every three weeks for a total of 18 doses or until disease recurrence or unacceptable toxicity. In the overall population, the three-year cumulative incidence of distant metastasis being the first recurrence was 22.3% (pembrolizumab group) vs 37.3% (placebo group) (HR 0.55, 95% CI 0.44-0.69). Relapse-free survival was increased in all patient subgroups, including stage, Braf-V600E/K mutation status, and PD-L1 score. Clinical trial information: NCT02362594 Medical Informatics: Database Evaluation Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2+/HR+ metastatic breast cancer: TABITHA Database Analysis. Endocrine therapy is the backbone of treatment in hormone receptor positive (HR+) disease, but the role of the addition of endocrine therapy following chemotherapy in HER2+/HR+ disease remains unclear as pivotal first line clinical trials excluded endocrine therapy use. Data from a multi-site community cohort of consecutive HER2+ metastatic breast cancer patients diagnosed between 1 January 2012 and 31 August 2019 was examined. Of 132 eligible patients included in the analysis, 78 (59.1%) received endocrine therapy and 54 (40.9%) did not. Median follow up was 25.9 months. The addition of endocrine therapy was associated with improved progression free (HR 2.1, 95% CI 1.2-3.5, p = 0.007) and overall survival (HR 2.7, 95% CI 1.2-5.5, p = 0.007) in multivariate analysis. C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

IN THE SPOTLIGHT

Dr Anis Hamid PRINCIPAL INVESTIGATOR (PHASE I TRIALS)

Dr Anis Hamid has found great pleasure in joining the Cabrini Institute as a medical oncologist with a specific interest in the development and conduct of early phase cancer trials. Anis studied medicine at the University of Melbourne and completed clinical training at tertiary academic centres around Melbourne including Cabrini, culminating in a Clinical Trial Fellowship at the Olivia Newton-John Cancer Wellness and Research Centre focusing on early drug development, phase I and genitourinary cancer trials. He then worked at Dana-Farber Cancer Institute in Boston, Massachusetts as a translational researcher and PhD student with a focus on prostate cancer genomics, computational oncology and precision cancer medicine, ongoing between Boston and the University of Melbourne. Phase I trial program growth Anis returned to the Cabrini Institute to help spearhead the phase I trial program with Professor Gary Richardson OAM, a distinct privilege which enables him to translate his research interests to outstanding care for patients in the Cabrini community. The Cabrini Institute has grown an exceptional clinical trial program exemplified by diverse and novel studies in the phase I portfolio. Phase I or ‘early phase’ clinical trials are centered around offering patients the opportunity to participate in studies of novel drugs-in-development. Our mission is critical in the cancer journey of many patients with a diagnosis of advanced care. Enrolment in phase I trials often allows patients to trial a promising class of treatment, such as immunotherapy, that may be otherwise unavailable due to a lack of mature evidence from later phase

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

studies. Over the last six months, the phase I program has grown considerably as we assess and offer more patients the option of enrolment on up to six to ten trials at any one time. Teamwork has been crucial in the growth of the program, with medical investigators working closely with study coordinators, nursing staff, pharmacists, research associates and industry sponsors to deliver the exemplary level of care we expect for our patients at Cabrini. A growing team requires outstanding communication and commitment; indeed this is a cornerstone value of the Cabrini Institute as a center of excellence in clinical trial research. Future focus The future holds exciting opportunities to expand the diversity of early phase trials at Cabrini to ultimately provide more opportunity and choice for patients. We are actively pursuing trials of novel treatments: ‘pathway-directed’ therapies, immunotherapies and those that target specific genetic features of an individual patient’s cancer. In this sense, we are excited to build precision genomic therapies and tumour sequencing as a special area of focus. We have recently launched a multi-disciplinary molecular tumour board, chaired by Professor Gary Richardson OAM, to engage colleagues and partner institutions in this area. It is key that efforts to expand clinical trials and associated research are ultimately tied back to the needs of our patients. As a new Cancer Institute is realised at Cabrini in the coming years, the role developing effective cancer therapies and launching early phase clinical trials remains ever crucial in the mission of providing forwardlooking and holistic patient care.

Grant Success Profile Breast Cancer Organoid Program Dr Tali Lang Breast cancer is the most common cancer in Australian women with an estimated 20,000 new diagnoses in 2020. Treatment decisions are based on important biomarkers including hormone receptors (oestrogen (ER) and progesterone (PR)), and the human epidermal growth factor receptor 2 (HER2). Recently gene profiling of breast tumours has improved prognostic assessment and influenced treatment outcomes in early-stage breast cancer. Despite improved treatments, a significant number of women with early stage disease will relapse. This is thought to be due to tumour heterogeneity which occurs at the genomic, transcriptomic and proteomic levels creating therapeutic challenges. The use of in vitro 3D tumour organoid technology has the potential to accelerate clinical research studies, exploring associations between molecular changes in the primary tumour with clinical outcomes. Organoid cultures exhibit greater biological relevance due to maintenance of cellular organisation that mirrors the tissue of origin. Breast cancer organoids can be established in most breast cancer subtypes (80% success rate), and maintained long-term in culture. Organoids significantly expedite the ability of scientists to extend and translate in vitro findings of genes and signalling pathways to the clinically relevant situation. Importantly, organoids have the potential to be utilised as a clinical test, given they can be established quickly, reflect molecular features of the original tumour and can be used for drug testing prior to patients commencing treatment for the best chance of a curative outcome. The Szalmuk Family Department of Medical Oncology at Cabrini, in collaboration with Monash Biomedicine Discovery Institute, has established a living breast cancer organoid bioresource. This project was funded through the generous donation from the Barlow Foundation and Monash Biomedicine Discovery Institute. The project was designed to establish a clinically representative living bioresource of patient-derived breast tumour organoids, identify genetic alterations in breast cancer tissue and matched breast cancer organoids, and to characterise how specific genomic alterations correlate with sensitivity to existing or new cancer therapies using breast cancer organoids. We have collected 30 different breast tumours from women undergoing treatment at Cabrini with 23 breast cancer organoid lines successfully established. Our collection of breast cancer organoids comprises breast tumour subtypes including 14 luminal A, five luminal B, two HER2+, one triple negative and one mixed breast cancer. All have been cryopreserved and successfully revived from frozen stocks. Freshly resected primary breast tumours were divided and allocated for different research purposes. Some of the

(L-R) Malvernâ&#x20AC;&#x2122;s Day Oncology and Infusion Unit Nurse Unit Manager Kirsten Seletto and Dr Tali Lang were successfully awardedÂ the Cabrini Foundation Quality Improvement Grant (2019-2020), to create a Wellness Program for oncology nurses with the aim of combatting compassion fatigue and burnout.

primary tumour was snap frozen for DNA isolation and other sections fixed in formalin for histopathological analysis. The remainder of the tumour was processed by enzymatic digestion and epithelial cells resuspended in Matrigel. Cells in Matrigel were plated and overlaid with a culture medium containing essential growth factors. Established organoids were expanded and cryopreserved and a fraction of these were frozen and fixed for comparative molecular and histochemical analyses. Blood was also collected for genomic analysis. Fourteen individual organoid cultures and their corresponding primary tumour tissues have been processed into histological blocks and undergone histopathological evaluation using a defined set of markers, including ER, PR, Ki-67 and HER-2. Genomic DNA from 14 breast cancer organoids has been isolated from the blood (as a normal reference), primary breast tumour and corresponding organoid, and is currently being analysed by whole exome sequencing (GeneWiz, China). Bioinformatic analysis will be used to identify variants and copy number variations for targeted genes known to be involved in tumour formation. The continuing collaboration between Cabrini and Monash University will further expand our collection of breast cancer organoids to establish a more diverse bank of clinically relevant organoids reflecting the range of breast cancer sub-types. The use of breast organoids will significantly expedite the ability of scientists to extend and translate in vitro findings of genes and signalling pathways to the clinically relevant situations. Importantly, breast cancer organoids in the clinical setting can be used as a predictive tool to guide physicians regarding which patients are more likely to respond to specific treatments, and which treatments have the best chance of a curative outcome, based on the molecular profiling of the tumour.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

IN THE SPOTLIGHT

Li Hoon Lai ONCOLOGY RESEARCH TEAM LEADER

Li Hoon Lai grew up in a small town of Malacca, Malaysia. She moved to Kuala Lumpur immediately after obtaining her Bachelor of Applied Chemistry in 1998 and married her high school sweetheart not long after. They were blessed with a daughter in 2008 and decided to take a leap of faith and build a life in Melbourne, moving here in early December 2016. Throughout Li Hoon’s 18 years of working with pharmaceutical and clinical research organisations, she worked with excellent talent globally. She contributed to pipeline developments in therapeutic areas such as oncology, cardiology, infectious diseases, immunology, psychiatry and neurology for both established pharmaceutical companies and newly formed biotech organisations. Li Hoon held various roles over the years. Starting in sales with a pharmaceutical company and moving into clinical research as a Clinical Research Associate, Li Hoon progressed to project management and then through the ranks into line management and was fortunate to be given the responsibilities of country and subsequently regional head. Road to Cabrini Just before her move to Melbourne, Li Hoon was the Director of Clinical Operations with a clinical research organisation based in Kuala Lumpur, heading a regional team within a specific geographic region. This included managing teams in Malaysia, Singapore, India, Taiwan and Indonesia. The role included crafting strategy to meet bottom line targets, training and talent management to support the vision and achieve company targets. The role that Li Hoon landed when she first arrived in Melbourne was Clinical Trial Team Manager with Monash Alfred Psychiatry Research at Caulfield Hospital, managing a team of study

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

coordinators working on Alzheimer’s disease and Major Depressive Disorder clinical trials. She moved to the Cabrini Institute in January 2018, as Team Leader of the Oncology Research Department, an exciting time to join as not too long after, Cabrini received $6m in Federal Government funding commitment that will enable the establishment of a new Cancer Institute at Cabrini Malvern. Li Hoon is thrilled at the prospect of applying her experience and contributing to the success of the new Cancer Institute. A strong future ahead Li Hoon’s focus in the near future is cultivating a stronger network within Cabrini and strengthening collaboration with other services, beyond the Oncology Research Team. She is excited for the Oncology Research Team as, with the expected growth in clinical trials, there will be opportunities for them to further enhance and enrich their experiences. To successfully deliver the Cancer Institute’s value proposition would require every employee and stakeholder at Cabrini to translate enthusiasm into action, working cohesively with a shared sense of responsibility for success. She believes we have what it takes to make this a reality.

+$2.8m IN TRIAL REVENUE

IN THE SPOTLIGHT

Dr Tali Lang SENIOR RESEARCH FELLOW

Dr Tali Lang received her PhD in Immunology at Monash Institute of Medical Research in 2011. At the completion of her PhD, she was recruited as a postdoctoral researcher to the Institute for Anatomy and Cell Biology, University of Giessen, Germany and subsequently to the Rheumatology Research Group, Monash Health. During this time she developed expertise in molecular and cellular dissection of inflammatory signaling pathways which also included a translational component of in vivo mouse models of autoimmune, inflammatory and infectious diseases. Tali’s work has transformed the understanding of how inflammation and immunity is regulated when challenged under conditions of infection. Her work has revealed mechanisms by which pathogens can suppress host immunity in order to escape detection and eradication. Her most recent discovery was the identification of a new role for Macrophage Migration Inhibitory Factor, which is required for activation of the NLRP3 inflammasome. Inflammasomes promote the release of inflammatory proteins and cell death. All her discoveries have resulted in numerous publications in top-tier journals including Nature Communications, Journal of Hepatology, Autophagy, Clinical Translational Immunology, Frontiers in Immunology and Immunology Cell

Biology. Tali has successfully obtained national and international competitive research funding to support her research endeavours. Translational research Tali is currently a Senior Research Fellow leading clinical studies within the Department of Medical Oncology. Her research interests include developing innovative tools for capturing patient-reported outcome measures (PROMs), and translating these into changes within clinical practice for improved health outcomes. The development of these tools is designed to capture patient-reported clinical data electronically, which can be fed back to treating physicians to improve communication between patientclinician, advance treatment outcomes and identify unmet needs of oncology patients. Since 2018, Tali has undertaken studies using paper and electronic PROMs evaluating toxicities associated with chemotherapy. This involved participation of over 200 cancer patients being treated at Cabrini, and the engagement and support of medical oncologists and haematologists. As an extension of these projects, she has also established a new collaboration with the Department of Information Technology at Monash University, to develop an app which patients, in the future can use to electronically report symptoms they may

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

experience during cancer treatment, via their mobile devices. Tali also coordinates patient tumour samples for use in translational research as part of a larger collaboration between Cabrini Health and researchers within Professor Helen Abudâ&#x20AC;&#x2122;s group at Monash Biomedicine Discovery Institute. This collaboration aims to generate a living breast cancer organoid bioresource, the first of its kind in Australia. The use of patientderived breast cancer organoids in pre-clinical research will transform our understanding of molecular mechanisms involved in breast cancer development, and provide insight into genomic and proteomic alterations that lead to drug resistance, increased susceptibility of recurrence and progression to metastatic disease. Future impact Recently Tali was awarded funding to create a Cabrini lung cancer registry that will provide crucial data to meet the challenges of lung cancer management and research. The development of a lung cancer registry will facilitate collection of data on symptoms, diagnostic tests, treatments, quality of life indicators and overall health outcomes for patients at Cabrini. The clinical data will also contribute to greater research efforts

in the community as data will be linked to the Victorian Lung Cancer Registry as part of a newly formed collaborative partnership. The creation of a lung cancer registry will be a substantial resource of information on lung tumours for clinicians, as well as support translational research. Tali is optimistic that the development of a lung cancer registry, in combination with ongoing clinical studies at Cabrini, will contribute to improved outcomes for patients living with lung cancer, and provide information resources for clinicians. Over the past two years working alongside nurses, oncologists, surgeons and researchers at Cabrini, Tali has undertaken a huge learning curve changing fields from basic laboratory research in Immunology, to clinical and translational projects which address current challenges in cancer care. Tali is passionate about being involved and contributing to meaningful research, and is excited with the opportunities she has been given to develop new clinical and translational projects to improve patient care, health outcomes and survival of cancer patients.

Above: Microscopic image of a patient-derived breast tumour organoid labelled with fluorescent dyes to visualise live (Hoescht,blue) versus dead cells (PI, red).

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

$205k IN GRANT FUNDING

P U B L I C AT I O N S

P R E S E N TAT I O N S

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Palliative and Supportive Care Research Unit

Head: Associate Professor Natasha Michael The Palliative and Supportive Care Research Unit aims to work towards the integration of clinical practice and research, aiming for a translation from evidence to care. The department has focused on conducting research in the psychosocial and ethical aspects of care of patients with a life limiting illness, and more recently in the area of complex symptom management and patient reported outcomes.

Head of Department Associate Professor Natasha Michael Research Nurses Sonia Maleki Adelaide Melia Palliative Care Consultant Dr Kathy Hauser Dr Patrick Tee Dr Merlina Sulistio Acknowledgement of Staff who have left (2019-2020) Associate Professor Clare O’Callaghan AM, Senior Research Fellow

We aim to align with the Institute's strategy of focusing on patient and family centered care, ensuring our work is in keeping with Cabrini Health’s aspiration to be a major site for clinical research in cancer care and in keeping with the mission of Catholic Healthcare.

Highlights Our ongoing highlight has been the fostering of multisite collaborations, strengthening our relationships with St Vincent’s Health, Eastern Palliative Care, The University of Notre Dame and Monash University. Additionally this year, we have engaged our clinicians into the research team. We continue to invest in teaching and training of students from Monash University and The University of Notre Dame as well as advance trainees in palliative medicine and geriatrics. We participate in assessments and examinations, working closely with training bodies and specialist colleges. Our highlight for this year has been the completion of Australia’s first multisite project in Spirituality led by Cabrini in collaboration with Hammond Care and St Vincent’s Hospital. The study recruited 261 patients and 109 caregivers over two years and has been published in three leading peer reviewed palliative care journals. These studies demonstrate the need for respectful inquiry into patients’ spiritual/religious requirements in hospitals to allow for an attuned approach to addressing such care needs whilst considerately accommodating those disinterested in such support. The studies were funded by the Cabrini Foundation Sambor Family Clinical Research Grant, St. Vincent’s Curran Foundation Grant and The University of Notre Dame Australia SoMS Research Support Grant. We are particularly grateful to Associate Professor Clare O’Callaghan AM for her many years of service and her assistance with setting up and establishing our research department.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Our Research A prospective open label study of methadone rotation for the management of cancer induced bone pain RESEARCHERS: SULISTIO M, MICHAEL N, WOJNAR R, HAUSER K, AL-RUBAIE Z

Cancer induced bone pain (CIBP) is a mixed mechanism pain state, typically presenting with a combination of background and breakthrough (spontaneous and incident) cancer pain. Opioids remain the mainstay treatment despite animal modelling revealing a degree of opioid resistance in CIBP and no evidence to guide the choice of opioids. Methadone is a synthetic opioid often used in refractory cancer pain with properties affecting multiple receptors and complex pharmacokinetics. This prospective open-label study aims to explore the efficacy, safety and tolerability of inpatient methadone rotation for the treatment of CIBP. Efficacy of ambulatory supportive care clinic on patient reported outcomes and clinical service utilisation: a retrospective, single centre observation study RESEARCHERS: MICHAEL N, TEE P, SHAH R, NGO K, BAIRD A, FARRINGTON J

Ambulatory palliative and supportive care is a recognised model of care that complements cancer care by promoting early integration to reduce symptom burden, improve quality of life and survival and provide value-based care to patients and families. This three-phase study will aim to utilise electronic patient-reported symptom outcome measures to promote further modelling and development of ambulatory supportive care services across cancer care. Routine Clinical Assessment of Psychosocial and Existential Symptoms in Palliative Care: A National Quality Improvement Project through Education and Supervision RESEARCHERS: KISSANE D, DEVERY K, MICHAEL N ET AL.

Patients with unrecognised depression, unaddressed demoralisation and unabating anxiety account for some

(L-R) Dr Merlina Surlistio (Deputy Director of Palliative and Supportive Care) and Ms Lisa Candid at the 20 Years of Palliative Care celebration.

of the most vulnerable patients in palliative care. Despite effective, evidence-based treatments being available, non-recognition has been a major barrier. This national study will promote through education routine screening to build cliniciansâ&#x20AC;&#x2122; confidence and competence in discussion and management of psycho-existential symptoms.

Grant success profile We are in the final stages of completing data analysis for a randomised controlled trial of a video decision support tool to promote values based discussion in advance care planning in cancer patients (funded by the Bethlehem Griffith Research Foundation and the Cabrini Foundation). The study has demonstrated that patients exposed to a video intervention have improved understanding and appreciation of advance care planning, are open to considering it but discussions with family elicit distress. Our study also demonstrates that the process of advance care planning improve congruence in patient-caregiver communication. Cabrini will be a major recruiting site for a National Palliative Care Quality Improvement Project funded by the Australian Department of Health National Palliative Care Projects Grant Opportunity and led by Professor David Kissane AC at The University of Notre Dame. The study will be conducted across palliative care sites in Australia. As of July 2020, the Palliative Care Research Department and the Szalmuk Family Psycho-Oncology Department will combine to form the Supportive, Psychosocial and Palliative Care Research Department.

Associate Professor Natasha Michael speaking at the 20 Years of Palliative Care celebration.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

23 Masters and PhD students supervised across seven research departments

= 1 student C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

+$1.3m IN GRANT FUNDING

P U B L I C AT I O N S

ACTIVE CLINICAL TRIAL

VISITING SCHOLAR

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Szalmuk Family Psycho-Oncology Research Unit

Head: Professor David Kissane AC Our research interests cover the full trajectory of cancer experiences, including diagnosis, treatment decision making, psychosocial factors that influence adjustment to cancer, unmet needs of cancer patients and their families, psychosocial interventions for people affected by cancer and psychosocial factors in the supportive care of cancer patients across the disease continuum.

Head of Department Professor David Kissane AC Oncology Research Nurses Genevieve Murphy Jill Wilson Honorary Research Fellow Dr Irene Bobevski Visiting Scholar Associate Professor Seon Young Kim (South Korea) PhD Students Associate Professor Natasha Michael, The University of Notre Dame Felicity Moon, Monash University Doctor of Philosophy (Clinical Psychology) Students Rebecca Chau, Monash University Alexandra Creighton, Monash University

Our Research Development of a spiritual concerns checklist RESEARCHERS: Oâ&#x20AC;&#x2122;CONNOR C (PI), MICHAEL N, KISSANE DW

A spiritual concerns checklist will help identify patients with advanced cancer who may hold unrecognised spiritual concerns that could be readily addressed. Validation of a clinical interview for demoralization RESEARCHERS: BOBEVSKI I (PI), KISSANE DW, MICHAEL N

A structured set of questions that can be asked in a clinical interview to assist in the diagnosis of the mental state of demoralisation. Meaning & Purpose Therapy Randomized Controlled Trial RESEARCHERS: KISSANE DW (PI), LETHBORG C, BOBEVSKI I, MICHAEL N

A formal randomised controlled trial of a manualised psychological intervention delivered over six sessions to help restore morale and a sense of the value and meaning of the personâ&#x20AC;&#x2122;s life. Video tools to assist with advance care planning in cancer RESEARCHERS: MICHAEL N (PI), KISSANE DW, JIWA M, BURKE A

A video tool shown to patients and their carers in the advanced cancer setting to help them talk about advance care planning and assess whether this helps them complete a personal advance care plan. Education and assessment of psychosocial and existential wellbeing in palliative care. RESEARCHERS: KISSANE DW (PI), LOBB E, MICHAEL N

Implementation of a screening tool to assess psycho-existential symptoms in palliative care patients.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

$660k IN GRANT FUNDING

P U B L I C AT I O N S

P R E S E N TAT I O N S

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Alan, Ada and Eva Selwyn Emergency Department

Head: Associate Professor Katie Walker Cabrini Emergency Research Department is interested in novel and innovative attempts to improve patientsâ&#x20AC;&#x2122; and staff experiences and outcomes of attending and working in an emergency department (ED). Our focus is on using novel technology or novel system design to solve the complex and often vexing problems encountered in Emergency Medicine.

Director of Emergency Medicine Research Associate Professor Katie Walker Director of Emergency Medicine Associate Professor Michael Ben-Meir Clinical Director of Emergency Medicine Dr Rohan Laging Emergency Physicians Dr Gabriel Blecher Associate Professor Keith Joe, IT lead Dr Christine Jackman Directors of Emergency Medicine Training Dr Dane Horsfall Dr Ian Turner PhD Candidates Troy McGee, Monash University Alexandra Mullins, Monash University ACEM trainee Dr Melanie Stephenson, Monash University Medical Students David Cui, Monash University Ian Shijie Tan, Monash University Acknowledgement of Staff who have left (2019-2020) Anne Loupis, Project Manager

We are interested in partnering with university and industry colleagues to investigate novel and emerging technologies, as well as new service design approaches. By collaborating with experts in diverse areas, such as mathematics, data analytics, visualisation, aged care, graphic design and consumers we hope to generate, investigate and implement improvements that can positively affect the experience, safety and efficiency of attending an ED. Our aim is to increase the research complexity and output of our department over the coming years. The highly successful year we have had in terms of publications, presentations and grants success demonstrates significant progress towards our goal.

Highlights 1. 2. 3. 4.

MRFF grant Gilroy Potts award for best original research paper: Scribe BMJ publication ACEM research registrar rotation ED wait time project and its progress so far

Our Research Wait time visibility for emergency medicine patients RESEARCHERS: WALKER K (PI), STEPHENSON MEL, BEN-MEIR M, JOE K, LOUPIS A, STEPHENSON MICH, LOWTHIAN J, HUTTON J, BLECHER G, BUNTINE P, ET AL

Patients attend emergency departments seeking urgent care. Most have to wait to see a doctor. The majority of patients arenâ&#x20AC;&#x2122;t provided with any estimate of how long they are likely to wait, which causes major issues for them, their families and their paramedics. A $250,000 Monash Partners grant from the Medical Research Futures Fund is being used to determine whether consumers want access to wait times, how they should be displayed and how to accurately predict their wait times. It will also allow us to go live with predicted wait times at some of our local hospitals, improving health service transparency and the patient experience.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

(R-L) Associate Professor Katie Walker with Medical Scribe Jennifer Hanning.

Developing and testing virtual reality tools to reduce agitation in cognitively impaired older people in emergency departments

My Health Record in the emergency department: An investigation of adoption, utilisation and utility

RESEARCHERS: BLECHER G, KUHN L, RUSSO P, FLYNN D, PAGE R, WALKER K ET AL

Given the amount of funding invested into the implementation and development of My Health Record (MHR) and the accelerated rate of adoption of MHR across emergency departments, it is timely that this evidence base is enriched. This research takes leadership in this untapped area to generate new knowledge, through codesign with Monash University (this research forms part of a PhD). The aims of this research include: (1) Systematically review the health outcome and healthcare efficiency benefits associated with MHR use during clinical time in the emergency department; (2) Explore MHR use by physicians and pharmacists in the emergency department; (3) Explore the barriers to regular MHR use, by physicians and pharmacists, in the emergency department; and (4) Explore the impact of MHR use on physician and pharmacist decision making, patient outcomes and healthcare efficiencies in the emergency department.

Cognitively impaired older adults often have to attend emergency departments to obtain acute healthcare. Some experience significant agitation, delirium and distress. For their safety, sedative medications or physical restraints are sometimes used in the emergency department to allow care to be provided. A $147,000 grant from the Cabrini Foundation Auric program is being used to develop and evaluate whether virtual reality tools can be used to calm people instead.

RESEARCHERS: MULLINS A, M BEN-MEIR M, RANKIN D, Oâ&#x20AC;&#x2122;DONNELL R, SKOUTERIS H

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

By collaborating with experts in diverse areas, such as mathematics, data analytics, visualisation, aged care, graphic design and consumers we hope to generate, investigate and implement improvements that can positively affect the experience, safety and efficiency of attending an ED.

ASSOCIATE PROFESSOR MICHAEL BEN-MEIR

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

CLINICAL TRIALS

P U B L I C AT I O N S

P R E S E N TAT I O N S

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Intensive Care Research Unit

Head: Associate Professor Vineet Sarode The Cabrini Intensive Care Unit admits approximately 1570 patients per year following procedures such as cardiothoracic and abdominal surgery as well as medical admissions requiring multi organ support. The average length of stay in our unit is 48 hours.

Director Intensive Care Unit Associate Professor Vineet Sarode Deputy Director Intensive Care Unit, Head of ICU Research Associate Professor David Brewster Intensive Care Physicians Professor Warwick Butt Dr Deirdre Murphy Dr Steve Philpot ICU Research Coordinator Shannon Simpson

Research in the intensive care unit (ICU) is particularly about questioning current practices and determining how we can get the best outcomes for our patients based on the evidence found. ICU research is increasingly trending towards examining patient outcomes post ICU discharge by following up patients for extended time periods to determine quality of life and disability as well as the standard outcome measures such as morbidity and mortality. Through this extended follow up of patients, we hope to ascertain the long term impacts an Intensive Care admission can have on both patients and their families â&#x20AC;&#x201C; emotionally, physically, financially and socially. This would ultimately lead to standard practices and procedures possibly being changed or modified to ensure beneficial long term outcomes for our patients. The COVID-19 pandemic has presented challenges to all healthcare workers, and Cabrini ICU is no exception. It is through research that we can learn more about this virus, the immediate impact it has on patients and communities as well as the medium to long term impacts, giving us more knowledge in uncertain times.

Highlights Cabrini ICU landmark paper leads the country in national guidelines for the airway management of patients with COVID-19 A highlight for this year has been a major publication in the face of the COVID-19 pandemic. Associate Professor David Brewster first authored an influential medical research article in Australia for 2020. The national guidelines for the airway management of patients with severe COVID-19 disease has been the most viewed, downloaded and cited article in the Medical Journal of Australia (MJA) for 2020. This article has guided the doctors from anaesthesia, emergency medicine and intensive care units in all hospitals in Australia and New Zealand to manage extremely unwell patients as they are put onto a life-saving mechanical ventilator. It has also been used in numerous other countries as their guidelines. Associate Professor Brewster authored these guidelines along with 14 other national experts on airway management through his role on both the board and clinical council for the Safe Airway Society of Australia and New Zealand.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

These guidelines were widely endorsed by specialty colleges and societies including ANZICS, ASA, CICM, ACEM, NZSA, ACCCN, AHONHS and recommended by the COVID-19 collaborative.Â Cabrini is a part of a thriving ICU research community led by the Australia New Zealand Intensive Care Society Clinical Trials Group (ANZICS CTG). Our research team collaborates with multiple sites including Monash Partners, Australia New Zealand Intensive Care Society Research Centre (ANZICS RC), Sunnybrook Research Centre, Toronto and the Medical Research Institute of New Zealand. We are collaborating with the Cabrini physiotherapy team participating in a study investigating early mobilisation vs standard in the mechanically ventilated cohort of ICU patients. This again will aim to improve our patient outcomes for their ICU stay and beyond.

Our Research BALANCE RESEARCHERS: SARODE V, BREWSTER D, MURPHY D, SIMPSON S

Bacteraemia Length Actually Needed for Clinical Effectiveness. Upon confirmation of positive blood culture in the ICU, patients are randomised to receive 7 days vs 14 days of appropriate antibiotic. The purpose is to determine survival rates at 90 days and whether patients can ultimately be treated with a shorter duration of antibiotics. We are currently in the recruitment phase of this study. TEAM RESEARCHERS: MURPHY D, SARODE V, BREWSTER D, PHILPOT S, SIMPSON S

Treatment of invasively ventilated adults with Early Activity and Mobilisation. A prospective multicentre phase 3 randomised controlled trial of early activity and mobilisation compared with standard care in invasively ventilated patients in intensive care. We are currently in the recruitment phase for this very exciting study working in partnership with allied health including the physiotherapists. ICU ROX TRIPS RESEARCHERS: BREWSTER D, SIMPSON S

Standard vs Intervention use of oxygen in mechanically ventilated patients, Translating Research Into Practice

Staff from the Intensive Care Unit preparing to care for patientâ&#x20AC;&#x2122;s during the COVID-19 pandemic.

(TRIPS). With the ICU ROX study now having completed recruitment, the focus shifts to TRIPS. Do we change our practice in line with recommendations from research? Practice of clinicians was examined pre commencement of ICU ROX, after recruitment was completed and now that the ICU ROX study has been published. Data analysis of all three time periods is currently being completed. SPRINT- SARI RESEARCHERS: BREWSTER D, SIMPSON S

Short Period Incidence study of Severe Acute Respiratory Infection. SPRINT-SARI is an ambitious international collaborative project aimed at characterising SARI patients as a global problem to better inform management strategies and ultimately to improve the ability of healthcare systems to rapidly respond to emerging infectious causes of SARI. We are currently in the recruiting phase of any patients diagnosed with COVID-19.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Total research projects approved and ongoing in 2020

336 C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

+$10.9m IN GRANT FUNDING

P U B L I C AT I O N S

P R E S E N TAT I O N S

CLINICAL TRIALS

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Department of Urology

Head: Professor Mark Frydenberg The Urology Department joined the Cabrini Institute in July 2019 under the leadership of Professor Mark Frydenberg who has been actively researching this field for many years. This department contributes to two outcomes registries – the Prostate Cancer Outcomes Registry and the nephrectomy clinical outcomes registry.

Director of Urology Professor Mark Frydenberg PHD Student Arveen Kalapara, Monash University Medical Students Yash Khanna Kavitha Gnanasambantham

Professor Frydenberg collaborates with Monash University on xenograft and genomics research. Professor Frydenberg aims to improve the multi-disciplinary model and quality of care; benchmark across organisations; improve patient access to modern imaging/ diagnostics and new technologies; improve the focus on survivorship; and to contribute to the development of the new Cabrini Cancer Institute both academically and clinically.

Highlights The department’s main aim for 2021 is to develop Cabrini academically and clinically as a centre of excellence in focal therapy for prostate cancer, and to work with Genesis Care to develop and promote theranostics at Cabrini.

Recent grant success profile • • • • • • • • •

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Targeting lethal prostate cancer in its infancy (Monash) NHMRC $764,000 Developmental events affecting male fertility and reproductive pathologies (Monash) NHMRC $1.4m Inherited pathogenic mutations in prostate cancer (Monash) PCFA $490,000 Impact of PET PSMA in the management of prostate cancer (Monash Health, VCCC) PCFA $1.3m Centre of Research Excellence in prostate cancer survivorship (Multi-Centre) NHMRC $2.5m Can exercise delay transition to active therapy in low grade prostate cancer NHMRC $596,000 Targeting lipid metabolism in prostate cancer (Monash) CCV $300,000 Realtime app for PCOR-ANZ (Monash, USANZ) Movember $100,000 Predicting urinary incontinence and ED after prostate cancer surgery (Monash, USANZ) Movember $90,000

Our Education

02. 74

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Laruen Williams, educator, in full PPE. C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

14,400

S T U D E N T P L AC E M E N T DAY S O F F E R E D I N ( F Y ) 1 9/ 2 0

G R A D U AT E N U R S I N G P O S I T I O N S O F F E R E D ( F Y ) 1 9/ 2 0

P O S TG R A D U AT E N U R S I N G S T U D E N T S ENROLLED IN CABRINIâ&#x20AC;&#x2122;S SUPPORTED P O S TG R A D U AT E P RO G R A M

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Clinical Education Department

Head: Rick Peebles The Clinical Education department has a centralised model of education with a core curriculum informed by organisational risk, workforce requirements and Cabriniâ&#x20AC;&#x2122;s customers. Our department develops resources and training programs for nursing, midwifery and allied health staff, ensuring quality standards are maintained throughout our organisation. Our focus is to provide educational opportunities that build a smart, change enabled workforce inspiring confidence, professionalism, expertise and excellence in clinical care.

Director Rick Peebles, Acting Director of Clinical Education Administration Support Barbara Miles, Curriculum Administrator Donna Li, Infrastructure & STP Coordinator Leesa Horrigan, Undergraduate Student Coordinator Jacky Fernandez, Clinical Placement Administrator Clinical Education and Allied Health Education Team Tanya Harding, Clinical Education Curriculum Developer Lauren Williams, Clinical Education Curriculum Developer

Amanda Peat, Quality and Safety Curriculum Developer Abby Falla, Transition to Professional Practice Educator Louise Suttie, Transition to Professional Practice Educator Natalie Horvath, Perioperative Educator Tegan Proctor, Adult Deterioration and Resuscitation Educator Kelly Sherman, Paediatric Deterioration and Resuscitation and Undergraduate Educator Sophie Jennings, Allied Health Educator Anie Abraham, Medical Clinical Support Nurse Jess Bakouline, Emergency Department Clinical Support Nurse Irene Zhao, Perioperative Clinical Support Nurse

Lydia Burnage, Midwifery Clinical Support Nurse Illona McArthur, Cancer and Palliative Care Clinical Support Nurse Andrea McDonald, Cardiac Clinical Support Nurse Michelle Wigg, Perioperative Clinical Support Nurse Margot Dobie, Perioperative Clinical Support Nurse Claire Loveridge, Deterioration Clinical Support Nurse Clare McCosker, Intensive Care Clinical Support Nurse Madeline Marcelino, Emergency Department Clinical Support Nurse Lauren Boyce, Physiotherapy Clinical Supervisor Ran Li, Physiotherapy Clinical Supervisor

James Gaudin, Physiotherapy Clinical Supervisor Clinical Placement Facilitators Marina Necoski Stefanie Adlam-Smeele Chris Stafford-Arnold Gail Iglesia Cassie Lieschke Megan Hayes Sarah Nettleton Jess Radin Nicole Milne Jordan Lakin Sabrina Velik Acknowledgement of Staff who have left (2019-2020) Jo Schlieff, Director of Clinical Education Kristen Hamer Sarah Mann Alice Wandke

Highlights Undergraduate Program Cabrini is a teaching hospital, providing clinical training opportunities for our future health professionals. Over the 2019-20 year, Cabrini provided 14,400 placement days for nursing, midwifery and allied health students. Across the year Allied Health and Ambulatory Services worked collaboratively with our education providers to support student programs across seven disciplines and three education provider partnerships.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Our primary partnerships remain strong for nursing, midwifery and allied health with Monash University, Australian Catholic University (ACU) and ACU College, La Trobe University and Swinburne University. The ‘ACCENT program’ (ACU College and Cabrini Educating Nurses Together) is in its second intake. The ACCENT program has seen the transition of eight students complete their Diploma of Nursing and all clinical placements at Cabrini. The opening of the Gandel Wing in June of 2019 extended a range of exciting clinical opportunities for students, including the addition of clinical placements now being offered in chronic disease services. Graduate Program Our Transition to Professional Practice (TTPP) program for newly registered nurses, enrolled nurses and midwives is designed to support the transition from an undergraduate into the workforce. The structured program enables consolidation of clinical skills whilst enhancing critical thinking and clinical reasoning in a supported learning environment. The program also incorporates simulation scenarios based on Cabrini’s risk data with a focus on patient deterioration, communication skills and cognitive impairment. In 2019-20 our team provided learning opportunities and clinical support to over 67 graduates. Postgraduate Program Cabrini offers several postgraduate programs to support nurses to expand their scope of practice and pursue their personal and professional development goals. We offer courses in Cancer Nursing (University of Melbourne), Emergency Nursing (Monash University), Intensive Care Nursing (Monash University), Perioperative Nursing (Monash University) and Cardiac Nursing (La Trobe University). We have a team of dedicated Clinical Support Nurses who provide clinical learning opportunities to assist course

participants to contextualise their academic learning. There are currently 25 postgraduate nursing students progressing well through their studies alongside six allied health staff members who are undertaking postgraduate qualifications. A further four allied health staff members are completing Higher Degree by Research. Curriculum Development Nursing, allied health and medical staff have access to a wide variety of professional development opportunities. Cabrini’s eLearning platform, provides staff with access to eLearning courses that support their clinical practice and align with workforce needs. This platform also offers bookings into face-to-face workshops where staff can apply their knowledge, develop new skills and collaborate with peers to explore complex case scenarios and topics. Our curriculum development team have developed 44 new courses throughout 2019-20. Clinical Support Nurses We have nine Clinical Support Nurse (CSN) roles across Cabrini that are designed to support novices, postgraduates and clinical staff. There are three additional CSN roles this year to ensure timely, context relevant teaching occurs at the patient’s bedside. In addition to this we have a clinical facilitation team who provide support to our undergraduate students and their preceptors.

Interprofessional Learning In Situ Simulation Program Last year the Clinical Education department piloted a customer led program titled ‘In Situ Simulation Program – Clinical Handover’. The program involved collaborative design with a previous Cabrini patient, who guided the content and learning outcomes. This program set out to

NEW COURSES WERE DEVELOPED (R-L) Clinical Educator Anie Abraham with ACU student Teonnie Dimitrakis and RN Carissa Long.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

create an authentic learning context by simulating a clinical handover scenario, utilising the past patient to encourage active consumer involvement in clinical handover and provide feedback to participants. A total of six sessions were delivered with 12 participants with approximately half of the Prahran inpatient nursing workforce. Evaluation data demonstrated that: • 86% of participants felt more confident in clinical handover and admission planning with consumer involvement • 86% believed they would change their handover performance as a result of participating in the training • 100% of participants felt the learning that occurred during the simulation training is transferable to the care of future patients • 93% of participants were satisfied with the program and felt well supported by the educators running the simulation • 93% of participants believed the program should be offered ongoing Medical Mystery Evenings Clinical Education, nursing, allied health and medicine, facilitated a series of inter-professional learning events. These Medical Mystery Evenings focused on providing an opportunity for undergraduate students to collaboratively explore an evolving patient case and develop team based clinical care pathways. The learning session is designed to engage the participants in discussions that will promote interdisciplinary understanding and collaboration. Simulation Centre

promoting the delivery of safe and high quality patient care. The Simulation Centre has state of the art mannequins which provide staff and students with the opportunity to practice their skills in a safe learning environment prior to performing these clinically. Last year there were over 95 sessions held in the Simulation Centre. These sessions included; Advanced Life Support training, graduate study days, clinical skills workshops and medical student training.

COVID-19 Response The leadership, professionalism and responsiveness of the Clinical Education department during these challenging times was recognised organisationally. The Clinical Education COVID-19 response focused on Personal Protective Equipment (PPE) training, simulation training in the Emergency Department, Perioperative Services and Intensive Care Unit (ICU). In addition, we rapidly developed a program to support nurses returning to work in the ICU to increase the ICU workforce staff numbers. We delivered over 30 sessions of PPE training which captured approximately 1700 clinical and non-clinical staff. This training is essential in ensuring our staff, patients and visitors are protected and safe and aids in reducing the spread of COVID-19. To support predicted increase in bed capacity in ICU an additional 15 nurses were upskilled in BASIC training. This course involved; lectures, case studies and simulation, which were all delivered remotely. Additionally, COVID-19 has provided many challenges for student placements and program delivery however the Clinical Education team has developed innovative models of delivery to ensure we continue to meet our focus on a smart, change enabled workforce inspiring confidence, professionalism, expertise and excellence in clinical care.

Clinical simulation is used in the training and assessment of healthcare professionals. Cabrini’s simulation activities provide engaging learning opportunities, ultimately

121

PRACTICAL PPE TRAINING SESSIONS WERE PROVIDED (L-R) Graduate Nurse Raj Kayastha being supervised by Transition to Professional Practice Program Educator Louise Suttie in safe preparation and checking of intravenous medication using electronic medication management (eMM). C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

MEDICAL STUDENT RESEARCH SCHOLARSHIP RECIPIENTS ( $ 2 1,0 0 0 TOTA L I N R E S E A RC H G R A N T S )

260

MONASH UNIVERSITY STUDENTS AT T E N D E D C A B R I N I F O R C L I N I C A L ROTAT I O N S

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Department of Medical Student Education

Head: Associate Professor David Brewster This has been a challenging time for all medical students. Although 2019 brought outstanding academic success for Cabrini medical students once more, as well as multiple publications and research grants, the COVID-19 pandemic has brought new challenges to our learning including remote learning from home for many of the students in the first half of 2020. Their resilience has been tested and their attitudes to this change have been inspiring. This courage displayed by our student body aligns itself with Cabrini’s mission.

Clinical Dean Associate Professor David Brewster, Cabrini-Monash University Clinical School Dr Abhay Umranikar, Acting Clinical Dean during COVID-19 Phase 1 Clinical Site Administrator Jennie McInerney, Cabrini-Monash University Clinical School Clinical Educator Naomi Snowden, Cabrini-Monash University Clinical School

Highlights The highlight of 2019 for our department occurred when Associate Professor David Brewster was asked to be a key speaker at the Kindness in Healthcare Conference run in Melbourne by the Hush Foundation and KPMG during the Gathering of Kindness week. This included a trip to Government House for lunch as well as the opportunity for two Cabrini medical students to present alongside Associate Professor Brewster at the conference. India Marks and Lauren Vallely discussed the kindness they have seen during their clinical rotation at Cabrini and the difference this has made to their educational journey so far. During our first lockdown in March, the year three Monash medical student placements were suspended and all teaching reverted to remote learning. Due to the reduction in elective surgery and clinical activity, we saw an opportunity to reach out to our Cabrini Visiting Medical Officers (VMOs) to see if they would have time to deliver remote teaching to our students. We had a great response and managed to set up quite a few lectures via zoom with some of our specialists. The students greatly appreciated the commitment from our VMOs and it definitely helped keep them engaged and positive during such a difficult and challenging period. Learning from senior medical staff of this calibre is a privilege the students value greatly. Monash University undergraduates As a member of the Central Clinical School for Monash University, Cabrini provides high quality clinical placements for students from Monash University’s Bachelor of Medical Science and Doctor of Medicine (MD) course, formerly Bachelor of Medicine and Bachelor of Surgery (MBBS). Associate Professor Brewster and Jennie McInerney continue to develop and oversee the undergraduate educational program at Cabrini. During 2019, approximately 260 Monash University students attended Cabrini for clinical rotations.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Senior Medical Staff Association research scholarship program Excellent engagement of Cabrini senior medical staff saw a hugely successful program again this year with 14 students each awarded $1500 research scholarships. Third-year program Up to 29 medical students were placed simultaneously at Cabrini for six-week rotations in various specialties of medicine and surgery at Cabrini Malvern in 2019. “ProblemBased Learning” was conducted at The Alfred Hospital and an extremely popular “Curriculum Enhancement” program was conducted at Cabrini. Our Cabrini specialists ran a “Local Lectures Series” throughout the year and Naomi Snowden conducted weekly procedural skills training and simulation teaching. Students received a weekly bedside teaching session from their tutors and had summer research grants available. Fourth-year program Thirty-two, fourth-year students experienced a four-week paediatric rotation at Cabrini Health under the supervision of Dr Debbie Kipen in 2019. Approximately 70 students experienced their Women’s Health ‘Mentor Week’ at Cabrini following a Cabrini Specialist. Fifth-year program

The University of Notre Dame In the past financial year we have seen 33 final-year medical students from The University of Notre Dame (UND) rotate through Cabrini in the specialties of Cardiology; Obstetrics and Gynaecology; Orthopaedics and Rehabilitation; and Palliative Care. These students are all postgraduate students, having already completed an undergraduate degree in a relevant field and often having worked in that field before commencing their medical degree with UND. Three years ago, Cabrini introduced a Notre Dame Student Representative as a first point of contact to assist the smooth transition of students rotating at Cabrini and give us feedback first hand. Interestingly, UND has now introduced this successful concept with other healthcare education providers. Our student representative for the 2019 year was Olivia Szwarcberg and for 2020 is Katie Goldman. They have been great ambassadors for UND and for Cabrini. We have a large team of consultants and other health professionals who assist in the education of these medical students and give freely of their time. We thank them for the wonderful work they do. At the conclusion of each rotation students are given the opportunity to vote for the Cabrini/ UND Student Choice Award for excellence in teaching. Congratulations go to last year’s joint winners Dr Danielle Wilkins for her work in the Obstetrics and Gynaecology rotation and Associate Professor Natasha Michael for her work in the Palliative Care rotation.

Approximately 80 fifth-year students completed a six-week pre-intern rotation at Cabrini. These placements occurred in many medical specialties and general surgery. Our registrars and supervising specialists provided valuable guidance and preparation to these students.

Associate Professor David Brewster (right) and Jennie McInerney (left) with Third Year Monash Medical Student Class of 2019.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Due to the reduction in elective surgery and clinical activity, we saw an opportunity to reach out to our Cabrini Visiting Medical Officers (VMOs) to see if they would have time to deliver remote teaching to our students. We had a great response and managed to set up quite a few lectures via Zoom with some of our specialists.

JENNIE MCINERNEY

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Broader Medical Education STP Program

Quick Clinical Updates Program

The Specialist Training Program at Cabrini continues to enhance our culture in terms of education, research, team work, patient care, attracting the best clinicians and supporting our medical student program. Federal Government support of the STP program continues to diminish. Partner hospitals have withdrawn support of partnerships due to challenges in recruiting sufficient trainees for their own needs, especially in general medicine. We have directly employed some trainees but this is an unsustainable model and does not attract the best talent. Trainees continue to report an excellent learning experience. Cabrini’s Transition to Consultant program led by Dr Tim Gray is a unique structure designed to help build resilience and skills to enjoy consultant life.

The Quick Clinical Updates series aims to provide education to our clinical workforce, particularly specialist trainees, about the translation of new research into practice across specialties. We are grateful to the local Cabrini expert clinicians and our special guests who generously share their knowledge. Our sessions this year included: • Atrial fibriliation – an update by Professor Peter Kistler • Diet and the microbiome in cancer management by Dr Despina Hondolias • Cabrini is autism aware: How can we improve the hospital experience for children with Autism Spectrum disorder by Kelly Sherman • Code Sepsis: improving outcomes in hospital acquired sepsis by Dr Ryan Salter • Innovation in patient experience and continuity of care in ED by Associate Professor Michael Ben-Meir • Exercise limitation in health and cardiopulmonary disease by Dr David Systrom • The role of comprehensive geriatric assessment in the management of pain by Associate Professor Benny Katz • Victoria’s real time prescription monitoring system by Dr Malcolm Dobbin • COVID-19 Update by Dr Fergus Kerr and Dr James Pollard • The COVID-19 Pandemic – opportunity from crisis by Professor Gary Richardson OAM • Precision medicine by Dr Anis Hamid

GP Series The Institute’s long running GP series has come to an end! We have been privileged to work with local GP, Dr Neil McNab, who has led the education of GPs from the Cabrini Institute for decades. Thank you to all those who have provided education to these GPs who are important partners in the healthcare of our shared patients. GP education is now conducted through Cabrini’s Business Development function. We express our gratitude to Dr Neil McNab and Leesa Horrigan for their commitment to excellence.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Highlights included Dr David Systrom’s visit as he is employed at Massachusetts General Hospital cardiopulmonary laboratory and has authored more than 130 peer reviewed publications. Local guests Associate Professor Benny Katz, who specialises in geriatric and pain medicine at St Vincent’s and Dr Malcolm Dobbin from SafeScript Victoria also attracted large audiences. Like other education offerings, this series has moved to Zoom. Sessions are recorded and available for those who are unable to attend in real time.

Q & A Program This education program invites participation of the whole Cabrini community including patients and families. We focus on learning towards meeting the National Safety and Quality Health Service (NSQHS) Standards. Highlights of the year included sessions examining: • Frailty – does it matter? • Pressure injuries and wound management • Cybersecurity – our collective challenge to manage risk • Open disclosure – what it is and is not • Protecting our patients and staff – why immunise? • Chief Executive’s vision for Cabrini • Cabrini’s new Cancer Institute

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Our Q & A in July on frailty was a wonderful learning opportunity to explore this topic so relevant to our Cabrini cohort of patients. Feedback from attendees included the comments: “The information consistently reflected the learning objectives and speakers presented information and graphics which was right on topic and clear.” “Looking at the same problems differently can be insightful and exciting.” Over the last 12 months we have featured reflections from both our outgoing Chief Executive Michael Walsh and our current Chief Executive Sue Williams. Both sessions were well attended and of great interest to our Cabrini community. Our final session for the year was on the Cabrini Cancer Institute. This was an interactive session with a diverse audience including a very personal approach from a former patient’s perspective. The session ran as a question-and-answer style of content delivery and was extremely engaging. As COVID-19 emerged, it was necessary to modify our program and move from face-to-face delivery to virtual sessions via Zoom. This transition has enabled an increase in participation and we are enjoying the benefits of hosting larger audiences. Feedback has encouraged us to start transitioning the format away from short presentations and panel discussions to be a more authentic Q and A format. We welcome suggestions for future topics.

Our Research Infrastructure CABRINI INSTITUTE TEAM

Director of Institute Infrastructure Anne Spence

Institute Administration and Infrastructure Jacky Fernandez, Coordinator Infrastructure Leesa Horrigan, Coordinator Engagement and Undergraduate Education Donna Li, Coordinator Postgraduate Education Bianca Noble, Coordinator Scholarships, Grants and Communications Ioana Logan, Cabrini Institute Receptionist

Director of Research Dr Emma Baker

Biostatistician Associate Professor Wei Wang

Director, Cabrini Institute and Medical Education, Director, Szalmuk Family Department of Medical OncologyDirector, Oncology Clinics Victoria Professor of Medicine, Monash University Professor Gary Richardson OAM

03. Institute Health Data Management Justin Lang Mr Gilbert Shardey

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Medical student Mika Sood practicing clinical skills in the Cabrini Simulation Lab. C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

25,372 FULL TEXT ARTICLES DOWNLOADED FROM LIBRARY

69,647 DATA B A S E S E A RC H E S ACC E S S E D FROM LIBRARY

1651

EBOOK CHAPTERS VIEWED

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Cabrini Library

The Peter and Judy Lowthian and Family, Lee and Brian Johnstone Library continues to provide the Cabrini community with valuable resources and an expert library service.

Di Horrigan, Manager of Library Services

Di Horrigan

As the start of the 2020 year has evolved into a challenging COVID-19 environment the library continues to be an essential partner to the research and clinical areas of Cabrini. As of March 2020, the librarian has worked remotely maintaining 24/7 continuous online electronic access; offering consultations via online forums, continuing to answer clinical and other reference questions, providing literature searches and document delivery service. The librarian Di Horrigan was the recipient of a Health Libraries grant to attend the VALA conference in Melbourne in February 2020. VALA is an internationally recognised conference supporting the latest development in information technology and library services. The librarian will report on her findings at the Health Libraries Victoria virtual conference in October.

COVID-19 Resources & Support To support the clinical workforce with COVID-19 resources; a dedicated COVID-19 subject guide, https://libguides.cabrini.com.au/coronavirus, was developed to provide links to search filters, provide a live feed of the latest articles, link to export podcasts and present the information in a structured evidence based format. So far 450 staff have viewed this guide.

Information Teaching The librarian has worked with the allied health research group to teach critical appraisal skills using formal appraisal tools to evaluate various formats of information â&#x20AC;&#x201C; websites, clinical guidelines and journal articles. Introduction to library services was presented at both Malvern and Brighton campuses targeting specific information skills to the pathology and dietetics groups.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

C A B R I N I M O N A S H CO LO R E C TA L N E O P L A S I A DATA B A S E

AU S T R A L I A N R H E U M ATO LO GY A S S O C I AT I O N DATA B A S E ( A R A D)

5000 5799

E X T E N S I V E DATA C A P T U R E ON ALMOST

PAT I E N T S F RO M M O N A S H A F F I L I AT E D H O S P I TA L S

PAT I E N T S W I T H S U RV E YS I N DATA B A S E

B R I G H T WAY S : A C A B R I N I B R E A S T C A N C E R S E RV I C E DATA B A S E

CABRINI SITE COLLECTION: P RO S TAT E C A N C E R O U TCO M E S REGISTRY - VICTORIA (PCOR-VIC)

1550

DATA H A S B E E N CO L L E C T E D F O R

PAT I E N T S R E C E I V I N G T R E ATM E N T AT C A B R I N I

490

PAT I E N T S R E G I S T E R E D A P RO S TAT E C A N C E R D I AG N O S I S T H RO U G H C A B R I N I A F F I L I AT E D CLINICIANS WERE RECORDED I N TO T H E DATA B A S E F O R SCREENING AND COLLECTION

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Clinical Database Registries

Without some form of clinical audit, it is difficult to know if healthcare is being delivered efficiently or effectively and even more difficult to demonstrate to others.

The purpose of clinical database registries is to improve the safety and/or quality of healthcare provided to patients by collecting key clinical information from individual healthcare encounters. This enables risk-adjusted outcomes to be used in evidencebased quality improvement. Cabrini leads the development and application of a number of high quality clinical database registries.

Cabrini Monash Colorectal Neoplasia Database Bowel cancer is a major cause of illness, disability and death worldwide. Complete and accurate data remain the key requirements to describe processes and outcomes of care for all patients with bowel cancer. Registries play a critical role in cancer surveillance allowing us to evaluate survival, new cases and deaths. The primary purpose of this surgical audit is to monitor outcomes and report on quality of care and report this back to the treating clinicians. Clinicians, researchers and others use audit data to answer questions like, “What is the surgical complication rate after treatment for bowel cancer?”, “Should malignant polyps be treated differently depending on their location?” and “What are the predictive factors of a complete pathological response in patients with locally advanced rectal cancer?” Bowel cancer is the third most common type of newly diagnosed cancer in Australia and is the second biggest cancer killer. The Colorectal Database Registry, conceived and entirely funded by the Cabrini Monash Department of Surgery in 2007, implemented in 2010, is now a well-established registry capturing data on patients with either bowel cancer or benign bowel neoplasia surgically treated at Cabrini Health and other Monash affiliated hospitals, including The Alfred, Peninsula Health and Monash Medical Centre, Dandenong. In 2013, the Colorectal Surgical Society of Australia and New Zealand (CSSANZ) developed the Bi-National Colorectal Cancer Audit (BCCA), a minimally scaled duplicate version, with participation from over 97 sites across Australia and New Zealand contributing data from over 38,000 patients. The registry allows surgeons to benchmark their performance amongst their peers, ensuring a commitment to the highest standards of patient care. The role of the database manager is to also inform patients of the leading-edge research we are conducting in collaboration with laboratories at Monash Biomedicine Discovery Institute, Department of Anatomy and Developmental Biology. Patients willing to provide consent allow us to collect valuable clinical samples such as tumour and

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

normal tissue, enabling us to undertake research projects as follows: 1. Tissue microarray (TMA) TMAs allow multiple sources of tissue to be analysed simultaneously and allow for the rapid identification of prognostic and predictive biomarkers resulting in improved patient management. 2. Organoids Organoids are miniature replicas of both cancer and normal tissue, grown in the laboratory, providing scientists with model systems to assist researchers to quickly identify and optimise targeted anticancer therapies. 3. Human tissue-slice assay A model for studying the development of colorectal cancer as well as providing a novel platform for testing new immunotherapy drugs on thin slices of tumour tissue in culture.

the long-term safety and effectiveness of biologic disease modifying antirheumatic drugs (bDMARDs). ARAD is participating in the value-based prescribing of bDMARDs, a coordinated national program, a large ($8.4m) grant funded by the federal Department of Health. This program aims to optimise use of biologics in Australia. A survey of ARAD participants was conducted to evaluate their attitudes with respect to biologic therapy and biosimilars. A separate study evaluating their experience of COVID-19 was also conducted in collaboration with the COVID-19 Global Rheumatology Alliance.

Patient Reported Outcome Measures (PROMS)

•

We are excited to announce a standardised set of colorectal cancer PROMS is currently being incorporated into the registry and will allow direct patient entry of data relating to all aspects of quality of life and functional outcomes following surgical treatment for bowel cancer. What matters most are the outcomes that patients experience and this data will provide a feedback loop between the patient and the clinician to ensure optimised treatment for all patients.

Australian Rheumatology Association Database (ARAD)

Research Projects: • •

•

• • •

Value-based prescribing of bDMARDS – Rachelle Buchbinder, Catherine Hill, Sam Whittle Patient Experience of COVID-19; Collaboration between ARAD and COVID-19 Global Rheumatology Alliance – Catherine Hill, Rachelle Buchbinder, David Liew, Phillip Robinson Australian rheumatoid arthritis (RA) biologic treatment pathways: Australian Rheumatology Association Database (ARAD) analysis – Ashley Fletcher, Rachelle Buchbinder Socioeconomic Differences in Opioid Use by People with Inflammatory Arthritis – Ashley Fletcher, Catherine Hill, Marissa Lassere, Rachelle Buchbinder Survey on biologic/biosimilar/vaccination – Alannah Quinlaven Dyadic coping survey – Manasi Mittinty Propensity score methods for estimating causal effects in non-experimental settings – Marissa Lassere

The Australian Rheumatology Association Database (ARAD) collects long-term observational data about the outcomes of Australians with inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis). Its primary aim is to determine

ARAD is now listed on the Australian Commission on Safety and Quality in Health Care list of registries. It aims to facilitate collaboration and awareness of registry activity among key stakeholders. ARAD supports three PhD students who completed their PhD in 2019-20 with Dr Rachel Black being awarded the Barbara Cameron ARA Research Establishment Fellowship

C A B R I N I M O N A S H C O L O R E C TA L N E O P L A S I A D ATA B A S E

A U S T R A L I A N R H E U M AT O L O G Y A S S O C I AT I O N D ATA B A S E ( A R A D )

THE AVER AGE AGE OF PATIENTS AT DIAGNOSIS

ME AN FOLLOW UP TIME OF E ACH PATIENT

69 yrs 5.7 yrs 92

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Brightways: A Cabrini Breast Cancer Service Database

(L-R) Dr Simon Wilkins, Karen Oliva and Caroline Xue. Karen Oliva received the prize for best Cancer Poster ‘Influence of primary site on metastatic distribution and survival or early-stage colorectal cancer’.

(Reassessing the Mortality Gap in Rheumatoid Arthritis in Australia). ARAD also supports four Rheumatology Advanced Trainees, one MD student and one Masters student, Dr Oscar Russell, who won the Best Oral Presentation by Clinical Trainee at The Queen Elizabeth Hospital Research Expo 2019. ARAD is also currently collaborating with the Australian Arthritis and Autoimmune Biobank Collaborative (A3BC), a large network of clinicians, researchers and scientists from across Australia who are working together to develop a national, data-linked, open-access biobanking network to integrate with the established ARAD questionnaire and data linkage framework. They have established a national, openaccess, best-practice biobank network to collect, process and store a broad range of biospecimens (blood, tissue, saliva, stool etc) from participants with rheumatic diseases and controls (including at-risk relatives). Biological data will be integrated with multiple datasets, including self-reported outcome/experience and environmental data, electronic medical records, commonwealth data (Medicare Benefits Scheme, Pharmaceutical Benefits Scheme, Australian Immunisation Register) and cancer/death registries.

Breast cancer is the most common cancer among Australian women and is the second leading cause of cancer related death in Australian women, after lung cancer. One in eight Australian women will be diagnosed with breast cancer in their lifetime. The rate of mortality is decreasing due to earlier detection by screening mammography and advances in treatment. Using the Brightways Breast Cancer Database, we aim to monitor and improve the quality of breast cancer treatment and outcomes at Cabrini. The information is used to: • Compare variations in care and outcomes with clinical quality indicators • Provide feedback to participating clinicians • Promote compliance with breast cancer guidelines • Reduce unfavourable variation • Support epidemiological studies and translational research The registry was established in November 2016 and data has been collected for 1550 patients receiving treatment at Cabrini. This database supports management of multidisciplinary team (MDT) meetings, decision-making, cancer staging and patient treatment recommendations in line with Victorian Cancer Service performance indicators. Clinicians receive patient clinical and treatment summaries prior to the weekly MDT meetings. The recommended care plan and staging are recorded at the meeting and the care team receives a record of their patient’s care plan. Data for 2970 patients referred to the breast MDT meetings at Cabrini has been captured. An audit has been conducted to compare hospital admissions data with our database to ensure all patients, treatment and outcomes are captured. In 2019, 99.7% of patients with a first diagnosis of early invasive breast cancer were referred for discussion at the breast MDT meeting.

B R I G H T W AY S : A C A B R I N I B R E A S T C A N C E R S E R V I C E D ATA B A S E

C A B R I N I S I T E C O L L E C T I O N : P R O S TAT E C A N C E R OUTCOME S REGISTRY – VICTORIA (PCOR-VIC )

OF PATIENTS WITH A FIR ST DIAGNOS IS OF E ARLY INVA SIVE BRE A ST C ANCER WERE REFERRED FOR DISCUS SION AT A BRE A ST MDT MEE TING

CURRENT E STIM ATED P OP UL ATION COVER AGE , WITH THE AIM OF ACHIEVING 90%

99.7% 54%

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

The database is a powerful tool for translational bioinformatics. Unlike other cancer databases, this database has been specifically designed to capture complexity and variation in tumour heterogeneity and hormone-receptor expression for core biopsies, primary and metastatic tumours. The database also collects vital outcomes information including treatment modification, response to therapy, toxicity, disease progression, recurrence and cancer status at death. The information in our database will be integrated with research findings to identify new biomarkers for prognosis, improve our understanding of tumour behaviour and heterogeneity, rapidly evaluate the effectiveness of anti-cancer agents for specific tumour molecular subtypes and identify molecular subtypes and variation in hormone receptor expression, which may lead to a poorer response or drug resistance. Research Projects 1. 2.

5. 6.

State wide quality audit of MDMs. I Solo, Peter MacCallum, I Campbell, May 2019 Impact of multidisciplinary team meetings on the management of patients with breast cancer at Cabrini Hospitals in Melbourne. J Lai, Y Antill, G Richardson, M Vereker, S David, July 2019 Return to usual activities after breast cancer treatment. Monash University, S-Y Kim, D Kissane, S Birks, P Gregory, J Morgan, C Ooi, J Senior, I Bobevski, N Michael, M Vereker, G Richardson, Y Antill, L Lipton, December 2019 Whole genome sequencing project. T Jarde, Department of Anatomy and Developmental Biology, Monash Biomedicine Discovery Institute, May 2020 ASCO quality oncology initiative program. J A Chow, G Richardson, February 2020 A multi-centre national study of COVID-19 infection in cancer patients. C Lim, National Centre for Infection in Cancer, Department of Infectious Diseases, Peter MacCallum, May 2020 Development and Implementation of a Gynaecological Cancer Database, July 2020

Cabrini site collection: Prostate Cancer Outcomes Registry – Victoria (PCOR-VIC) The Prostate Cancer Outcomes Registry – Australia and New Zealand (PCOR-ANZ) database is building a populationbased prostate cancer clinical registry to improve the quality of care provided to men diagnosed with prostate cancer. According to the World Health Organisation, Australia and New Zealand have one of the highest rates of prostate cancer. Fortunately, the improvement in screening and treatment is contributing to better survival rates. An important part of helping more men survive is enabling best-practice treatment and improvements in quality of life. PCOR-ANZ aims to build understanding of the disease burden of prostate cancer, and aid the implementation of evidence-based support services. The registry collects treatment data as well as surveying patients’ quality of life before and after treatment. By reporting on these factors, the goal is to reduce the negative effects of urinary, bowel and sexual function and increase general physical health and mental wellbeing. The quality indicator reports to clinicians provide a cross-sectional view of clinical and demographic aspects of prostate cancer and patterns of care, which helps understand the uptake of evidence-based practice. By contribution to a robust dataset, patient data across many institutions assists in the design of clinical trials and identification of questions for study. Overall, clinicians and institutions can be provided with mortality and morbidity data associated with various risk and treatment groups, both for their own patients and the wider cohort of men with prostate cancer. PCOR-ANZ seeks to deliver data that is fully representative of prostate cancer practice and outcomes across Australia and New Zealand in the near future. Highlights Quality Indicator (QI) reports for Cabrini were completed, helping provide clinicians with treatment outcomes to better inform practices. The first bi-national QI report from PCOR-ANZ was delivered in 2019. For the first time, more men who have been diagnosed with prostate cancer across the ANZ region have joined PCOR-ANZ than those who have not.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

IN THE SPOTLIGHT

Melissa Vereker

DATA MANAGER AND MDT MEETING COORDINATOR

Melissa Vereker is the Data Manager for the Cabrini Monash Department of Medical Oncology and MDT Meeting Coordinator for Cabrini Breast Cancer Care. Since joining Cabrini in 2016, she has developed the Breast Cancer Database and the Breast MDT Meeting Database. Melissa has extensive experience in IT, clinical data management and cancer research. She has previously worked as a national IT Desktop Training Manager at Optus, Data Manager for the Department of General Surgery at The Alfred, Thyroid Cancer Registry Coordinator for the Monash Endocrine Surgery Unit and Research Associate at the Hudson Institute of Medical Research. Melissa believes monitoring and measuring safety and patient care is an essential part of healthcare delivery. At Cabrini Breast Cancer Care, routine data collection is integrated with clinical practice to support the management of multidisciplinary team meetings, document patient treatment summaries and care plans, quality activities and research. Data is captured throughout the patientâ&#x20AC;&#x2122;s journey, from diagnosis to follow-up care. The data is used to measure quality of cancer care, compliance with best practice guidelines, identify areas for service improvement and ensure patients receive safe and effective treatment. The data will help improve the management, treatment and outcomes of future breast cancer patients, identify patients who may benefit from new treatments or clinical trials and evaluate long term effects and outcomes for treatment that was provided many years ago.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Melissa is an Adjunct Associate at Monash University and a member of the MPCCC Advisory Group. She has presented at Cabrini Research Meetings, Cabrini Breast Cancer Care Governance Meetings, the Cabrini Oncology Craft Group Meeting and the Department of Biochemistry at Monash University. Melissa has been an investigator for clinical and translational research projects including the ASCO quality oncology initiative program, impact of multidisciplinary team meetings on the management of patients with breast cancer at Cabrini hospital, return to usual activities after breast cancer treatment, state wide quality audit of multidisciplinary team meetings, patient self-reported outcomes of toxicity during chemotherapy and modelling human breast cancer disease using an experimental in vitro organoid culture system. Melissaâ&#x20AC;&#x2122;s current interests are using health information technology to improve processes and outcomes in cancer care and breast/ gynaecological clinical research. Melissa is developing a web-based gynaecological cancer database. Prospective data will be collected for patients receiving treatment at Cabrini for ovarian, cervical, uterus, vulva, vagina and other gynaecological cancers. Information collected will include patient demographics, diagnosis, tumour characteristics, stage, treatment and outcomes. Melissa will also be involved in the establishment of the Department of Medical Informatics at the Cabrini Cancer Institute.

Providing Best Cancer Management for our Patients – Multidisciplinary Team Meetings Cabrini is committed to providing best practice management of patients with cancer. We provide personalised multidisciplinary care, from diagnosis to treatment, rehabilitation and recovery. Multidisciplinary team (MDT) meetings are a vital part of treatment planning and effective management of cancer at Cabrini. Our dedicated team of health professionals – surgeons, radiologists, medical and radiation oncologists, breast care nurses, physiotherapists and counsellors ‒ work together to determine the best, individualised treatment and care plan for every patient. Our decision-making is guided by our patients and their individual needs and preferences. Our collaborative team approach to cancer treatment ensures continuity of care throughout the patient’s cancer journey. Cancer stream

Frequency

Breast Weekly Colorectal Fortnightly Haematology Fortnightly Lung Fortnightly Melanoma/skin Fortnightly Neuro-oncology Bi-monthly Upper GI Fortnightly Urology Fortnightly The benefits of multidisciplinary care include: • Shorter time frames from diagnosis to treatment • Improved coordination of care • Improved treatment planning • Improved communication and sharing of information • Identification of patient supportive care needs and other factors which may impact treatment and care • Recruitment for clinical trials and cancer research projects • Clinical data captured during MDT meetings is used for clinical audit and quality improvement • Educational opportunities for healthcare professionals At Cabrini, we strive to deliver a high standard of care by continuously measuring, evaluating and improving the quality of care. In 2019, our team of healthcare professionals participated in a multidisciplinary team meeting audit conducted by the Victorian Department of Health and

Human Services. The aim of the audit is to monitor, enhance and support the quality, effectiveness and consistency of cancer multidisciplinary team meetings in Victoria. During the COVID-19 pandemic, Cabrini has implemented new procedures to optimise safety for healthcare professionals and patients. MDT meetings are facilitated using a video conferencing program. Virtual breast MDT meetings are an effective alternative to faceto-face meetings and will continue to be a part of clinical practice in the future. The breast cancer MDT is currently the highest subscribed meeting at Cabrini. Statistics show: Total number of patients referred in 2017

658

Total number of patients referred in 2018

775

Total number of patients referred in 2019

859

Number of patients discussed in 2019

842

Number of patients referred, not discussed in 2019*

Number of patients discussed more than once in 2019 Percentage of patients with a documented MDT care plan in 2019

217 99%

Average number of patients referred per MDT meeting in 2019

Minimum number of patients referred per MDT meeting in 2019

Maximum number of patients referred per MDT meeting in 2019

* 15 patients were not discussed as the histology was benign In 2019, 99.7% of patients with a first diagnosis of early invasive breast cancer were referred for discussion at the breast MDT meeting.

A Cabrini Colorectal MDM initiative With Zoom capability now we have the opportunity to invite treating clinicians to be involved in the Multidisciplinary Meeting utilising a secure login via Zoom. This allows the GP/clinician to hear the discussion about their mutual patient and to participate in this discussion if they wish, a first for Cabrini!

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

IN THE SPOTLIGHT

Associate Professor Wei C. Wang BIOSTATISTICIAN

Associate Professor Wei C. Wang’s interdisciplinary research profile concentrates on behavioral nutrition, healthy ageing, health services, mental health, nursing, and medical research. Despite the depth and breadth of her research, the major contribution of her work concerns research methodology (e.g. study design, data management, manipulation of large datasets, data analysis using applied statistical modelling techniques). Wei has provided statistical support for research staff and graduate students across several universities. Her expertise is in applied statistical modelling including structural equation modeling, latent growth curve modeling, latent class modeling, mixture modeling, and multilevel modeling inter alia. Moreover, Wei’s research has involved analysing, exploring, and interpreting complex data employing a range of statistics packages: MPLUS, AMOS, LISREL, SPSS, R, and Stata. Wei’s past research has targeted Alzheimer’s Disease Neuroimaging Initiative (ADNI); Diabetes and Cognition in Older Tasmanians (TASCOG); Exercise during Haemodialysis among patients with late stage kidney disease; Mental Health in Multicultural Australia (MHiMA); Medicine in Australia: Balancing Employment and Life (MEBAL); Social Psychological Influences on Food Consumption and BMI; Addressing the food and health needs of ageing Baby Boomers; Weekly Meal Repertoire study (Meat & Livestock Australia); Resilience for Eating and Activity Despite Inequality (READI) study; Wellbeing,

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Eating and Exercise for a Long Life (WELL) study; and Melbourne Longitudinal Studies on Healthy Ageing (MELSHA). The impact of Wei’s research is demonstrated by a Google Scholar h-index of 29 and a Research Gate score of 35.14, with 989 citations (August 2020). She has secured top tier competitive external research funding including ARC (Discovery) and industry grants. Wei has also presented the outcome of this research at international and national conferences, and co-authored several industry reports. Wei joined Cabrini Institute as a biostatistician in July 2019. Since this time, she has provided research support to medical and nursing researchers, and graduate students across several departments as well as to research teams affiliated with Cabrini. Given her statistical and research background, Wei is cognisant of the most appropriate up-to-date statistical techniques and procedures to deploy when testing research hypotheses and ensuring the reliability of results. Wei has developed an exceptional way of helping investigators to identify and understand statistical issues related to their research so that they can improve the overall quality of their research proposals and studies. She provides her colleagues with links to relevant literature and resources that assist with explaining simply the statistical concepts and analysis related to their projects. Furthermore, Wei proffers useful feedback and support to researchers on writing and reporting relating to the statistical and results sections of their manuscripts.

NEW RESEARCH PROJECTS APPROVED BY CHREC AND RESEARCH GOVERNANCE IN FY19-20

P ROJ E C T S H AV E B E E N A P P ROV E D TO - DAT E I N 2 0 2 0 BY T H E N E W R E S E A RC H GOVERNANCE OFFICE (CRGO)

A P P R OX I M AT E LY

22%

O F P ROJ E C T A P P L I C AT I O N S W E R E FOR NEW DRUG TRIALS

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Cabrini Research Governance Office

Cabrini’s Research Governance Office (CRGO) provides ethical review of low or negligible risk projects as well as site governance for moderate to high risk studies. Low or negligible risk projects are those which cause little or no discomfort to the participant. Such research activities may include anonymised surveys, short structured interviews, secondary use of non-identifiable data, audits and observational studies.

Deb Macdonald, Research Governance Officer Michele Tonkin, Research Governance Officer

The CRGO ensures all projects conducted at Cabrini abide by our mission statement whilst adhering to our Catholic values. All projects must respect patient confidentiality and safety in order for research integrity to be maintained. Cabrini fosters a culture of research and innovation, welcoming applications from both novice and seasoned researchers alike. Research conducted at Cabrini must be underpinned by the four pillars of the Cabrini Institute Strategy which are value-based care, advanced precision medicine, a smart, change enabled clinical workforce and an innovative partner of choice.

Highlights Farewell Deb Macdonald

Grace Wijnen, Acting Manager, Cabrini Human Research Ethics Committee and Research Governance Office, was farewelled in September 2019 after eight years working for CHREC as we transitioned to the Monash Partners shared HREC model. Evolving Service

Michele Tonkin

The CHREC was disbanded on 31 December 2019 and the CRGO created. The CRGO website has been updated to reflect our new charter. Michele Tonkin joined the team in February 2020 and quickly became invaluable for her attention to detail and customer service. The CRGO is tasked with delivering an efficient review service that maximises Cabrini’s ability to host high quality single and multi-site research projects. Part of the CRGO’s remit is ensuring all researchers have current Good Clinical Practice credentialing, their projects are insured, contributing parties are indemnified, and adequate funding exists to support the anticipated project expenses. Matching approved projects with their funding sources, whether internal or external, and facilitating greater financial transparency in all research activity is a key priority for 2020-21.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

The impacts of COVID-19 The COVID-19 global pandemic meant we began working from home in March 2020 however we have embraced the challenges and continue to review and approve projects in a timely manner. COVID-19 has generated significant research activity in terms of the multitude of opportunities to investigate new drugs for curative or preventative purposes, studies addressing new models of inpatient treatment, data collection for epidemiological review, impact studies on health workers and much more. This surge in research activity has required that the CRGO demonstrate agility to ensure that researchers can move swiftly in response to the evolving nature of the virus and its impact on society.

CHREC Monash Partnerships Monash Health and Alfred Health are being utilised to provide full HREC reviews for moderate to high risk projects. The cooperation between all the Monash Partners stakeholders has been gratifying and ensures a more streamlined and collaborative approach to multi-site projects. We will continue to review the appropriateness of this model for Cabrini.

Projects Approved RESEARCHER NAME PRINCIPAL

TITLE A new risk prediction model incorporating both surgical and morbidity factors to predict outcomes after colorectal cancer surgery patients in Australia

Dr Simon Wilkins

COVID ICU airway survey

Associate Professor David Brewster

Improving Patient-centred Care through Digital Change: Implementing a â&#x20AC;&#x2DC;lightweightâ&#x20AC;&#x2122; digital platform to link with patient systems and mobile devices

Associate Professor Philip Russo

A phase 1a/1b, open-label, dose-escalation and dose-expansion study of the anti-CTLA-4 monoclonal antibody CS1002 as monotherapy and in combination with anti-PD-1 monoclonal antibody CS1003 in subjects with advanced solid tumors [CS1002-101]

Professor Gary Richardson OAM

Trends and outcomes in neoadjuvant chemotherapy and radiotherapy for rectal cancer

Dr Simon Wilkins

An open label phase 1B dose finding study of BI 836880 in combination with BI 754091 to characterise safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in patients with locally advanced or metastatic non-squamous non-small cell lung cancer and in other solid tumours

Professor Gary Richardson OAM

Efficacy of an ambulatory supportive care clinic on patient reported outcomes and clinical service utilisation in a pallliative and supportive care service: A retrospective, single-centre observational study

Associate Professor Natasha Michael

Effects of changing dose grid and statistical uncertainty settings in Monaco 5.10 for Stereotactic Radiotherapy planning

Dr Simon Goodall

A confirmatory, prospective, open-label, multi-centre phase 3 study to evaluate diagnostic performance of 89 Zirconium-labelled girentuximab (89Zr-TLX250) to non-invasively detect clear cell renal cell carcinoma (ccRCC) by positron emission tomography/CT (PET/CT) imaging in patients with indeterminate renal masses [Zr-TLX250-003] [ZIRCON]

Professor Mark Frydenberg

Examining treatment and survival outcomes for BRAF mutant colorectal cancer patients

Dr Rebekah Engel

Impact of anastomotic leak on long-term oncological outcomes after rectal cancer surgery

Dr Rebekah Engel

A simulation study of novel personal protective equipment for intubation

Dr Jonathan Begley

Redefining guidelines for germline testing in pancreatic and prostate cancer

Dr Lucy Gately

A phase 2b/3, randomised, double-blind, placebo-controlled, parallel-group, multicenter protocol to evaluate the efficacy and safety of Guselkumab in participants with moderately to severely active Ulcerative Colitis [CNTO1959UCO3001]

Dr Edward Shelton

100

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

TITLE

RESEARCHER NAME PRINCIPAL

Open-label phase 2 study of Ladiratuzumab Vedotin (LV) for unresectable locally advanced or metastatic solid tumors [SGNLVA-005]

Professor Gary Richardson OAM

5-year retrospective review of rectal cancer patients treated with neoadjuvent chemoradiation and the rates of complete pathological response

Dr Vidhya Ramani

Co-design of a prostate cancer support portal - BroSupPORT

Professor Mark Frydenberg

Impact of anastomotic leak on long-term oncological outcomes after curative stage I-III colon cancer surgery

Karen Oliva

The use of My Health Record in the emergency department: An investigation of utility

Associate Professor Michael Ben-Meir

A phase 3 randomised, double-blind study of Nivolumab or Placebo in combination with Doctaxel, in men with metastatic castration-resistant Prostate Cancer [CA209-7DX]

Dr David Pook

Volumetric modulated arc therapy (VMAT) for extensive skin field cancerisation (ESFC) – exploring the limits of treatment volumes with a case series of backs

Dr Bradley Wong

SpaceOAR Audit

Dr Vidhya Ramani

Implementation of a ‘Rapid Myocardial Infarction Pathway’ to improve outcomes of in-hospital STEMIs in Victoria

Associate Professor Jeffrey Lefkovits

Evaluation of the implementation process of submissions for re-classifications made by Pastoral Practitioners at Cabrini, working in the field of spiritual care, according to the SHA capability framework and the SCA eligibility criteria for membership, for inclusion in the Cabrini EBA 2019

Ms Catherine Carr

HEAR ME service pilot process evaluation

Ms Michele Speak

Use of a Supportive Screening Tool in blood cancer patients undergoing treatment; feasibility and success of an electronic PROMs (Patient Reported Outcomes Measures) and nurse led assessment to meet patients’ wellness needs: a pilot study

Associate Professor Melita Kenealy

Impact of time of radiotherapy treatment on patient outcomes in rectal adenocarcinoma

Dr Kendrick Koo

A phase 1, multi-centre, open-label, dose escalation study of CS3005 in subjects with advanced solid tumors

Professor Gary Richardson OAM

The Alfred, Cabrini, Epworth (A.C.E.) hospitals Interventional Structural Heart Procedures Outcomes Registry

Associate Professor Dion Stub

A single centre retrospective clinical audit: outcomes of self-funded immunotherapy in patients with mesothelioma

Dr Samantha Dean

An open-label, multi-center, long-term extension study of Zanubrutinib (BGB-3111) in patients with Bcell Malignancies [BGB-3111-LTE1]

Associate Professor Melita Kenealy

EUROBACT II: Epidemiology and determinants of outcomes of hospital acquired blood stream infections in the intensive care

Associate Professor Vineet Sarode

Factors influencing the management of people presenting with rotator cuff related shoulder pain to Australian general practitioners: a study using the Theoretical Domains Framework

Romi Haas

GLA:D Back Australia: improving self-management for people with persistent or recurrent low back pain through the implementation of evidence based patient education and exercises: a feasibility study

Dr Jason Wallis

PROpatient: A registry based randomised controlled trial of symptom monitoring, using patientreported outcomes, and care coordination to improve quality of life for patients with upper gastrointestinal cancer

Mr Marty Smith

Return to usual activities after breast cancer treatment

Professor David Kissane

Smartphone utlisation by anaesthetists in Australia

Associate Professor David Brewster

A prospective, observational study in patients receiving adjuvant Nivolumab therapy for resected melanoma in Australia [CA209-7CK]

Professor Ben Brady

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

101

RESEARCHER NAME PRINCIPAL

TITLE Recognising and reporting changes in resident’s health: Measuring the effectiveness of an aged care education and training package

Ann MacRae

Pressure injury surveillance and prevention to reduce avoidable harm

Dr Victoria Team

Uptake and costs of early supported discharge and hospital in the home in Australian public and private hospitals

Dr Emma Gearon

A review of physiotherapy practice for people with bronchiectasis

Dr Annemarie Lee

A multicentre, randomised double-blind, placebo controlled 52 week maintenance and an open label extension study of the efficacy and safety of Risankizumab in subjects with Crohn’s Disease who responsed to induction treatment in M16-006 or M15-991; or completed M15-989 [M16-000]

Professor Stephen Hall

Investigating the ability of algorithms and machine learning to predict emergency department wait times for patients

Associate Professor Katie Walker

Phase II trial PD-L1/PD-1 blockade Avelumab (MSB0010718C() with chemoradiotherapy for locally advanced resectable rectal cancer [AveRec]

Dr Ben Markman

A phase 1b/III study of ipatasertib plus palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in hormone receptor positive and Her2 negative locally advanced unresectable or metastatic breast cancer [Ipatunity150] [CO41012]

Dr Yoland Antill

Is spontaneous swallowing reduced in Parkinson’s compared to healthy controls?

Dr John Pierce

A randomised controlled trial of exercise medicine for men undergoing active surveillance for prostate cancer

Professor Mark Frydenberg

Towards control of an endoscope-holding robot by foot in laparoscopic surgery

Dr Charles Pilgrim

The Ritchie Centre Human Tissue Bank: gynaecological/perinatal

Professor Caroline Gargett

Exploring the regenerative and reparative potential of stem-like cells from gestational tissues

Associate Professor Rebecca Lim

Stereotactic ablative body radiotherapy (SABR) for oligometastatic prostate cancer – multi-institutional retrospective study

Dr Michael Chao

Accuracy and clinical utility of genomic profiling using next generation sequencing of Thyroid Fine Needle Aspiration (FNA) samples

Dr Simon Grodski

Using the consumers voice to inform interprofessional education: Safe enough to connect, real enough to provoke

Jordana (Jo) Schlieff

Translating organoids, tissue microarrays and molecular subtypes into personalised care for colorectal cancer patients

Professor Paul McMurrick

Barriers, enablers and acceptability of home-based rehabilitation following a total hip or knee replacement at Cabrini: A qualitative study using the theoretical domains framework

Dr Jason Wallis

Er:YAG surgical laser for treatment for vaginal laxity – a randomised controlled trial

Associate Professor Anna Rosamilia

The relationship between cardiorespiratory parameters and physical activity following cardiac surgery

Dr Annemarie Lee

Choosing wisely staff perceptions survey

Associate Professor Philip Russo

A study into the effectiveness and delivery of pre-treatment education at Cabrini for patients receiving systemic cancer therapy

Tracey Bucki

Preventing hospital acquired malnutrition: best practice patient care and the role of clinical nurse education

Nadine Lawson

Are we managing Hypos and Hypers well? A look at inpatient diabetes management at Cabrini Health. Are we following Best Practice Guidelines?

Ian Campbell

102

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

TITLE

RESEARCHER NAME PRINCIPAL

ALBICS: Albumin infusion and AKI following cardiac surgery – randomised trial

Associate Professor Vineet Sarode

Influence of primary site on metastatic distribution and survival of early stage colorectal cancer

Karen Oliva

Nurses’ perceptions and learning preferences for patient participation in clinical handover

Rick Peebles

Factors influencing the timely development of the intrapartum woman-midwife relationship in one Victorian private hospital model of care

Madelaine Clark

A multicentre, randomised, double-blind, placebo-controlled induction study of the efficacy and safety of Risankizumab in subjects with moderately to severely active Crohn’s disease [M16-006]

Professor Stephen Hall

A multicentre, randomised, double-blind, placebo-controlled induction study of the efficacy and safety of Risankizumab in subjects with moderately to severely active Crohn’s Disease who failed prior biologic treatment [M15-991]

Professor Stephen Hall

The development and implementation of a pictorial hospital food menu

Claire Matthews

Combatting compassion, fatigue and burnout of Oncology nurses

Dr Tali Lang

First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (D4194R00005) [PACIFIC-R]

Dr Ben Markman

Outcomes following sacrocolpopexy for Pelvic Organ Prolapse [OsPOP]

Associate Professor Anna Rosamilia

The NOURISH point prevalence study – Nutritional Outcomes of patients Undergoing Resection for upper gastroIntestinal cancer in AuStralian Hospitals

Annika Dorey

A phase 3, Randomised, 3-Part Study To Investigate The Efficacy And Safety Of Dupilumab In Adult And Adolescent Patients With Eosinophilic Esophagitis

Dr Jeremy Rosenbaum

A phase 2, randomised, placebo-controlled, double-masked study to assess safety and efficacy of multiple doses of IONIS-FB-LRX, an antisense inhibitor of complement factor B, in patients with geographic atrophy secondary to age-related macular degeneration (AMD) [ISIS 696844-CS5]

Associate Professor Heather Mack

A phase 1/2, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of AGEN2034 in subjects with metastatic or locally advanced solid tumors, with expansion to second line cervical cancer [C-700-001]

Professor Gary Richardson OAM

Urology Society of Australia and New Zealand clinical quality registry [USANZ Renal Surgery Clinical Quality Registry]

Professor Mark Frydenberg

A 3 year, multi-centre, long-term safety (LTS) study to evaluate the safety and tolerability of TD1473 in subjects with ulcerative colitis (UC) [0164]

Associate Professor Henry Debinski

A phase 2b/3 multi-centre, randomised, double-blind, multi-dose, placebo-controlled, parallel – group set of studies to evaluate the efficacy and safety of induction and maintenance therapy with TD-1473 in subjects with moderately to severely active ulcerative colitis [0157]

Associate Professor Henry Debinski

A phase 1, open-label, multi-centre, non randomised, dose escalation study to evaluate the safety, tolerability and pharmacokinetic profile of XNW7201 in subjects with advanced solid tumors [XNW7201-1-02)

Professor Gary Richardson OAM

A phase 3 randomised, placebo-controlled, double-blind study of Niraparib in combination with Abiraterone acetate and Prednisone versus Abiraterone acetate and Prednisone for treatment of subjects with metastatic prostate cancer [MAGNITUDE]

Dr David Pook

A prospective observational study to measure the angle of the long axis of the upper trachea in relation to the anterior skin surface of the neck during voluntary neck extension using computed tomography

Associate Professor David Brewster

Surveying patients, visitors and staff on their experience of the palliative community musician program at Cabrini Prahran

Ms Caitlin Bull

The National Gynae-Oncology Registry (NGOR)

Professor Gary Richardson OAM

Myelodysplastic syndromes (MDS) registry [MDSlink]

Associate Professor Melita Kenealy

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

103

Publications, Books, Book Chapters, Reports and Grants Held

Cabrini Monash University Department of Nursing Research Publications, books, book chapters, reports Russo PL, Stewardson AJ, Cheng AC, Bucknall T, Mitchell BG. (2019) The prevalence of healthcare associated infections among adult inpatients at nineteen large Australian acute-care public hospitals: a point prevalence survey. Antimicrobial Resistance & Infection Control. 8(1):1-8. doi: 10.1186/s13756-019-0570-y Russo PL. (2019) Bundles of bundles. Infection, Disease & Health. 24(3):113-114. doi: 10.1016/j.idh.2019.06.001 Mitchell BG, Fasugba O, Russo PL. (2020) Where is the strength of evidence? A review of infection prevention and control guidelines. J Hosp Infect. 105(2):242-251. doi: 10.1016/j.jhin.2020.01.008 Shaban RZ, SotomayorCastillo C, Nahidi S, Li C, Macbeth D, Mitchell BG, Russo PL. (2020) Global burden, pointsources and outbreak management of healthcareassociated Burkholderia cepacia infections: an integrative review. Infect Control Hosp Epidemiol. 41(7):777-783 doi: 10.1017/ ice.2020.184. (Online ahead of print.) Nayna Schwerdtle P, Connell CJ, Lee S, Plummer V, Russo PL, Endacott R, Kuhn, L. (2020) Nurse expertise: a critical 104

resource in the COVID-19 pandemic response. Annals of Global Health. 86(1):1-5. doi: 10.5334/aogh.2898 Russo PL, Stewardson AJ, Cheng AC, Bucknall T, Mitchell BG. (2020) Prevalence of device use and transmission based precautions in nineteen large Australian acute care public hospitals: secondary outcomes from a national healthcare associated infection point prevalence survey. Infection Disease and Health. doi: 10.1016/j.idh.2020.05.006. (Online ahead of print.) Russo PL. Ask the Experts: Healthcare-associated infections – surveillance, prevention and control. Infectious Diseases Hub. https://www.id-hub. com/2019/09/24/ask-theexperts-healthcare-associatedinfections-surveillanceprevention-and-control/

Grants held Alan Jackson Research Grant. ‘The effect of COVID-19 on healthcare associated infections in a multi-campus private healthcare facility.’ (2020) $49,461. Russo P (PI), Renton R (CI), Wang W (CI), Mitchell B (CI). Alan Jackson Research Grant. ‘The experience of the healthcare worker during the COVID-19 response.’ (2020) $47,211. Russo P (PI), Ilangakoon C (CI), Richardson G (CI), Ben-Meir M(CI). Auric Innovation Grant (Johnstone Family, via Cabrini Foundation). ‘Development of customised distraction techniques for managing acute behavioural disturbance of elderly patients in the

emergency department setting to limit use of chemical and physical restraint.’ (2019), $146,993. Blecher G, Kuhn L, Walker K, Flynn D, Joe K, Russo P, Page R, Peisah C.

Monash-Cabrini Department of Clinical Epidemiology

NHMRC Early Career Fellowship. ‘Improved Detection of Infections Following Surgery for Meaningful Public Reporting.’ (2019) $327,192.00. Russo P (PI), Cheng A, Bucknall T.

Publications, books, book chapters, reports

Industry Grant – Covidien. ‘Establishing the prevalence of healthcare associated infections in two large Australian private hospitals.’ (2020) $15,000. Russo P (PI), Cheng A, Stewardson A, Mitchell B. Industry Grant – Covidien. ‘Patient perspectives of healthcare associated infection.’ (2019), $15,000. Mitchell B, Northcote M, Rickett C, Russo P. NHMRC Ideas Grant. ‘A new approach to disinvestment: Application to falls prevention mobilisation alarms.’ (2020) $1.1M. CIs: Haines T, Shorr B, Botti M, Brusco N, O’Brien E, Redley B, Bowles KA. AIs: Hutchinson A, Mitchell D, Jellete J, Steen K, Boyd L, Russo P, Webb M, Raymond M, Hunter P. Rosemary Norman Foundation. "Establishing the prevelence of healthcare associated infections in Australian hospitals'. Russo PL, Cheng A, Stewardson A, Bucknall T, Mitchell BG. $180,000 (20172020).

Black R, Richards B, Lester S, Buchbinder R, Barrett C, Lassere M, March L, Hill CL. (2019) Factors associated with commencing and ceasing opioid therapy in patients with rheumatoid arthritis. Semin Arthritis Rheum. 49(3):351-7. Rozbroj T, Lyons A, Lucke J. (2019) The mad leading the blind: Perceptions of the vaccine-refusal movement among Australians who support vaccination. Vaccine. 37(40):5986-93. Ebeling PR, Akesson K, Bauer DC, Buchbinder R, Eastell R, Fink HA, Giangregorio L, Guanabens N, Kado D, Kallmes D, Katzman W, Rodriguez A, Wermers R, Wilson HA, Bouxsein ML. (2019). Response Letter to the Editor-Diamond et al, JBMR. J Bone Miner Res. 34(6):1185-6. Buchbinder R, Busija L. (2019) Why we should stop performing vertebroplasties for osteoporotic spinal fractures [Current Controversies]. Intern Med J. 49:1367-71. Maher CG, O’Keeffe M, Buchbinder R, Harris IA. (2019) Musculoskeletal healthcare: Have we over-egged the pudding? Int J Rheum Dis. 22:1957-60. Dan M, Phillips A, Johnston RV, Harris IA. (2019) Surgery for patellar tendinopathy

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

( jumper’s knee). Cochrane Database of Systematic Reviews. 9:CD013034CD013034. Cross AJ, Buchbinder R, Bourne A, Maher C, Mathieson S, Lin CC, O’Connor DA. (2019) Barriers and enablers to monitoring and deprescribing opioid analgesics for chronic non-cancer pain: protocol for a qualitative evidence synthesis using the Theoretical Domains Framework. BMJ Open. 9(11): e034039. Jessup RL, Oates MJ, Johnston RV, Buchbinder R. (2019). Shockwave therapy for plantar heel pain (plantar fasciitis) [Protocol] Cochrane Database of Systematic Reviews. 11:CD013490. Sidhu VS, Graves SE, Buchbinder R, Naylor JM, Pratt NL, de Steiger RS, Chong BH, Ackerman IN, Adie S, Harris A, Hansen A, Cripps M, Lorimer M, Webb S, Clavisi O, Griffith EC, Anandan D, O’Donohue G, Kelly TL, Harris IA. (2019) CRISTAL: protocol for a cluster randomised, crossover, non-inferiority trial of aspirin compared to low molecular weight heparin for venous thromboembolism prophylaxis in hip or knee arthroplasty, a registry nested study. BMJ Open. 9(11):e031657. O’Keeffe M, Buchbinder R. (2019) Management of nonspecific low back pain: a growing issue. Pain Management Today. 6(2):46-53. Karjalainen TV, Jain NB, Heikkinen H, Johnston RV, Page CM, Buchbinder R. (2019) Surgery for rotator cuff tears. Cochrane Database Syst Rev. 12:CD013502. Joyce K, Staples M, Beauchamp A, Jessup R, Buchbinder R. (2019) The health literacy profile of clients attending a community rehabilitation program: A survey using the Health Literacy Questionnaire (HLQ). Rehabil Res Policy Educ. 34(1):1-10. Major DH, Røe Y, Grotle M, Jessup R, Farmer C, Småstuen MC, Buchbinder R. (2019) Content reporting of exercise interventions in

rotator cuff disease trials: Results from application of the Consensus on Exercise Reporting Template (CERT). BMJ Open Sport Ex Med. 5:e000656. Suman A, Schaafsma FG, van Dongen JM, Elders PJM, Buchbinder R, van Tulder M, Anema JR. (2019) Effectiveness and cost-effectiveness of a multifaceted eHealth strategy to improve back pain beliefs of patients with non-specific low back pain: a cluster randomised trial. BMJ Open. 9:e030879. Cai K, Whittle SL, Richards BL, Ramiro S, Falzon L, Buchbinder R. Marine oil supplements for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2019, Issue 12. Art. No.: CD010250. Lähdeoja T, Karjalainen TV, Jokihaara J, Kavaja L, Salamh P, Agarwal A, Winters M, Buchbinder R, Vandvik PO, Arden C (2020). Subacromial decompression surgery for adults with shoulder pain – a systematic review with meta-analysis. Br J Sports Med. 54:665-73. McKenzie JE, Brennan SE, Ryan RE, Thomson HJ, Johnston RV, Thomas J. (2020) Chapter 3: Defining the criteria for including studies and how they will be grouped for the synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions. 2nd Edition. Chichester (UK): John Wiley & Sons, [33–66]. © 2020 The Cochrane Collaboration. Published 2020 by John Wiley & Sons Ltd. McKenzie JE, Brennan SE, Ryan RE, Thomson HJ, Johnston RV. (2020) Chapter 9: Summarizing study characteristics and preparing for synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions. 2nd Edition. Chichester (UK): John Wiley & Sons, [229–240]. © 2020 The Cochrane Collaboration. Published 2020 by John Wiley & Sons Ltd. Wu A, March L, Zheng X, Huang J, Wang X, Zhao J,

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Blyth F, Smith E, Buchbinder R, Hoy D. (2020) Global Low Back Pain Prevalence and Years Lived With Disability From 1990 to 2017: Estimates From the Global Burden of Disease Study 2017. Ann Translational Med. 8(6):299. Saeid S, Hoy D, March L, Buchbinder R, Ferreira M. (2020) Global, Regional, and National Burden of Neck Pain in the General Population, 19902017: Systematic Analysis of the Global Burden of Disease Study 2017. BMJ. 368:m791. Hazlewood GS, Whittle SL, Kamso MM, Akl EA, Wells G, Tugwell P, Thomas M, Lee C, Choudhary D, Neuen DR, New-Tolley J, Powell M, Quinlivan A, Qaddoura A, Dearddon R, Maxwell LJ, Pardo JP, Buchbinder R. (2020) Disease-modifying anti-rheumatic drugs for rheumatoid arthritis: a systematic review and network meta-analysis [Protocol]. Cochrane Database Syst Rev. 3:CD013562. Jessup RL, Putrik P, Buchbinder R, Nezon J, Rischin K, Cyril S, Shepperd S, O’Connor DA. (2020) Identifying alternative models of healthcare service delivery to inform health system improvement: scoping review of systematic reviews. BMJ Open. 10(3):e036112. Suman A, Armijo-Olivo S, Deshpande S, Marietta J, Miciak M, Werner EL, Straube S, Buchbinder R, Gross D. (2020) A systematic review of the effectiveness of mass media campaigns for the management of low back pain. Disab Rehabil. doi: 10.1080/09638288.2020. 1743777. Buchbinder R, Busija L. (2020) Author reply to Clark et al. IMJ. 50(5):648-9. Farmer CI, Bourne AM, O’Connor D, Jarvik JG, Buchbinder R. (2020) Enhancing clinician and patient understanding of radiology reports: a scoping review of international guidelines. Insights Imaging. 11(1):62. Bråten LCH, Schistad EI, Espeland A, Kristoffersen PM, Haugen AJ, Marchand GH, Vetti N, Pripp AH, Kadar TI,

Skouen JS, Grotle M, Grøvle L, Zwart JA, Brox JI, Storheim K; AIM-study group. (2020) Association of modic change types and their short tau inversion recovery signals with clinical characteristics – A cross sectional study of chronic low back pain patients in the AIM-study. BMC Musculoskelet Disord. 21(1):368. Fletcher A, Lassere M, March L, Hill C, Carroll G, Barrett C, Buchbinder R. (2020) Oral complementary medicine use among people with inflammatory arthritis: An Australian Rheumatology Association Database analysis. International Journal of Rheumatology. (2):1-9. Gearon E, Backholer K, Lal A, Nusselder W, Peeters A. (2020) The case for action on socioeconomic differences in overweight and obesity among Australian adults: modelling the disease burden and healthcare costs. ANZ J Public Health. 44(2):121-8. Haas R, Bowles K, O’Brien L, Haines T. (2020) The effect of transferring weekend physical therapy services from the acute to sub-acute setting in patients following hip and knee arthroplasty: A quasiexperimental study. Physiother Theory Pract. doi:10.1080/09593 985.2020.1777604. Di Donato M, Buchbinder R, Iles R, Gray S, Collie A. (2020) Comparison of Compensated Low Back Pain Claims Experience in Australia with Limb Fracture and Non-Specific Limb Condition Claims: A Retrospective Cohort Study. J Occup Rehabil. doi:10.1007/ s10926-020-09906-x. Leonardo N, Lester S, Graham M, Whittle S, Rowett D, Buchbinder R, Hill CL. (2020) Selection and perception of methotrexate treatment information in people with rheumatoid arthritis. Int J Rheum Dis. 3(6):805-12. Rozbroj T, Haas R, O’Connor D, Thomas R, McCaffery K, Carter S, Buchbinder R. (2020) Patient and public understanding of overtesting and overdiagnosis: Protocol of a thematic meta-synthesis of qualitative studies. BMJ Open. 10:e037283.

105

Buchbinder R, Maher C, Underwood M, Hartvigsen J. The Lancet series call to action to reduce low value care for low back pain: An update (invited). Pain. Accepted 2020. Buchbinder R, Huang H, Ramiro S, Jia Y, Gagnier J, Whittle S. Measures of adult shoulder function (invited). Arthritis Care Res. Rozbroj T, Lyons A, Lucke J. (2020) Vaccine-Hesitant and Vaccine-Refusing Parents’ Reflections on the Way Parenthood Changed Their Attitudes to Vaccination. J Community Health. 45(1):63-72. Buchbinder R, Ebeling PR, Akesson K, Bauer DC, Eastell R, Fink GA, Giangregorio L, Guanabens N, Kado D, Kallmes D, Katzman W, Rodriguez A, Wermers R, Wilson HA, Bouxsein ML. (2020) Response to: Some Questions About the Article “The Efficacy and Safety of Vertebral Augmentation: A Second ASBMR Task Force Report”. J Bone Miner Res. 35(1):212-3. Buchbinder R, Bourne A, Harris I, Latimer J, Taylor W, Whittle S, Richards B, Clavisi O, Green S, Hinman RS, March L, Day R, Ferreira ML, Billot L, Maher C, on behalf of the ANZMUSC Clinical Trials Network. (2020) Early Development of the Australia and New Zealand Musculoskeletal Clinical Trials Network. Intern Med J. 50(1):17-23. Shaheed CA, Maher CG, Buchbinder R, Ng B, Enke O, Guzowski R, McLachlan AJ, Day RO, Richards B, Latimer J, Lin CW. (2020) Efficacy and harms of orally, intramuscularly or intravenously administered glucocorticoids for sciatica: A systematic review and meta-Analysis. Eur Spine J. 24(3):518-35. Smith L, Barratt A, Buchbinder R, Harris I, Doust J, Bell K. (2020) Trends in knee magnetic resonance imaging, arthroscopies and joint replacements in older Australians: still too much low-value care? ANZ J Surgery. 90(5):833-9. 106

Roe Y, Buchbinder R, Grotle M, Whittle S, Huang W, Gagnier J, Ramiro S, Verhagen A, Page M, Østensjø S. (2020) What do the OMERACT candidate instruments for shoulder disorders measure? An analysis using the refined ICF linking rules. J Rheumatol. doi: doi. org/10.3899/jrheum.190832. Mathieson S, Wertheimer G, Maher CG, Lin CWW, McLachlan A, Buchbinder R, Pearson SA, Underwood M. (2020) What proportion of patients with chronic noncancer pain are prescribed an opioid medicine? Systematic review and meta-regression of observational studies. J Intern Med. 287(5):458-474. Surace SJ, Deitch J, Johnston RV, Buchbinder R. (2020) Shock wave therapy for rotator cuff disease with or without calcification. Cochrane Database Syst Rev. 3:CD008962. Beard DJ, Campbell M, Blazeby JM, Carr AJ, Weijer C, Cuthberson B, Buchbinder R, Pinkney T, Bishop F, Pugh J, Cousins S, Harris I, Lohmander S, Blencowe N, Gillies K, Probst P, Brennan C, Farrah-Hockley D, Cook A, Savalescu J, Huxtable R, Rangan A, Tracey I, Brocklehurst P, Lee N, Nicholl J, Reeves B, Hamdy F, Rowley S, Cook J. (2020) Considerations and methods for placebo controls in surgical trials (ASPIRE guidelines). The Lancet. 395(10226):828-38. Busija L, Ackerman I, Haas R, Wallis J, Nolte S, Bentley S, Miura D, Hawkins M, Buchbinder R. Adult measures of general health and health-related quality of life (invited). Arthritis Care Res. Di Donato M, Iles R, Lane T, Buchbinder R, Collie A. The impact of income support systems on healthcare quality and functional capacity in workers with low back pain: a realist review. Pain. Malliaris P, Johnston RV, Seneque G, Littlewood C, Bennell K, Haines T, Buchbinder R. The efficacy of higher versus lower dose exercise in rotator cuff tendinopathy: A systematic

review of randomised controlled trials. Arch Phys Med Rehab.

Elderly’. (2016-2019) $511,076. Harris I, Buchbinder R, Ivers R, Naylor J, Baloh Z, Smith P.

Sharma S, Traeger AC, Reed BJ, Hamilton M, O’Connor DA, Hoffmann TC, Bonner C, Buchbinder R, Maher CG. Clinician and patient beliefs about diagnostic imaging for low back pain: a qualitative evidence synthesis. BMJ Open.

NHMRC Program Grant. ‘Musculoskeletal pain and disability: improving outcomes through conservative interventions’. (2016-2020), $8,268,140. Hodges P, Bennell K, et al. Buchbinder R (AI).

Åkesson K, Chang LY, Yang RS, Chan DC, Buchbinder R, Overgaard S, Bengtsson A, Hurley M, Nordin M, Dahlberg L, Woolf A. Advances in delivery of health care for musculoskeletal conditions (invited). Best Practice Res Clin Rheumatol.

Grants held NHMRC Senior Principal Research Fellowship. (20152019) $911,915. Buchbinder R. NHMRC Translating Research into Practice Fellowship. (20192020) $181,066. O’Connor DA. NHMRC Centre of Research Excellence in Translation of Research into Improved OUtcomes in Musculoskeletal Pain & Health (CRE TRIUMPH). (2015-2019) $2,500,000. Bennell K, Hunter D, Hodges P, Buchbinder R, Pirotta M, Hinman R, Harris A, Foster N, Michie S, Vicenzino B NHMRC Project Grant. ‘Hype or Hope? platelet-Rich plasma as a symptom- and disEaSemodifying Treatment fOR knee ostEoarthritis - the RESTORE trial’. (2016-2019) $1,400,359. Bennell K, Buchbinder R, Wang Y, Forbes A. Cabrini Foundation Clinical Research Grant. ‘The Back Pain Quest: Understanding beliefs about low back pain’. (20182019) $30,000. Buchbinder R, Hawkins M, Osborne R.

NHMRC Partnership Grant. ‘Patient-centred eHealth approach to improving outcomes for gout sufferers’. (2016-2020) $660,656. Day R, et al. Buchbinder R (AI). NHMRC Program Grant. ‘Using healthcare wisely: reducing inappropriate use of tests and treatments’. (20172021) $9,578,895. Glasziou P, Buchbinder R, Maher C, McCaffery K. NHMRC Partnership Centre in Health System Sustainability. (2017-2022) $10,700,000. (NHMRC $5,250,000; Partners: Bupa Health Foundation, NSW Health, Telstra and the University of Notre Dame Australia). Braithwaite J, Ward RL, Anderson T, Teede H, Wells L, Gray LC, Yeend T, Coiera E, Westbrook J, Glasziou P, Scott A, Karnon JD, Buchbinder R. NHMRC Project Grant. ‘SUcceSS: Surgery for Spinal Stenosis – a randomised placebo-controlled trial’. (2017-2021) $2,300,000. Ferreira M, Harris I, Davis G, Latimer J, Beard D, Li Q, Mobbs R, Buchbinder R (AI). NHMRC The Cochrane Collaboration Round 7 Funding Program. ‘Cochrane Musculoskeletal Review Group, Australian Editorial Base’. (20172020) $368,086. Buchbinder R, O’Connor D, Winzenberg T, Johnston R.

RACGP Foundation – HCF Grant. ‘OCEAn - NETs (Occasions of Care Explained and Analysed - nominated extra topics).’ (2018-2019) $60,000. Harrison C, Poon S, Gorji N, Gordon J, Bonner C, Bayram C, Maher C, Buchbinder R.

NHMRC Centre of Research Excellence. ‘ANZMUSC – Australia and New Zealand Musculoskeletal Clinical Trials Network’. (2018-2022) $2,497,653. Buchbinder R (CI), Maher C, March L, Day R, Hinman R, Harris I, Ferreira M, Glasziou P, Green S, Billot L.

NHMRC Project Grant. ‘CROSSFIRE: Combined Randomised and Observational Study of Surgery for Fractures in the Distal Radius in the

NHMRC Medical Research Future Fund Research Grant. ‘CRISTAL: Cluster Randomised Trial of Aspirin versus Low molecular

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

weight heparin for venous thromboembolism prophylaxis in joint replacement surgery, a registry-nested study’. (20182022) $910,700. Harris I, Graves S, Buchbinder R, Naylor J, Pratt N, de Steiger R, Chong B, Ackerman I, Harris A. Academy of Finland. ‘Finnish Imaging of Degenerative Shoulder Study (FIMAGE): A study on the prevalence of degenerative imaging changes of the shoulder and their relevance to clinical symptoms in the general population’. (2018-2022) $450,000. Taimela S, et al. NHMRC Project grant. ‘Trial of glucocorticoids in acute sciatica’. (2019-2022) $1,142,038. Lin CWC, McLachlan A, Latimer J, Abdel Shaheed C, Li Q. Buchbinder R (CI on trial but AI on grant application as hold a program grant). Arthritis Queensland, Arthritis South Australia and the Allan and Beryl Stephens Grant. ‘Patterns of care for low back, knee and shoulder conditions by general practitioners in Victoria, Australia’. (2019 – 2020) $31,000. Haas R, Buchbinder R, O’Connor D, Mazza D. Australian Government Department of Health. ‘Value in Prescribing Program: Biological Disease Modifying AntiRheumatic Drugs (bDMARDs): Value-based prescribing of bDMARDs: a coordinated national program’. (20192022) $8,411,413. Partnership between: NPS MedicineWise (Dartnell J, London J, Heaney A, Hosking K, Yoo J, Elliott J, Granger R, Blogg S, Antonio G), ARA (Hill C, Barrett C, Morabani M, Kubler P, Day R, Clancy M, Buchbinder R [also representing ANZMUSC and Cochrane Musculoskeletal]), ANZMUSC (Whittle S, O’Connor D), Cochrane Musculoskeletal (Johnston R), Arthritis Australia (Mills A, Marine F), Quality Use of Medicines and Pharmacy Research Centre (Rowett D, Roughead L, Ward M, Wiese M), Pharmaceutical Society of Australia (Jackson S, Freeman C, McMaugh J, Ridd J), Society of Hospital Pharmacists of Australia (Michaels K, Jerry Yik J, Hayward K), Council

of Australian Therapeutic Advisory Groups (EthertonBeer C, Donnelly J, Bennett S).

McGowan S, Tendal B, Tate R, Turner T, McDonald S, Murano M.

Therapeutic Guidelines LTD (TGL)/RACGP Foundation Research Grant (TGL -03). ‘Use of Osteoarthritis Guidelines in General Practice: An Analysis of Work-as-Done Using the Functional Resonance Analysis Method’. (2019-2021) $19,968. Stocks N, Whittle S, ClayWilliams, Buchbinder R.

Australian Government Department of Health. Public Health and Chronic Disease Program Arthritis - Health Professional Education and Training. (2020-23) $2,018,464. Partnership between: Arthritis Australia, University of Sydney, University of Melbourne, Arthritis and Osteoporosis Australia in partnership with Curtin University, Monash University on behalf of ANZMUSC and Cochrane Musculoskeletal, Australian Rheumatology Association (Buchbinder R, Whittle S).

NHMRC Partnership Project Grant. ‘Improving communication about heart disease risk assessment using translational research strategies in general practice: A project to implement evidence-based guidelines and shared decision-making tools for CVD prevention’. (20192020) $449,368. Bonner C, Trevena L, Doust J, McGeechan K, Greaves K, O’Connor DA, Morgan M, de Wet C. NHMRC The Cochrane Collaboration Round 8 Funding Program. ‘Cochrane Musculoskeletal Review Group, Australian Editorial base’. (2020-2023) $384,204. Buchbinder R, Johnson R, O’Connor D, Winzenberg T, Maher C, Whittle S. Cabrini Foundation Clinical Research Grant. ‘Using SUpported Motivational InTervention (SUMIT) to improve physical activity in people with knee osteoarthritis’. (2020-2022) $29,999. Bell E, Wallis J, Barton C, O’Halloran P, Crossley K, Lee A, Jennings S, Gibbs A. NHMRC Medical Research Future Fund project grant. ‘Reducing inappropriate knee joint replacement surgery and hospital burden’. (2020-2022) $1,337,750. Barton C, Dowsey M, Choong P, Ademi Z, Smith Curtin A, Crossley KM, Wallis JA, Ackerman I, Bunzli S, Kemp JL. National COVID-19 Clinical Evidence Taskforce. (20202025) Equity Trustees – Walter Cottman Endowment Fund: $100,000 (25/3/20 to 31/12/20); Ian Potter Foundation: $2,500,000 (1/4/2020 to 31/12/2025); MRFF: $1,500,000 (1/4/2020 to 31/3/2022) Elliott J, Green S, Zoungas S, Buchbinder R, Craig J,

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

NHMRC Low Back Pain Centre for Research Excellence (CRE). (2020-2024) $2,499,189. Maher C, Buchbinder R, Hancock M, O’Sullivan P, McAuley J, Blyth F, Jorm L, Collie A, McCaffery K, Hayes A, O’Connor DA (AI). Arthritis Australia Grant-inAid. ‘The development of a patient decision aid to reduce subacromial decompression’. (2020) $15,000. Zadro J, Maher C, Buchbinder R, Harris I. NHMRC Ideas Project. ‘TOPCHILD: Transforming Obesity Prevention for CHILDren – Looking into the black box of interventions’. (2020-2023) $411,926. Seidler L. O’Connor DA (AI). Cabrini Foundation Clinical Research Grant. ‘Evaluating a patient decision aid for people with degenerative knee disease considering arthroscopic surgery: a randomised controlled trial. O’Connor D, Buchbinder R. (2020-2021) $29,745. O’Connor DA, Buchbinder R, Hoffmann T, McCaffery K, Maher C, Harris I, Glasziou P, Billot L, Haas R (AIs: Clavisi O, Gorelik A). NHMRC Investigator Grant: Leadership 3. (2021-2025) $2,914,215. Buchbinder R.

Cabrini Monash University Department of Surgery, The Fröhlich West Chair of Surgery Publications, books, book chapters, reports Bell SW, Heriot AG, Warrier SK, Farmer C, Stevenson A, Bissett I, Kong J, Solomon M. (2019) Surgical techniques in the Management of Rectal Cancer: A Modified-Delphi Method by Colorectal Surgeons in Australia and New Zealand. Techniques in Coloproctology 23:743-749. Bell S, Venchiarutti R, Warrier S, Stevenson A, Solomon M. (2019) A Perspective on Surgical Randomised Controlled Trials. ANZ Journal of Surgery 89 (9) 998-999. Bell S, Malouf P, Johnson N, Wale R, Peng Q, Nottle P, Warrier S. (2019) Pelvic fat volume reduction with preoperative VLED: Implications for rectal cancer surgery in the obese. Techniques in Coloproctology 23:887-892. Engel RM, Chen WH, Nickless D, Hlavca S, Richards E, Kerr G, Oliva K, McMurrick PJ, Jarde T, Abud HE. (2019) Patient-derived colorectal cancer organoids upregulate revival stem cell marker genes following chemotherapeutic treatment. Journal of Clinical Medicine 9, 128; doi:10.3390/jcm9010128 Yap R, Nassif G, Hwang G, Mendez A, Erkan A, Kelly J, Debeche-Adams T, Albert M, Monson J. (2020) Achieving opioid-free major colorectal surgery; is it possible? Digestive Surgery 30:1-7 Rudloff I, Jarde T, Bachmann M, Kerr G, Engel R, Oliva K, Wilkins S, McMurrick P, Abud H, Muhl H, Nold M. (2020) Molecular signature of interlukin-22 in colon carcinoma cells and organoid models. Translational Research 2020; 216:1-22. Ashkar C, Britto M, Carne P, Cheung W, Mirbagheri N. (2020) Perianal sepsis in neutropaenic patients with 107

haematological malignancies: the role of magnetic resonance imaging and surgery. ANZ Journal of Surgery doi: 10.1111/ ans.15744.

Bell S. (2020) A perspective on Colorectal Surgery Training in Australia and New Zealand. ANZ Journal of Surgery -202000570 In Press

Baqar A, Wilkins S, Staples M, Oliva K, McMurrick P. (2020) The post-operative impact of oversewing stapled anastomoses in colorectal surgery: A retrospective Australian cohort study. International Journal of Surgery Open 24:91-95.

Book Chapters

Albert M, Yap R. (2020) Surgical complications and pitfalls in taTME. Digestive Medicine Research 3:8 Mileto SJ, Jarde T, Childress KO, Jensen JL, Rogers AP, Kerr G, Hutton ML, Sheedio MJ, Bloch SC, Shupe JA, Horvay K, Flores T, Engel R, Wilkins S, McMurrick PJ, Lacy DB, Abud HE, Lyras D. (2020) Clostridioides difficile infection damages colonic stem cells via TcdB, impairing epithelial repair and recovery from disease. Proceedings of the National Academy of Sciences of the United States of America (PNAS) 117(4) 8064-8073 Koulis C, Yap R, Engel R, Jarde T,Wilkins S, Solon G, Shapiro JD, Abud H, McMurrick P. (2020) Personalised medicine-current and emerging predictive and prognostic biomarkers in colorectal cancer. Cancers 12(4) e812. Engel R, Oliva K, Koulis C, Yap R, McMurrick P. (2020) Predictive factors of complete pathological response in patients with locally advanced rectal cancer International Journal of Colorectal Disease Doi.org/10.1007/s00384-02003633-8 Bell SW, Stevenson A. (2020) Training and accreditation in transanal total mesorectal excision (taTME) (Australasia). Annals of Laparoscopic and Endoscopic Surgery 5:11 Scott M, Konstantatos AH, Bui T, Carne P, O’Donohoe R, Dearaugo S, Donovan S. (2020) Acute colonic pseudoobstruction leading to perforation: a case-control study investigating associations to tapentadol. Journal of Pharmacy Practice and Research 50 (3) 226-232 108

Debeche-Adams T, Yap R, Nassif G. Operating Theater Setup and Perioperative Considerations; In: Transanal Minimally Invasive Surgery and Transanal Total Mesorectal Excision (taTME); Ed. Attalah, S; Springer International Publishing 2019 Yap R, Monson J. Condyloma acuminata, In: Current Surgery Therapy, Ed. Cameron, J, 13th Edition, Elsevier, Saunders 2019 Yap R. Focus on Theory: Mastery Learning; In: Advances in Health Professions Education; Ed: Nestal, D (In press)

Grants held Eirene Lucas Foundation 2019 ‘Anti-cancer compound library resource for drug discovery’ (2019-2020) $10,000 Engel R (CI), McMurrick P (CI) Cabrini Foundation Research Grant 2020 ‘Personalising cancer medicine: the development of a high throughput drug screening platform using patient-derived colorectal cancer organoids’ (2020-2021) $30,000 Engel R (CI), McMurrick P (CI) Alan, Ada and Eva Selwyn Clinical Research Grant for the research project titled ‘Personalised medicine for colorectal cancer patients: Utilisation of Organoid Technology, Tissue microarrays and Consensus Molecular Subtypes’ (2019-2020), $30,000 Koulis C (CI), Engel R (CI), McMurrick P (CI) Cabrini Foundation Research Grant for the research project title ‘Developing a new tissueslice assay for modelling colorectal cancer tumours’ (2019-2020), $30,000 Wilkins S (CI), Fletcher A (CI), Knoblich K (CI), McMurrick P (CI) Cabrini Institute/Cabrini Foundation Grant ‘Using patient-derived organoids to guide the “watch and wait” nonsurgical approach for rectal

cancer’ (2018-2019) $30,000 Engel R (CI), McMurrick P (CI), Abud H (CI) Collie Foundation ‘Patient reported outcome measures’ $40,000 Wilkins S (CI), McMurrick P (CI) Collie Foundation ‘Human Organoids’ (2017-2019) $300,000 Wilkins S (CI), McMurrick P (CI) Victorian Cancer Agency ‘Super enhancer templated RNAs as predictive biomarkers of BET inhibitor sensitivity in prostate and colorectal cancer (20162019) $2,000,000 Firestein R (CI), Azad A (CI), Abud H (CI), McMurrick P (CI), Risbridger G (CI), Wilkins S (CI) Cancer Australia ‘Translating colorectal cancer organoids into patient care’ (20182020) $597,557 Abud H (CI) Worthley D (CI), Burgess A (CI), McMurrick P (CI), Firestein R (CI), Gibbs P (CI), Clevers H (CI), Price T (CI), Padbury R (CI), Hewett P (CI) NHMRC Project Grant ‘Role of Snail proteins in mediating intestinal stem cell identity’ (2016-2019) $646,698 Abud H (CI), Hime G (CI), Jones L (CI), McMurrick P (CI) Margaret Walkom Trust (20182019) $30,000 Koulis C (CI), Wilkins S (CI), McMurrick P (CI)

Centre for Allied Health Research and Education (CAHRE) Publications, books, book chapters, reports Brusco NK, Tilley L, Walpole B, Kugler H, Li R, Kennedy E. Morris ME. (2019) Feasibility of increasing the dosage of inpatient occupational therapy and physiotherapy rehabilitation via independent tasks and exercises: ‘My Therapy’. Australian Occupational Therapy Journal. 66(6):739-752. Pierce JE, O’Halloran R, Menahemi-Falkov M, Togher L, Rose M. (2020) Comparing higher and lower

weekly treatment intensity for chronic aphasia: A systematic review and metaanalysis. Neuropsychological Rehabilitation, pp. 1-25. doi: 10.1080/09602011.2020.1768127 Frawley HC, Lin K-Y, Granger C, Higgins R, Butler MDenehy L. (2019) An allied health rehabilitation program for patients following surgery for abdomino-pelvic cancer: a feasibility and pilot clinical study. Supportive Care in Cancer. 28(3):1335-1350. Cox N, Wilson C, Bennett K, Johnston K, Potter A, Lee AL. (2019) Health-related quality of life and psychological wellbeing are poor in children with bronchiectasis and their parents. ERJ Open Research. 5(3):00063-2019. doi: 10.1183/23120541.00063-2019 Wallis JA, Taylor NF, Bunzli S, Shields N. Experience of living with knee osteoarthritis: a systematic review of qualitative studies. BMJ Open 2019; 9: e030060. Smith R, Osadnik C, Lee AL. (2020) Educational topics and their rationale for inclusion within pulmonary rehabilitation – a systematic review. Patient Education and Counseling. S0738-3991(20)30196-8. doi: 10.1016/j.pec.2020.04.009

Grants held Cabrini Foundation. Supported Motivational Interviewing (SUMIT) to improve physical activity for people with knee osteoarthritis, $29,999.65 M Bell (PI), J Wallis, C Barton, P O’Halloran, K Crossley, N Taylor, A Lee, S Jennings, A Gibbs. ERS/ELF Travel grant award for the best abstract in patientcentred research 2020, €1,500, Lee A (CI) Cabrini Foundation. The relationship between cardiorespiratory parameters during physical activity following cardiac surgery, $15,000, A Lee (PI), J Gaudin, S Jennings, M Bergin, O Collicoat, B Armstrong, D El-ansary AURIC Innovation grant. Development and implementation of an academic exercise physiology program

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

at Cabrini, $200,000, G Richardson (PI), A Lee, P McMurrick, D Rankin, K Young Cabrini Foundation. Barriers and enablers for referrals and participation in Cabrini’s new evidence-based osteoarthritis management program: Capturing referrer and patient perspectives $30,000, Wallis J (PI), Sherwood J, Brusco NK, Barton C, Crossley K, Ackerman IN, Young K, Jennings S, Cabrini Foundation, Is spontaneous swallowing reduced in Parkinson’s compared to healthy controls? $20,000, Pierce J (CI), Vogel A, Cormick M, Lawson N

Bryce AH, McDermott R, Ricci F, Rowe J, Zhang J, Piulats JM, Fizazi K, Merseburger AS, Higano CS, Krieger LE, Ryan CJ, Feng FY, Simmons AD, Loehr A, Despain D, Dowson M, Green F, Watkins SP, Golsorkhi T, Chowdhury. (2020) Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the phase II TRITON2 Study. Clin Cancer Res. 26(11):24872496. doi:10.1158/1078-0432. ccr-20-0394

Cabrini Foundation. The development and implementation of a pictorial hospital food menu, $15,000, Matthews C (CI), Coletti S, Kelaart A, Lawson N, Dowd J

Lau DK, Burge M, Roy A, Chau I, Haller DG, Shapiro JD, Peeters M, Pavlakis N, Karapetis CS, Tebbutt NC, Segelov E, Price TJ. (2020) Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. Expert Review of Anticancer Therapy. 20(4):251-270. doi:10.1 080/14737140.2020.1744439

Cabrini Monash University Department of Medical Oncology – The Szalmuk Family Department of Medical Oncology

Roy AC,  Shapiro J, Burge M, Karapetis CS, Pavlakis N, Segelov E, Chau I, Lordick F, Chen LT, Barbour A, Tebbutt N, Price T. (2020) Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy. 20(4):305-324. doi: 10.1080/14737140.2020.1746185

Publications, books, book chapters, reports Desai J, Gan H, Barrow C, Jameson M, Atkinson V, Haydon A, Millward M, Begbie S, Brown M, Markman B, Patterson W, Hill A, Horvath L, Nagrial A,  Richardson G, Jackson C, Friedlander M, Parente P, Tran B, Wang L, Chen Y, Tang Z, Huang W, Wu J, Zeng D, Luo L, Solomon B.J. (2020) Phase I, Open-Label, Dose-Escalation/DoseExpansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors. J Clin Oncol. 38(19):2140-2150. doi:10.1200/ jco.19.02654 Abida W, Campbell D, Patnaik A, Shapiro JD, Sautois B, Vogelzang NJ, Voog EG,

Kumari S, Semira C, Lee M, Lee B, Wong R, Nott L,  Shapiro J, Gibbs P. (2020) Resection of colorectal cancer liver metastases in older patients. ANZ J Surg. 90(5):796801. doi: 10.1111/ans.15750. Mason R, Dearden HC, Nguyen B, Soon JA, Smith JL, Randhawa M, Mant A, Warburton L, Lo S, Meniawy T, Guminski A, Parente P, Ali S,  Haydon A, Long GV, Carlino MS, Millward M, Atkinson VG, Menzies AM. (2019) Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma. Pigment Cell & Melanoma Research. 33(2):358-365. doi: 10.1111/ pcmr.12831 Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A,

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Krepler C, Ibrahim N, Marreaud S, van Akkooi A, Robert C, Suciu S.(2020) Association Between ImmuneRelated Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomised to Receive Pembrolizumab or Placebo. JAMA Oncol. 6(4):519. doi: 10.1001/ jamaoncol.2019.5570 Bhave P,  Haydon A. (2020) Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises. Australas J Dermatol. 61(3):203-209. doi: 10.1111/ajd.13309 Owen CN, Shoushtari AN, Chauhan D, Palmieri DJ, Lee B, Rohaan MW, Mangana J, Atkinson V, Zaman F, Young A, Hoeller C, Hersey P, Dummer R, Khattak MA, Millward M, Patel SP, Haydon A, Johnson DB, Lo S, Blank CU, Sandhu S, Carlino MS, Larkin JMG, Menzies AM, Long GV. (2020) Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy. Ann Oncol. 31(8):1075-1082. doi: 10.1016/j. annonc.2020.04.471 Nguyen J, Clements W, McLean C, Haydon A, Moore M, Yap KS, Mar V, Shackleton M. (2020) Metastatic melanoma presenting as intravenous tumour thrombus. Journal of Medical Imaging and Radiat Oncol. doi: 10.1111/17549485.13019.

Grants held Medical Research Future Funds: Measuring adherence to best practice guidelines for the management of ovarian cancer in Australia to determine the extent to which variation in care influences clinical and patient-reported outcomes, $2.4 million. State Government: Victorian COVID-19 Cancer Network Grant $5 million

AURIC Innovation grant. Development and implementation of an academic exercise physiology program at Cabrini, $200,000, G Richardson (PI), A Lee, P McMurrick, D Rankin, K Young Freda Castan Grant for Lung Cancer $100,000 annually for at least three years Freda Castran Grant for Lung Cancer $100,000 annually for at least three years (2020-2022) Paula Reinders Grant $20,000 Cabrini Foundation Grant Round 'Validation of Cabrini's new chemotherapy app'. (20192020) $25,000, Richardson G, Lang T, Seletto K, Hastings J Cabrini Foundation Quality Improvement Grant 'Combatting Compassion Fatigue and Burnout of oncology nurses through wellness activities'. (2019-2020) $15,000, Seletto K, Lang T Telematics Trust. 'Patient self-reporting outcomes of chemotherapy app' (2018-2019) $50,000, Richardson G, Lang T Peter Meese Memorial Oncology Nursing Research Grant. 'Patient Self reported outcomes of toxicity experienced during chemotherapy (2018-2019) $15,000, Hastings J, Lang T, Richardson G Beverly Barlow Genetic Cancer Research Grant. 'Modelling Human Breast Cancer Disease using an Experimental in-vitro organoid culture system. (20182019) $100,000, Richardson G Veronica Choo Neo Png Grant for Pancreatic cancer database $100, 000

Palliative and Supportive Care Research Unit Publications, books, book chapters, reports Sulistio M, Wojnar R, Key S, Kwok J, Al-Rubaie Z, Michael N. (2020). The role of methadone in cancer-induced bone pain: a retrospective cohort study. Supp Care Cancer. 2020 10.1007/s00520-020-05606-7. 109

O’Callaghan C, Seah D, Clayton JM, Welz M, Kissane D, Michael N. Spirituality and religiosity in a palliative medicine population: a mixedmethods study. [published online ahead of print, 2020 Jun 4]. BMJ Support Palliat Care. 2020;bmjspcare-2020-002261. doi:10.1136/bmjspcare- 2020002261 O’Callaghan C, Seah D, Clayton JM, Welz M, Kissane D, Georgousopoulou E, Michael N. Palliative Caregivers’ Spirituality, Views About Spiritual Care, and Associations With Spiritual Well-Being: A Mixed Methods Study. Am J Hosp Palliat Care. 2020; 37: 305-313. Sulistio M, Wojnar R, Michael N. Propofol for palliative sedation. BMJ Support Palliat Care. 2020;10(1):4-6.

Grants held Cabrini Foundation Medical Oncology Research Grant. A pilot randomised control trial of a video decision support tool (VDST) for advanced care planning in cancer patient caregiver dyads. Michael N (CI), O’Callaghan C (AI), Kissane D. $45,000 AUD (20192020). Bethlehem Research Foundation Grant, Cabrini Foundation Clinical Research Grant. A diagnostic interview for psychological adjustment and demoralisation. Bobevski I, Burke A, Michael N (AI), Kissane D. $50,000 AUD (20192020). Cabrini Foundation Clinical Research Grant. A diagnostic interview for psychological adjustment and demoralisation. Bobevski I, Burke A, Michael N (AI), Kissane D. $30,000 AUD (2019-2020).

The Code of Ethical Standards for Catholic Health and Aged Care Services in the clinical setting’ (2018-2019) $30,000 O’Callaghan C, Michael N, Fleming D, Symons X, Lynch S, Garner C, Kissane D.

Szalmuk Family Psycho-Oncology Research Unit Publications, books, book chapters, reports Aoun SM, Kissane DW, Cafarella PA, Rumbold B, Hogden A, Jiang L. (2020) Grief, depression and anxiety in bereaved caregivers of people with motor neurone disease: a population-based national study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration https://doi.org/ 10.1080/21678421.2020.1790610 Aoun SM, Cafarella PA, Rumbold B, Thomas G, Hogden A, Jiang L, Gregory S, Kissane DW. (2020). Who cares for the bereaved? A national survey of family caregivers of people with motor neurone disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration http://dx.doi.org /10.1080/21678421.2020.1813780 Bailey C, Doyle Z, Dearin J, Michael N, Kissane DW. (2020). Demoralisation and chronic illness in rural Australia: a cross-sectional survey. Palliative and Supportive Care, 18(3):271-276. https://doi. org/10.1017/S1478951519000841

Belvederi Murri M, Zerbinatia L, Ounallia H, Kissane D, Casonia B , Leonia M, Rossia G, Dall’Olioa R, Carusoa R, Nannia MG, Grassi L. (2020) Assessing demoralisation in medically ill patients: Factor structure of the Italian version of the demoralization scale and development of short versions with the item response theory framework. J Psychosomatic Research. 128: 109889. https://doi.org/10.1016/j. jpsychores.2019.109889

Cabrini Foundation Clinical Grant Round ‘Using the modified Delphi method to establish expert consensus on optimising the applicability of

Belvederi Murri M, Caruso R, Ounalli H, Zerbinati L, Berretti E, Costa S, Recla E, Folesani F, Kissane DW, Nanni MG, Grassi L. (2020).

110

The relationship between demoralisation and depressive symptoms among patients from the general hospital: network and exploratory graph analysis. Journal of Affective Disorders 276: 137-146. Brooker J, Julian J, Millar J, Prince HM, Kenealy M, Herbert K, Graham A, Smith R, Kissane DW, Taylor K, Frydenberg M, Porter I, Fletcher J, Chipperfield K, Haines I, Burney S. (2020) A feasibility and acceptability study of an abbreviated version of the Mindful Self-Compassion program for adult cancer patients. Palliative & Supportive Care. 18(2):130-140. https://doi. org/10.1017/s1478951519000737 Cheng J, Chen J, Zhang Y, Kissane D, Yan J. (2020) Translation and psychometric properties for the Demoralisation Scale in Chinese breast cancer patients. European Journal of Oncology Nursing 42: 134140. https://doi.org/10.1016/j. ejon.2019.09.001 Grassi L, Pasquini M, Kissane D, Zerbinati L, Caruso R, Sabato S, Nanni MG, Ounalli H, Maraone A, Roselli V, Belvederi Murri M, Biancosino B, Biondi M. (2020). Exploring and assessing demoralisation in patients with non-psychotic affective disorders. Journal of Affective Disorders 274: 568575. https://doi.org/10.1016/j. jad.2020.05.043 Kelly, B., Handley, T., Kissane, D., Vamos, M., & Attia, J. (2020) “An indelible mark” the response to participation in euthanasia and physician-assisted suicide among doctors: A review of research findings. Palliative and Supportive Care, 18(1): 82-88. https://doi.org/10.1017/ S1478951519000518 Kissane DW. (2020). Education and assessment of psychoexistential symptoms to prevent suicidality in cancer care. Psycho-Oncology vol 29, no 9; https://doi.org/10.1002/ pon5519 Latella LE, Rogers M, Leventhal H, Parker PA, Horowitz S, Matasar MJ, Bylund CL, Kissane DW, Franco K, Banerjee SC. (2020) Fear of cancer recurrence in lymphoma survivors: a

descriptive study. Journal of Psychosocial Oncology, 38(3):251-271. https://doi.org/10 .1080/07347332.2019.1677840 Manne S, Kashy D, Kissane D, Zaider T, Heckman C, Penedo F, Virtue S. (2020) Relationship Intimacy Processes During Treatment for CoupleFocused Interventions for Prostate Cancer Patients and their Spouses Journal of Psychosocial Oncology Research. 1(2):e7. https://doi.org/10.1097/ OR9.0000000000000007 Manne S, Kashy DA, Kissane DW, Zaider T, Heckman CJ, Myers Virtue S, Penedo F. (2020) In-session Intimacy Processes and Treatment Outcomes for Two Couple-Focused Interventions for Prostate Cancer Patients and their Spouses. Journal of Psychosocial Oncology Research. 2(2):e19. https://doi.org/10.1097/ OR9.0000000000000019 Mendz GL, Kissane DW. (2020). Agency, autonomy and euthanasia. Journal of Law, Medicine, Ethics. 48: 555-564. Pirola WE, Paiva BSR, De Oliveira CZ, Kissane DW, Paiva CE. (2020). Validation of the Brazilian version of the Shame and Stigma Scale (SSS-Br) for patients with head and neck cancer. Palliative and Supportive Care, e 1–7. https://doi.org/10.1017/ S1478951519000488

Grants held Commonwealth Department of Health grant, in collaboration with the University of Notre Dame Australia, as a multi-sited study. 'Education and Assessment of Psycho-existential wellbeing in palliative care.' $1,062,342 Kissane DW, Lobb E, Michael N Cabrini Foundation Clinical Research Grant. ‘Development of a spiritual concerns checklist. (2018-2020) $50,000. O’Callahan C, Michael N, Kissane DW Bethlehem Griffiths Research Foundation. ‘Validation of a clinical interview for demoralization’. (2019-2020) $50,000 Bobevski I, Kissane DW, Michael N.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Cabrini Foundation Clinical Research Grant. ‘Validation of a clinical interview for demoralisation’. (2019-2020) $30,000 Bobevski I, Kissane DW, Michael N.

(2020) Older person with vague symptoms in the emergency department: Where should I begin? Emergency medicine Australasia : EMA. 32(1):141-147. doi:10.1111/1742-6723.13433

Cabrini Foundation Clinical Research Grant. ‘A pilot randomised control trial of a video decision support tool (VDST) for advanced care planning in cancer patient caregiver dyads’. (2019-2020) $45,000 Michael N, Kissane DW, Jiwa M, Burke A.

Heydari F, Redoute J-M, Yuce M, Joe K, Walker K, Ebrahim M. (2020) Clinical study of a chest-based cuffless blood pressure monitoring system. Medical Devices and Sensors. doi:10.1002/mds3.10091

Doreen Johnson Oncology Research Grant, Cabrini Foundation Clinical Grant Round ‘Meaning and Purpose (MaP) Therapy in Advanced Cancer Patients: A Multi-site Randomised Controlled Trial’ (2018-2019) $50,000 Kissane D, Michael N. Cabrini Foundation Clinical Grant Round ‘Using the modified Delphi method to establish expert consensus on optimising the applicability of The Code of Ethical Standards for Catholic Health and Aged Care Services in the clinical setting’ (2018-2019) $30,000 O’Callaghan C, Michael N, Fleming D, Symons X, Lynch S, Garner C, Kissane D.

Alan, Ada and Eva Selwyn Emergency Department Publications, books, book chapters, reports Walker K, Tan SI, Fatovich D, et al. (2020) Research capacity of Australian and New Zealand emergency medicine departments. Int J Emerg Med. 13(1):16. doi:10.1186/s12245-02000275-z Keijzers G, Macdonald SP, Udy AA, et al. (2020) The Australasian Resuscitation In Sepsis Evaluation: Fluids or vasopressors in emergency department sepsis (ARISE FLUIDS), a multi-centre observational study describing current practice in Australia and New Zealand. Emergency medicine Australasia : EMA. doi:10.1111/1742-6723.13469 Jackman C, Laging R, Laging B, Honan B, Arendts G, Walker K.

Heydari F, Ebrahim MP, Redoute J-M, Joe K, Walker K, Rasit Yuce M. (2020) A chestbased continuous cuffless blood pressure method: Estimation and evaluation using multiple body sensors. Original Research. Information Fusion. 54:119-127. doi:10.1016/j. inffus.2019.07.001 Rahman MA, Honan B, Glanville T, Hough P, Walker K. (2019) Using data mining to predict emergency department length of stay greater than 4 hours: Derivation and singlesite validation of a decision tree algorithm. Emergency Medicine Australasia : EMA. doi:10.1111/1742-6723.13421

Grants held MRFF Monash Partners, Critical Care, rapid translational research flagship program. “Emergency medicine wait time visibility.” (2019-2021), $250,000 Walker K (CI), Joe K, Ben-Meir M. MRFF Monash Partners. 'Be your best: an innovative co-designed approach to frailty and care-transitions from hospital to home, in people aged 65 years or more.' (20192021), $198,000 Lowthian J (CI), Boyd L (AI), Rose M (AI), Walker K (AI) et al. Cabrini Auric grant. 'Developing and testing virtual reality tools to reduce agitation in cognitively impaired older people in emergency departments.' (2019-2021), $147,000 Blecher (CI), Walker K (AI) et al Cabrini Improvement Research Grant. 'My Health Record in the emergency department: An investigation of adoption, utilisation and utility' (20202021), $15,000. Mullins A (CI), M Ben-Meir M, Rankin D, Skouteris H.

Pour Ebrahim M, Heydari F, Wu T, et al. (2020) Blood Pressure Estimation Using On-body Continuous Wave Radar and Photoplethysmogram in Various Posture and Exercise Conditions. Sci Rep. 9(1):16346. doi:10.1038/s41598-019-52710-8

Telematics Trust. 'Development of IT software to support nextday nurse follow up phone calls to patients discharged from the emergency department'. (20182019) $50,000 Ben-Meir M, Joe K, Walker K

Cameron P, Mitra D, Walker K, Jackman C. (2019) Haemoptysis. Textbook Chapter. Textbook of adult emergency medicine 5th edition.

Intensive Care Research Unit

Cameron P, Mitra D, Walker K, Jackman C. (2019) Chronic obstructive pulmonary disease. Textbook Chapter. Textbook of adult emergency medicine 5th edition. Cameron P, Mitra D, Laging R. (2020) Chest pain. Textbook Chapter. Textbook of adult emergency medicine 5th edition. Cameron P, Mitra D, Laging R. (2019) Acute coronary syndromes. Textbook Chapter. Textbook of adult emergency medicine 5th edition.

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Publications, books, book chapters, reports Brewster DJ, Kerr F and Sarode V. (2020) Preparing the intensive care unit for COVID-19: an Australian experience. MJA Insight. https://insightplus.mja.com Whyler NC, Teng JC, Brewster DJ, Chin R, Cox I, Druce J, Prince HM, Sheffield DA, Teh E, Sarode V. (2019) Diagnosis of West Nile virus encephalitis in a returned traveller. Med J Aust. 211(11):501. doi: 10.5694/mja2.50416 Das A, Anstey M, Bass F, Blythe D, Buhr H, Campbell L,

Davda A, Delaney A, Gattas D, Green C, Ferrier J, Hammond N, Palermo A, Pellicano S, Phillips M, Regli A, Roberts B, Ross-King M, Sarode V, Simpson S, Spiller S, Sullivan K, Tiruvoipati R, Haren FV, Waterson S, Yaw LK, Litton E. (2019) Internet health information use by surrogate decision makers of patients admitted to the intensive care unit: a multicentre survey. Crit Care Resusc. 21(4):305-310. PMID: 31778639. David J Brewster, Nicholas C Chrimes, Thy BT Do, Kirstin Fraser, Chris J Groombridge, Andy Higgs, Matthew J Humar, Timothy J Leeuwenburg, Steven McGloughlin, Fiona G Newman, Chris P Nickson, Adam Rehak, David Vokes and Jonathan J Gatward.(2020) Consensus statement: Safe Airway Society principles of airway management and tracheal intubation specific to the COVID-19 adult patient group. Med J Aust. 212(10):472481. doi: 10.5694/mja2.50598 Begley JL, Lavery KE, Nickson CP, Brewster DJ. (2020) The aerosol box for intubation in coronavirus disease 2019 patients: an in-situ simulation crossover study. Anaesthesia. 75(8):1014-1021. doi: 10.1111/ anae.15115 Silver A, Adams M, Brewster DJ. (2020) Intubation and “aerosol generating procedures”: why language matters. MJA Insight. https://insightplus.mja.com Ihle, J. Burrel, A. Philpot, S. Pilcher, D. Murphy, D. Pellegrino, V. (2020) A Protocol that Mandates Postoxygenator and Arterial Blood Gases to Confirm Brain Death on Venoarterial Extracorporeal Membrane Oxygenation. ASAIO Journal. 66(2):e23-e28. doi: 10.1097/ MAT.0000000000001086 Philpot SJ. (2020) Discussing non-beneficial treatment. Emergency Medicine Australasia. 32(3):499-500. doi:10.1111/1742-6723.13529 Philpot SJ, Bilgrami I, Sullivan L. Communicating medical information over the phone in critical care. Crit Care Resuscitation. Accepted for publication June 2020. 111

McDonald C, Wackett J, Philpot S, Brady B. (2020) Myocarditis in a 47-year-old man with Myasthenia Gravis and Malignant Thymoma following the Administration of a Tyrosine Kinase/CDK Inhibitor. Cancer Therapy and Oncology International Journal. 16(3). doi: 10.19080/ CTOIJ.2020.16.555937 Murphy, D. Krepska, A. (2019) Acute heart failure. Challenging Concepts in Critical Care, pp. 23-34. doi: 10.1093/ med/9780198814924.003.0002 Brewster DJ and Crock C. The COVID-19 pandemic: an opportunity to embed kindness in our healthcare system MJAinsight. June 29 2020. Peebles RC, Nicholson IK, Schlieff J, Peat A and Brewster DJ. Nurses’ just-in-time training for clinical deterioration: development, implementation and evaluation. Nurse Education Today. 2020; 84 article 104265. https://doi. org/10.1016/j.nedt.2019.104265

Department of Urology Publications, books, book chapters, reports Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, Wong LM, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Link E, Marusic P, Matera A, Herschtal A, Iravani A, Hicks RJ, Williams S, Murphy DG; proPSMA Study Group Collaborators (2020). Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 395(10231):1208-1216. doi: 10.1016/S0140-6736(20)30314-7. Lawrence MG, Pidsley R, Niranjan B, Papargiris M, Pereira BA, Richards M, Teng L, Norden S, Ryan A, Frydenberg M, Stirzaker C, Taylor RA, Risbridger GP, Clark SJ (2020). Alterations in 112

the methylome of the stromal tumour microenvironment signal the presence and severity of prostate cancer. Clin Epigenetics. 12(1):48. doi: 10.1186/s13148-020-00836-2.

Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 77(4): 508-547. doi: 10.1016/j.eururo.2020.01.012.

Lawrence MG, Porter LH, Clouston D, Murphy DG, Frydenberg M, Taylor RA, Risbridger GP (2020). Knowing what’s growing: Why ductal and intraductal prostate cancer matter. Science Translational Medicine. 12(533): pii: eaaz0152. doi: 10.1126/scitranslmed. aaz0152

Dunn J, Green A Nicolas R, Newton R, Kneebone A, Frydenberg M, Chambers S, Heneka N (2020). Prostate Cancer Survivorship Essentials Framework: Guidelines for Practitioners. BJU International.

Grummet J, Gorin MA, Popoert R, O’Brien T, Lamb AD, Hadaschiks B, Radtke JP, Wagenlehner F, Baco E, Moore CM, Embertons M, George AK, Davis JW, Szabo RJ, Buckley R, Loblaw A, Allaway M, Kastner C, Briers E, Royce PL, Frydenberg M, Murphy DG, Woo HH (2020). Trexit 2020: Why the time to abandon transrectal prostate biopsy starts now. Prostate Cancer and Prostatic Diseases. 23(1):62-65. doi: 10.1038/s41391020-0204-8. Dunn J, Ralph N, Green A, Frydenberg M, Chambers S (2020). Contemporary consumer perspectives on prostate cancer survivorship: Fifty voices. Psycho-Oncology. 29(3):557-563. doi: 10.1002/ pon.5306 Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano CTS, Hofman MS, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli RB, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O’Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Reiter RE, Roach M, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Small E, Smith M, Soule H, Sternberg CN, Steuber T, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tombal B, Türkeri L, van Oort I, Zapatero A, Omlin A (2020). Management of

Kneebone A, Frase-Browne C, Duchesne G, Fisher R, Frydenberg M, Herschtal A, Williams SG, Delprado W, Haworth A, Joseph DJ, Martin JM, Matthews JHL, Millar JL, Sidhom M, Spry N, Tang CI, Turner S, Wiltshires KL, Woo H, Davis ID, Lim TS, Pearse M (2020). A phase III multicentre randomised trial comparing adjuvant versus early salvage Radiotherapy following a Radiotherapy following a Radical Prostatectomy: Results of the TROG 08.03 and ANZUP “RAVES” Trial. The Lancet. Kalapara A, Frydenberg M (2020). The role of open radical nephrectomy in contemporary management of renal cell carcinoma. Translational Andrology and Urology Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, LinaresEspinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC,

Moschini M, Mostafid H, Müller AC, Müller CR, N’Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Der Heijden AGV, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A (2020). EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAUESMO Guidelines Committees. Eur Urol. 77(2):223-250. doi: 10.1016/j.eururo.2019.09.035. Horwich A, Babjuk M, Bellmunt J, Bruins HM, Reijke TMD, Santis MD, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Kwast TVD, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, Bari BD, WD Blok, Visschere PD, Decaestecker K, Dimitropoulos K, Escrig JLD, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, LinaresEspinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller A-C, Müller CR, N’Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen W, PachecoFigueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg J, Roupret M, Rouviere O, Salembier C,

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Heijden AGVD, Poppel HV, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Witjes JA (2019). EAU–ESMO consensus statements on the management of advanced and variant bladder cancer – an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. Annals of Oncology. 30(11):1697- 1727. doi: 10.1093/ annonc/mdz296. Kalapara AA, Verbeek JFM, Nieboer D, Fahey M, Gnanapragasam V, Van Hemelrijck M, Lee LS, Bangma CH, Steyerberg EW, Harkin T, Helleman J, Roobol MJ, Frydenberg M; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium (2020). Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance Initiative. Eur Urol Oncol. 3(1):80-91. doi: 10.1016/j. euo.2019.08.014. Bowden P, See AW, Frydenberg M, Haxhimolla H, Costello AJ, Moon D, Ruljancich P, Grummet J, Crosthwaite A, Pranavan G, Peters J, So K, Gwini SM, McKenzie DP, Nolan S, Smyth LML, Everitt C (2020). Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: interim outcomes of a prospective clinical trial. International Journal of Cancer. 146(1):161168. doi: 10.1002/ijc.32509 Pillay B, Moon D, Meyer D, Crowe H, Mann S, Howard N, Wootten A, Frydenberg M (2020). Exploring the impact of providing men with information about potential prostate cancer treatment options prior to receiving biopsy results. Supportive Care in Cancer. 28(2):507-514. doi: 10.1007/s00520-019-04847-5. Drost FH, Nieboer D, Morgan TM, Carroll PR,

Roobol MJ; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP) Consortium, Trock B, Ehdaie B, Carroll P, Filson C, Kim J, Logothetis C, Morgan T, Klotz L, Pickles T, Hyndman E, Moore CM, Gnanapragasam V, Van Hemelrijck M, Dasgupta P, Bangma C, Roobol M, Villers A, Rannikko A, Perry A, Hugosson J, Rubio-Briones J, Bjartell A, Hefermehl L, Shiong LL, Frydenberg M, Kakehi Y, Chung BH (2019). Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. Eur Urol. 76(5):693-702. doi: 10.1016/j. eururo.2019.07.041. Chambers SK, Frydenberg M, Dunn J (2019). Quality of life considerations in the treatment of metastatic hormonesensitive prostate cancer. Lancet Oncology. 20(11):14691471. doi: 10.1016/S14702045(19)30628-X. Frydenberg M (2019). Avoiding biopsy in men with PIRADS 1,2 on multiparametric MRI of the prostate, ready for prime time? BJU International. 124(5):715716. doi: 10.1111/bju.14901. Frydenberg M. Editorial Comment. (2019). J Urol. 202(6):1247. doi: 10.1097/01. JU.0000585052.78904.db. Kalapara AA, Nzenza T, Pan HYC, Ballok Z, Ramdave S, O’Sullivan R, Ryan A, Cherk M, Hofman MS, Konety B, Lawrentschuk N, Bolton D, Murphy DG, Grummet JP, Frydenberg M (2019). Detection and localisation of primary prostate cancer using 68 GA-PSMA PET/CT compared with mpMRI and radical prostatectomy specimens. BJU Int. doi: 10.1111/bju.14858.[Epub ahead of print] (Accepted for publication: 30th June 2019). Pereira BA, Lister NL, Hashimoto K, Teng L, FlandesIparraguirre M, Eder A, Sanchez-Herrero A, Niranjan B, Melbourne Urological Research Alliance (MURAL), Frydenberg M, Papargiris MM, Lawrence MG, Taylor RA, Hutmacher DW, Ellem SJ, Risbridger GP,

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

De-Juan-Pardo EM (2019). Tissue engineered human prostate microtissues reveal key role of mast cell-derived tryptase in potentiating cancer-associated fibroblast (CAF)-induced morphometric transition in vitro. Biomaterials. 197:72-85. doi: 10.1016/j. biomaterials.2018.12.030. Sathianathen NJ, Kalapara A, Frydenberg M, Lawrentschuk N, Weight CJ, Parekh D, Konety BR (2019). Robotic-assisted radical cystectomy vs open radical cystectomy: systematic review and meta-analysis. J Urol. 201(4): 715-720. doi: 10.1016/j.juro.2018.10.006. van der Kwast TH, Helleman J, Nieboer D, Bruinsma SM, Roobol MJ; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium, Trock B, Ehdaie B, Carroll P, Filson C, Kim J, Logothetis C, Morgan T, Klotz L, Pickles T, Hyndman E, Moore CM, Gnanapragasam V, Van Hemelrijck M, Dasgupta P, Bangma C, Roobol M, Villers A, Rannikko A, Valdagni R, Perry A, Hugosson J, Rubio-Briones J, Bjartell A, Hefermehl L, Shiong LL, Frydenberg M, Kakehi Y, Chung BH, van der Kwast T, Obbink H, van der Linden W, Hulsen T, de Jonge C, Kattan M, Xinge J, Muir K, Lophatananon A, Fahey M, Steyerberg E, Nieboer D, Zhang L, Guo W, Benfante N, Cowan J, Patil D, Tolosa E, Kim TK, Mamedov A, LaPointe V, Crump T, KimberlyDuffell J, Santaolalla A, Nieboer D, Olivier JT, Rancati T, Ahlgren H, Mascarós J, Löfgren A, Lehmann K, Lin CH, Hirama H, Lee KS, Jenster G, Auvinen A, Bjartell A, Haider M, van Bochove K, Carter B, Gledhill S, Buzza M, Bangma C, Roobol M, Bruinsma S, Helleman J (2019). Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. Eur Urol Oncol. 2019 May;2(3):333-336. doi: 10.1016/j. euo.2018.08.017 Van Hemelrijck M, Ji X, Helleman J, Roobol MJ, van der Linden W, Nieboer D, Bangma CH, Frydenberg M, Rannikko A, Lee LS, Gnanapragasam VJ, Kattan MW; Members of the Movember Foundation's Global Action Plan Prostate Cancer

Active Surveillance GAP3 consortium; Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium (2019). Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. Eur Urol 75(3):523-531. doi: 10.1016/j.eururo.2018.10.025. Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano CTS, Hofman MS, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli RB, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Reiter RE, Roach M, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Small E, Smith M, Soule H, Sternberg CN, Steuber T, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tombal B, Türkeri L, van Oort I, Zapatero A, Omlin A. (2020). Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 77(4): 508-547. doi: 10.1016/j. eururo.2020.01.012. Bolton D, Frydenberg M (2019). From indecision to precision: advances in imaging in metastatic prostate cancer. World J Urol. 37(7):1237. doi: 10.1007/s00345-019-02820-9. Harkin T, Elhage O, Chandra A, Khan N, Kiberu Y, Frydenberg M, Dasgupta P (2019). High dectal proportion predicts biochemical recurrence in prostatic ductal adenocarcinoma. BJU International doi: 10.1111/ bju.14831. [Epub ahead of print] Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvarth LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, 113

Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu S, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ, for the ENZAMET trial investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2019). Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. New England Journal of Medicine. 381(2):121-131. doi: 10.1056/ NEJMoa1903835 Porter LH*, Lawrence MG*, Wang J, Clark AK, Bakshia A, Obinata D, Goode D, Papargiris M, MURAL, Clouston D, Ryan A, Norden S, Grummet J, Kourambas J, Pook D, Sandhu S, Frydenberg M, Murphy D, Taylor RA*, Risbridger GP * (2019). Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer. The Prostate. 79(11):1326-1337. doi: 10.1002/ pros.23839 Frydenberg M (2019). Re: 68Ga-Labeled Prostatespecific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 76(3): 405. doi: 10.1016/j. eururo.2019.03.039. McLennan V, Ludvik D, Chambers S, Frydenberg M (2019). Work after prostate cancer: a systematic review. J Cancer Surviv. 13(2): 282-291. doi: 10.1007/s11764-019-007504 - Review Watt MJ, Clark AK, Selth LA, Haynes VR, Lister N, Rebello R, Porter LH, Niranjan B, Whitby ST, Lo J, Huang C, Schittenhelm RB, Anderson KE, Furic L, Wijayaratne PR, Matzaris M, Montgomery MK,

1 14

Papargiris M, Norden S, Febbraio M, Risbridger GP, Frydenberg M, Nomura DK, Taylor RA (2019). Suppressing Fatty Acid Uptake has therapeutic effects in preclinical models of prostate cancer. Science Translational Medicine. 11(478). pii: eaau5758. doi: 10.1126/scitranslmed. aau5758.

Grants held NHMRC. 'Targeting lethal prostate cancer in its infancy'. Risbridger G, Clouston D, Frydenberg M, Murphy D. $764,363.50 (2020-2022) NHMRC 'Developmental events affecting male fertility and reproductive pathologies' Loveland K, Rajpert-De Meyts E, Schuppe H-C, Meinhardt A, Almstrup K, Jorgensen A, Guo J. (AIs) Frydenberg M, Hedger M, Hobbs R, Tran B. $1,430,000 (2020-2023) Inherited pathogenic mutations in prostate cancer (Monash) PCFA $490K Impact of PET PSMA in the management of prostate cancer (Monash Health, VCCC) PCFA $1.3M Prostate Cancer Foundation of Australia and It's A Bloke Thing Foundation through Prostate Cancer Foundation of Australia's Research Program. 'Inherited pathogenic mutations in prostate cancer: the next generation.' Taylor RA, Thorne H, Frydenberg M, Risbridger GP, Batra J, Schoch W. $490,670 (2019-2022) Movember Foundation. Prostate Cancer Outcomes Registry – Australia and New Zealand (PCOR-ANZ) Quality Improvement Research Fund. "Realtime App for PCOR-ANZ results: proof of concept and value to Urologists" Brough S,

Frydenberg M, Bax K, Clarke J, Frizelle F, Weston M, Evans S, Runting A, Nugara M. $100,000 (2019-2022) Movember Foundation. Prostate Cancer Outcomes Registry – Australia and New Zealand (PCOR-ANZ) Quality Improvement Research Fund. 'Predicting urinary incontinence and ED after prostate cancer surgery'. Moretti K, O'Callaghan M, Vincent A, Beckmann K, Smith D, Mark S, Frydenberg M, Evans S, Clarke J, Walsh S, Kopsaftis T, Evans M, Merry D. $90,250 (2019-2021)

D, Taaffe D, Spry N, Hart N. $596,083.90 (2018-2022) NHMRC. 'Centre for Research Excellence in Prostate Cancer Survivorship (CRE-PCS)' Frydenberg M (AI) $2,498,842 (2016-2020) Prostate Cancer Foundation of Australia – Movember Clinical Trial Award. 'A prospective multicentre study of the impact of Ga-68 PSMA-PET/CT imaging in the management of prostate cancer (proPSMA study)' CIs: Hofman M (PI), Williams S, Lawrentschuk N, Francis R, Martin J, Roach P, Frydenberg M, Thomas P. $1,272,142 (20162020)

Movember Foundation. Prostate Cancer Outcomes Registry – Australia and New Zealand (PCOR-ANZ) Quality Improvement Research Fund. 'Clinical-level quality of care reports – dealing with the complex issue of outliers' Evans S, Heathcote P, Fisher J, Kirkman M, Frydenberg M, Mark S, Currow D. $66,259 (2019-2020)

Clinical Education Department

Cancer Council Victoria. 'Targeting lipid metabolism in prostate cancer' Watts MJ, Taylor RA, Nomura D. (AI) Risbridger G, Frydenberg M, Ryan. $300,000 (2019-2021)

Peebles RC, Nicholson IK, Schlieff J, Peat A, Brewster DJ. (2020) Nurses’ just-intime training for clinical deterioration: Development, implementation and evaluation. Nurse Education Today, 84: 104265.

NHMRC 'BCG+MM Trial: Adding mitomycin to BCG as adjuvant intravesical therapy for high-risk, non-muscleinvasive bladder cancer: a 2-stage, randomised phase 3 trial' CIs: Hayne D, Stockler M, Frydenberg M, Martin A, Sengupta S, Patel M, Grummet J, Krieger L, McCombie S. $1,587,163.80 (2019-2023) NHMRC.'Can Exercise Delay Transition to Active Therapy in Men with Low Grade Prostate Cancer? A Multi-Centre Randomised Controlled Trial' CIs: Galvão D, Frydenberg M, Chambers S, Newton R, Hayne

Publications, books, book chapters, reports

Department of Medical Student Education Publications, books, book chapters, reports Brewster DJ and Crock C. (2020) The COVID-19 pandemic: an opportunity to embed kindness in our healthcare system. MJA Insight. https://insightplus.mja.com

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Key partners of the Cabrini Institute Cancer Trials Australia (CTA) Digital Health Cooperative Research Centre (DHCRC) Monash Partners Academic Health Science Centre (known as Monash Partners) Australian Catholic University (ACU) ACU College La Trobe University Monash University Swinburne University The University of Melbourne The University of Notre Dame

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

115

Cabrini Institute

154 Wattletree Road Malvern Victoria 3144 Australia ph (03) 9508 3434 email: institute@cabrini.com.au www.cabrini.com.au

116

C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0

Cabrini Institute Annual Report 2019-20

Articles inside

Publications, Books, Book Chapters, Reports and

Providing Best Cancer Management for our Patients

Department of Medical Student Education

Broader Medical Education

Clinical Education Department

Clinical Database Registries

Intensive Care Research Unit

Alan, Ada, and Eva Selwyn Emergency Department

In the Spotlight: Dr Tali Lang

In the Spotlight: Li Hoon Lai

Cabrini Monash University Department

Cabrini Monash University Department of

and Education (CAHRE) Cabrini Monash University Department of

In the Spotlight: Mr Raymond Yap

Let’s Beat Bowel Cancer

Monash-Cabrini Department of Clinical Epidemiology

In the Spotlight: Dr Anis Hamid